Xxxxxxxx Komise 2000/32/XX
xx xxx 19. xxxxxx 2000,
xxxxxx se po xxxxxxx xxxxx xxxxxxxxxxxx xxxxxxxxxxx xxxxxxx xxxxxxxx Xxxx 67/548/EHS x xxxxxxxxxx xxxxxxxx x xxxxxxxxx xxxxxxxx týkajících xx klasifikace, xxxxxx x označování xxxxxxxxxxxx xxxxx [1]
(Xxxx x xxxxxxxx pro XXX)
XXXXXX XXXXXXXXXX XXXXXXXXXXXX,
x xxxxxxx xx Xxxxxxx o xxxxxxxx Evropského xxxxxxxxxxxx,
x xxxxxxx xx xxxxxxxx Xxxx 67/548/XXX xx xxx 27. xxxxxx 1967 x xxxxxxxxxx xxxxxxxx x xxxxxxxxx xxxxxxxx xxxxxxxxxx xx xxxxxxxxxxx, xxxxxx x xxxxxxxxxx xxxxxxxxxxxx xxxxx [2], xxxxxxxxx pozměněnou xxxxxxxx Evropského parlamentu x Xxxx 1999/33/XX [3], x xxxxxxx xx xxxxxx 28 xxxxxxx směrnice,
vzhledem x xxxxx xxxxxxx:
(1) Xxxxxxx X xxxxxxxx 67/548/EHS xxxxxxxx xxxxxx xxxxxxxxxxxx xxxxx xxxxxxxx s xxxxxxxxxx xxxxx x xxxxxxxxxxx x xxxxxxxxxx xxxxx látky. Xxxxxxxx xxxxxxx a technické xxxxxxxx ukazují, xx xx xxx být xxxxxx xxxxxxxxxxxx xxxxx x uvedené xxxxxxx xxxxxxxxxxx. Xxxxxxx jazykové xxxxx směrnice xxxxxxxx xxxxxx určitých oddílů xxxxxxxxx a xxxxxxx X v xxxxxxx X.
(2) Xxxxxxx XXX xxxxxxxx 67/548/XXX obsahuje xxxxxx xxx xxxxxxxxxxx xxxxxx xxxxxxxxxx xxxxx xxxxxxxxx x xxxxxxxxxxxx xxxxxxx a xxxxxxxxx. Xxxxxxx IV xxxxxxxx 67/548/XXX xxxxxxxx seznam xxx s bezpečnostními xxxxxx xxxxxxxxxx xx xxxxxxxxxxxx látek x xxxxxxxxx. Xxxxxxx XX xxxxxxxx 67/548/XXX obsahuje xxxxx xx xxxxxxxxxxx x x xxxxxxxxxx xxxxxxxxxxxx xxxxx x xxxxxxxxx. Xxxxxxx jazykové xxxxx xxxxxxxx xxxxxxxx xxxxxx určitých xxxxxx xxxxxx XXX, IV x XX.
(3) V xxxxxxx V xxxxxxxx 67/548/XXX se stanoví xxxxxx xxx xxxxxxxxx xxxxxxxxx-xxxxxxxxxx vlastností, toxicity x xxxxxxxxxxx látek x přípravků. Xx xxxxxxxx xxxxxxxxxxx xxxx xxxxxxx xxxxxxxxxxx xxxxxxx.
(4) Xxxxxxx XX směrnice 67/548/XXX xxxxxxxx xxxxxxxx xxxxxxxx se xxxxxxx xxxxxxxx proti otevření xxxxx. Tyto xxxxxxxx xx měly xxx xxxxxxxxxxxx x xxxxxxxxxxxxx. Xx xxxxxxxx rozšířit xxxxxx, xxx xx xxxxxxx xxxxxx xxxxx xxxxxxxx xxxxx xxxxxxxxx.
(5) Xxxxxxxx xxxx xxxxxxxx xxxx x souladu xx stanoviskem Výboru xxx xxxxxxxxxxxx xxxxxxxxxxx xxxxxxx xxxxxxx xxx xxxxxxxxxx xxxxxxxxxxx xxxxxxxx xxxxxxx na xxxxx xxxxxxxxxxxx látek x xxxxxxxxx,
XXXXXXX XXXX SMĚRNICI:
Xxxxxx 1
Xxxxxxxx 67/548/XXX xx xxxx xxxxx:
1. Xxxxxxx X se xxxx xxxxx:
x) xxxxxxxxxxxx xxxxxxxx v předmluvě xx xxxxxxxxx xxxxxxxxx X v příloze 1X této směrnice;
b) xxxxxxxxxxxx řádky v xxxxxxx X xx xxxxxxxxx řádky v xxxxxxx 1X xxxx xxxxxxxx;
x) xxxxxxxxxxxx xxxxxxx xx nahrazují xxxxxxxxx x xxxxxxx 1X xxxx xxxxxxxx;
x) vkládají xx xxxxxxx x xxxxxxx 1D xxxx xxxxxxxx.
2. Odpovídající xxxx x xxxxxxx XXX xx xxxxxxxxx xxxxxxxxxx xxxxx xxxxxxxxxx xxxxxxxxxxx xxxxxxxxxx v xxxxxxx 2 xxxx xxxxxxxx.
3. Xxxxxxx XX xx xxxx takto:
a) odpovídající xxxxxx x příloze XX se nahrazují xxxxxxxxxxxx pokyny xxx xxxxxxxx zacházení x xxxxxxx 3X xxxx xxxxxxxx;
x) xxxxxxxxxxxx pokyny x xxxxxxx XX xx nahrazují kombinovanými xxxxxxxxxxxx xxxxxx xxx xxxxxxxx zacházení x xxxxxxx 3X xxxx xxxxxxxx.
4. Xxxx X xxxxxxx V xx xxxx takto:
a) kapitola X.10 xx nahrazuje xxxxxx v příloze 4X této xxxxxxxx;
x) xxxxxxxx X.11 xx xxxxxxxxx xxxxxx x xxxxxxx 4B této xxxxxxxx;
x) xxxxxxxx X.12 xx xxxxxxxxx xxxxxx x příloze 4X xxxx xxxxxxxx;
x) kapitoly X.13 x X.14 xx xxxxxxxxx textem x příloze 4X xxxx xxxxxxxx;
x) kapitola X.17 se xxxxxxxxx xxxxxx x xxxxxxx 4X xxxx xxxxxxxx;
x) xxxxxxxx B.23 se xxxxxxxxx textem v xxxxxxx 4F této xxxxxxxx. Xxxxx xxxxxxxx X.23 xx vysvětlivce xx mění odpovídajícím xxxxxxxx;
x) vkládá xx xxxx v xxxxxxx 4X této xxxxxxxx.
5. Xxxxxxx se xxxxxx xxxxxxx xxxxxxxx xxxxx x xxxxx X xxxxxxx X.
6. Odpovídající xxxxx v xxxxxxx XX se xxxxxxxxx xxxxx x xxxxxxx 5 této xxxxxxxx.
7. Xxxxxxx IX se xxxx xxxxxxxx xxxxxxxx x příloze 6 xxxx xxxxxxxx.
Xxxxxx 2
1. Xxxxxxx xxxxx uvedou x xxxxxxxx xxxxxx a xxxxxxx předpisy xxxxxxxx xxx xxxxxxxx xxxxxxx x xxxxx xxxxxxxx xxxxxxxxxx xx 1. xxxxxx 2001. Xxxxxxxxxx x nich xxxxxxx Xxxxxx.
Xxxx xxxxxxxx xxxxxxx xxxxxxxxx xxxxx xxxx xxxxxxxxx xxxxx na xxxx směrnici xxxx xxxx xxxxxx xxxxx xxx učiněn xxx xxxxxx xxxxxxx vyhlášení. Xxxxxx xxxxxx xx xxxxxxx xxxxxxx státy.
2. Xxxxxxx státy xxxxx Xxxxxx xxxxx xxxxxxxx xxxxxxxxxx vnitrostátních xxxxxxxx xxxxxxxx, xxxxx xxxxxxx x xxxxxxx xxxxxxxxxx xxxx xxxxxxxx, a xxxxxxxxxx tabulku xxxx xxxxxxxx x přijatými xxxxxxxxxxxxxx xxxxxxxxxxxx.
Xxxxxx 3
Tato směrnice xxxxxxxx x xxxxxxxx xxxxxx xxxx po xxxxxxxxx x Xxxxxxx xxxxxxxx Xxxxxxxxxx xxxxxxxxxxxx.
Xxxxxx 4
Xxxx směrnice xx xxxxxx členským xxxxxx.
V Bruselu dne 19. xxxxxx 2000.
Xx Xxxxxx
Xxxxxx Wallström
členka Komise
[1] Xxxxxxx po xxxxxxxxxxxx xx xxxxxxx xxxxx.
[2] Úř. xxxx. 196, 16.8.1967, x. 1.
[3] Xx. xxxx. X 199, 30.7.1999, x. 57.
PŘÍLOHA 1X
XXXXXXXXX X XXXXXXX I
Vysvětlení poznámek xxxxxxxxxx xx xxxxxxxxxxxx, xxxxxxxxxxx a xxxxxxxxxx xxxxx
(Xxxxxx se xxxxxxx xxxxx)
XXXXXXX 1X
"XXXXXXX X
|
X |
Xxxxxx |
XX |
XX |
XX |
XX |
XX |
XX |
XX |
XX |
XX |
XX |
XX |
|
18 |
Xx |
Xxxxx |
Xxxxx |
Xxxxx |
Αργό |
Xxxxx |
Xxxxx |
Xxxxx |
Xxxxx |
Xxxxx |
Xxxxx |
Xxxxx |
|
64 |
Xx |
Xxxxxxxxx |
Xxxxxxxxxx |
Xxxxxxxxxx |
Γαδολίνιο |
Xxxxxxxxxx |
Xxxxxxxxxx |
Xxxxxxxxxx |
Xxxxxxxxx |
Xxxxxxxxxx |
Xxxxxxxxx |
Xxxxxxxxxx" |
XXXXXXX 1X
|
Xxxxxxxx číslo |
Chemický xxxxx |
Xxxxxxxx k xxxxxx |
Xxxxx XX |
Xxxxx XXX |
Xxxxxxxxxxx |
Xxxxxxxx |
Xxxxxxxxxxxx xxxxxx |
Xxxxxxxx x xxxxxxxxxx |
|
006–011–00–7 |
xxxxxxxx (ISO) 1-xxxxxx-X-xxxxxxxxxxxxxx |
200–555–0 |
63–25–2 |
Xxxx. xxx. 3; X40 Xx; R22 X; X50 |
Xx; X X: 22–40–50 S: (2-)22–24–36/37–46–61 |
|||
|
006–013–00–8 |
xxxxxx-xxxxxxx (XXX) xxxxxxx-X-xxxxxxxxxxxxxxxxxxxx |
205–293–0 |
137–42–8 |
Xx; X22 X31 C; X34 R43 X; X50–53 |
X; X R: 22–31–34–43–50/53 X: (1/2-)26–36/37/39–45–60–61 |
|||
|
006–015–00–9 |
xxxxxx (XXX) 3-(3,4-dichlorfenyl)-1,1-dimethylmočovina |
206–354–4 |
330–54–1 |
Karc. xxx. 3; X40 Muta. xxx. 3; X40 Xx; X22–48/22 X; X50–53 |
Xx; X R: 22–40–48/22–50/53 S: (2-)13–22–23–37–46–60–61 |
|||
|
006–016–00–4 |
xxxxxxxx (XXX) 2- isopropoxyfenyl-N-methylkarbamát |
204–043–8 |
114–26–1 |
T; X25 X; X50–53 |
X; X R: 25–50/53 X: (1/2-)37–45–60–61 |
|||
|
006–017–00-X |
aldikarb (ISO) 2-xxxxxx-2-(xxxxxxxxxxxxxx)xxxxxxxx-X-(X-xxxxxxxxxxxxxxx)xxxx |
204–123–2 |
116–06–3 |
X+; X26/28 X; X24 N; X50–53 |
X+; X X: 24–26/28–50/53 X: (1/2-)22–36/37–45–60–61 |
|||
|
006–018–00–5 |
xxxxxxxxx (XXX) 4-(xxxxxxxxxxxxx)-3-xxxxxxxxxxx-X-xxxxxxxxxxxxxx |
217–990–7 |
2032–59–9 |
X; X24/25 N; X50–53 |
X; X X: 24/25–50/53 X: (1/2-)28–36/37–45–60–61 |
|||
|
006–019–00–0 |
di-allát (XXX) X-(2,3-xxxxxxxxxxxx)-X,X-xxxxxxxxxxxxxxxxxxxxxxx |
218–961–1 |
2303–16–4 |
Xxxx. kat. 3; R40 Xx; X22 X; X50–53 |
Xx; X X: 22–40–50/53 X: (2-)25–36/37–60–61 |
|||
|
006–020–00–6 |
xxxxxx (ISO) 4-xxxxxxxx-2-xx-1-xx-X -(3-xxxxxxxxxx)xxxxxxxx |
202–930–4 |
101–27–9 |
Xx; X22 X43 X; X50–53 |
Xx; X X: 22–43–50/53 X: (2-)24–36/37–60–61 |
|||
|
006–023–00–2 |
xxxxxxxxxxxxxxxx (XXX) xxxxxxxxxx 3,5-dimethyl-4-(methylsulfanyl)fenyl-N -xxxxxxxxxxxxxx |
217–991–2 |
2032–65–7 |
X; X25 X; X50–53 |
X; X R: 25–50/53 X: (1/2-)22–37–45–60–61 |
|||
|
006–024–00–8 |
xxxxxx-xxxxxxx (XXX) xxxxxxx-X-xxxxxxxxx-xxxxxxxxxxxxxx |
205–443–5 |
140–93–2 |
Xx; X22 Xx; X38 X; X51–53 |
Xx; X X: 22–38–51/53 X: (2-)13-61 |
|||
|
006–026–00–9 |
karbofuran (XXX) 2,2-xxxxxxxx-2,3-xxxxxxx-1-xxxxxxxxxx-7-xx-X-xxxxxxxxxxxxxx |
216–353–0 |
1563–66–2 |
X+; R26/28 X; X50–53 |
X+; X R: 26/28–50/53 X: (1/2-)36/37–45–60–61 |
|||
|
006–028–00-X |
dinobuton (XXX) 2-(1-xxxxxxxxxxxx)-4,6-xxxxxxxxxxxx-xxxxxxxxx-xxxxxxxx 2-xxx-xxxxx-4,6-xxxxxxxxxxxx-xxxxxxxxx-xxxxxxxx |
213–546–1 |
973–21–7 |
X; X25 X; R50–53 |
T; X R: 25–50/53 X: (1/2-)37–45–60–61 |
|||
|
006–029–00–5 |
xxxxxxxxx (ISO) 2-(1,3-xxxxxxxx-2-xx)xxxxx-X-xxxxxxxxxxxxxx |
230–253–4 |
6988–21–2 |
X; X25 X; X51–53 |
X; X X: 25–51/53 S: (1/2-)37–45–61 |
|||
|
006–033–00–7 |
xxxxxxxxx (XXX) 3-(3-chlor-4-methoxyfenyl)-1,1-dimethylmočovina |
243–433–2 |
19937–59–8 |
N; X50–53 |
X X: 5 0/ 5 3 S: 60-61 |
|||
|
006–034–00–2 |
xxxxxxx (XXX) X-xxxxxx-X-xxxxx-X-xxxxxxxxxxxxxxxxx |
214–215–4 |
1114–71–2 |
Xx; X22 X; X51–53 |
Xx; X X: 22–51/53 X: (2-)23-61 |
|||
|
006–035–00–8 |
xxxxxxxxxx (XXX) 2-(xxxxxxxxxxxxx)- 5,6-dimethyl pyrimidin-4-yl-N,N-dimethylkarbamát |
245–430–1 |
23103–98–2 |
T; X25 X; X50–53 |
X; X R: 25–50/53 X: (1/2)22–37–45–60–61 |
|||
|
006–037–00–9 |
promekarb (ISO) 3-xxxxxxxxx-5-xxxxxxxxxxx-X-xxxxxxxxxxxxxx |
220–113–0 |
2631–37–0 |
X; X25 X; X50–53 |
X; N X: 25–50/53 X: (1/2-)24–37–45–60–61 |
|||
|
006–038–00–4 |
xxxxxxxxx (XXX) 2-chlorallyl-N,N-dimethyldithiokarbamát |
E |
202–388–9 |
95–06–7 |
Karc. xxx. 2; X45 Xx; X22 X; R50–53 |
T; X R: 45–22–50/53 X: 53–45–60–61 |
||
|
006–039–00-X |
xxx-xxxxx (ISO) X-(2,3,3-xxxxxxxxxxxxx)-X,X-xxxxxxxxxxxxxxxxxxxxxxx |
218–962–7 |
2303–17–5 |
Xx; X22–48/22 X43 X; X50–53 |
Xx; X X: 22–43–48/22–50/53 S: (2-)24–37–60–61 |
|||
|
006–042–00–6 |
xxxxxxx (ISO) 3-(4-chlorfenyl)-1,1-dimethylmočovina |
205–766–1 |
150–68–5 |
Karc. xxx. 3; X40 Xx; X22 N; X50–53 |
Xx; N R: 22–40–50/53 S: (2-)36/37–60–61 |
|||
|
006–043–00–1 |
xxxxxxx-XXX 3-(4-xxxxxxxxxx)-1,1-xxxxxxxxxxxxxxx-xxxxxxxxxxxxxx |
— |
140–41–0 |
Xx; X36/38 Xxxx. xxx. 3; X40 X; X50–53 |
Xx; X X: 36/38–40–50/53 S: (2-)36/37–60–61 |
|||
|
006–045–00–2 |
xxxxxxxx (XXX) xxxxxx-X-[(X-xxxxxxxxxxxxxxx)xxx]xxxxxxxxxxxxxx |
240–815–0 |
16752–77–5 |
X+; X28 X; X50–53 |
X+; X X: 28–50/53 X: (1/2-)22–36/37–45–60–61 |
|||
|
006–046–00–8 |
xxxxxxxxxx (XXX) 2,2-xxxxxxxx-1,3-xxxxxxxxxxx-4-xx-X-xxxxxxxxxxxxxx |
245–216–8 |
22781–23–3 |
X; X23/25 Xn; X21 X; R50–53 |
T; X R: 21–23/25–50/53 X: (1/2-)22–36/37–45–60–61 |
|||
|
006–047–00–3 |
bufenkarb (XXX) xxxx: 3-(1-xxxxxxxxxxx)xxxxx-X-xxxxxxxxxxxxxxx a 3-(1-xxxxxxxxxxx)xxxxx-X-xxxxxxxxxxxxxxx |
— |
8065–36–9 |
X; X24/25 N; X50–53 |
X; X X: 24/25–50/53 S: (1/2-)28–36/37–45–60–61 |
|||
|
006–048–00–9 |
ethiofenkarb (XXX) 2-[(xxxxxxxxxxxxx)xxxxxx]xxxxx-X-xxxxxxxxxxxxxx |
249–981–9 |
29973–13–5 |
Xx; R22 X; R50–53 |
Xn; N X: 22–50/53 X: (2-)60-61 |
|||
|
006–050–00–X |
xxxxxxx-XXX 3-fenyl-1,1-dimethyluronium-trichloracetát |
— |
4482–55–7 |
Xi; R38 X; X50–53 |
Xx; X X: 38–50/53 X: (2-)60-61 |
|||
|
006–053–00–6 |
xxxxxxxxxx (XXX) 2-isopropylfenyl-N-methylkarbamát |
220–114–6 |
2631–40–5 |
Xn; X22 N; X50–53 |
Xx; X X: 22–50/53 X: (2-)60-61 |
|||
|
006–054–00–1 |
xxxxxxxxxx (XXX) 4-(xxxxxxxxxxxxx)-3,5-xxxxxxxxxxxxx-X-xxxxxxxxxxxxxx |
206–249–3 |
315–18–4 |
X+; X28 Xn; X21 N; R50–53 |
T+; X R: 21–28–50/53 X: (1/2-)36/37–45–60–61 |
|||
|
006–057–00–8 |
xxxxxxxxxx (ISO) 2-xxxxx-6-(xxxxxxxxxxxxxx)xxxxxxx |
217–682–2 |
1929–82–4 |
Xx; R22 X; X51–53 |
Xx; X X: 22–51/53 X: (2-)24-61 |
|||
|
006–060–00–4 |
oxykarboxin (XXX) 2-xxxxxx-4,4-xxxxx-5,6-xxxxxxx-4λ4-1,4-xxxxxxxx-3-xxxxxxxxxxxx |
226–066–2 |
5259–88–1 |
Xx; X22 X52–53 |
Xx X:22–52/53 S: (2-)61 |
|||
|
006–069–00–3 |
xxxxxxxxx-xxxxxx (XXX) 1,2-di[3-(methoxykarbonyl)thioureido]benzen |
245–740–7 |
23564–05–8 |
Muta. xxx. 3; X40 X; X50–53 |
Xx; X X: 40–50/53 S: (2-)36/37–60–61 |
|||
|
006–070–00–9 |
xxxxxxxxxxx N-cyklohexyl-N-methoxy-2,5-dimethyl-3-furamid |
262–302–0 |
60568–05–0 |
Karc. xxx. 3; X40 X; X50–53 |
Xx; N X: 40–50/53 X: (2-)36/37–60–61 |
|||
|
006–088–00–7 |
xxxxxxxxxxx (XXX) xxxxx-X -[({[(2,2-dimethyl-2,3-dihydro-1-benzofuran-7-yl)oxy]karbonyl}methylamino)sulfanyl]-N-isopropyl-β-alaninát(2,2-dimethyl-2,3-dihydro-1-benzofuran-7-yl)-N-({[2-(ethoxykarbonyl)ethyl]isopropylamino}sulfanyl)-N-methylkarbamát |
— |
82560–54–1 |
T; X23/25 X; X50–53 |
X; X R: 23/25–50/53 X: (1/2-)36/37–45–60–61 |
|||
|
007–012–00–5 |
X,X-xxxxxxxxxxxxxxxx 1,1-dimethylhydrazin |
E |
200–316–0 |
57–14–7 |
F; X11 Xxxx. xxx. 2; X45 X; X23/25 X; X34 X; X51–53 |
X; X; X R: 45–11–23/25–34–51/53 X: 53–45–61 |
||
|
007–013–00–0 |
N,N-dimethylhydrazin 1,2-xxxxxxxxxxxxxxxx |
X |
— |
540–73–8 |
Xxxx. xxx. 2; X45 X; R23/24/25 X; X51–53 |
X; X X: 45–23/24/25–51/53 X: 53–45–61 |
X ≥ 25 %: X; R45–23/24/25 3 % < C &xx; 25 %: X; R45–20/21/22 0,01 % < C &xx; 3 %: X; X45 |
|
|
009–003–00–1 |
xxxxxxxx xxxxxxxxxxxxxx … % |
X |
231–634–8 |
7664–39–3 |
X+; R26/27/28 X; R35 |
T+; X X: 26/27/28–35 S: (1/2-)7/9–26–36/37–45 |
X ≥ 7 %: X+; X; X26/27/28–35 1 % ≤ X &xx; 7 %: X; X23/24/25–34 0,1 % ≤ C &xx; 1 %: Xx; X20/21/22–36/37/38 |
|
|
015–039–00–9 |
xxxxxxx-xxxxxx (XXX) X,X-xxxxxxxx-X -[(4(3 H)-oxo-1,2,3-benzotriazin-3-yl)methyl]-fosforodithioát |
201–676–1 |
86–50–0 |
T+; X26/28 X; X24 R43 X; X50–53 |
X+; N X: 24–26/28–43–50/53 S: (1/2-)28–36/37–45–60–61 |
|||
|
015–048–00–8 |
xxxxxxxx (XXX) O,O-dimethyl-O-[3-methyl-4-(methylsulfanyl)fenyl]-fosforothioát |
200–231–9 |
55–38–9 |
Muta. xxx. 3; X40 X; X23–48/25 Xn; X21/22 N; R50–53 |
T; X X: 21/22–23–40–48/25–50/53 X: (1/2-)36/37–45–60–61 |
|||
|
015–056–00–1 |
xxxxxxx-xxxxx (XXX) X,X-xxxxxxx-X-[(4(3 X)-xxx-1,2,3-xxxxxxxxxxxx-3-xx)xxxxxx]-xxxxxxxxxxxxxxx |
220–147–6 |
2642–71–9 |
X+; X28 X; R24 N; X50–53 |
X+; X R: 24–28–50/53 X: (1/2-)28–36/37–45–60–61 |
|||
|
015–140–00–8 |
xxxxxxxxx (XXX) X,X-xxxxxxx-X-(1-xxxxx-1 X- 1,2,4-xxxxxxx-3-xx)-xxxxxxxxxxxxx |
245–986–5 |
24017–47–8 |
X; X23/25 Xn; X21 N; X50–53 |
X; X X: 21–23/25–50/53 X: (1/2-)36/37–45–60–61 |
|||
|
016–013–00-X |
xxxxxxx xxxxxxx |
234–129–0 |
10545–99–0 |
X14 X; X34 X; X50 |
X; N X: 14–34–50 X: (1/2-)26–36/37/39–45–61 |
C ≥ 10 %: X; X34 5 % ≤ X &xx; 10 %: Xx; R36/37/38 |
||
|
016–014–00–5 |
chlorid xxxxxxxx |
— |
13451–08–6 |
X14 X; R34 X; X50 |
X; N X: 14–34–50 X: (1/2-)26–36/37/39–45–61 |
C ≥ 10 %: X; R34 5 % ≤ C &xx; 10 %: Xx; X36/37/38 |
||
|
016–023–00–4 |
xxxxxxxx-xxxxxx |
X |
201–058–1 |
77–78–1 |
Xxxx. xxx. 2; X45 Xxxx. xxx. 3; X40 X+; X26 X; X25 X; R34 X43 |
X+ R: 45–25–26–34–43 X: 53-4 5 |
X ≥ 25 %: X+; X45–25–26–34–43 10 % ≤ C &xx; 25 %: X+; R45–22–26–34–43 7 % ≤ X &xx; 10 %: X+; R45–22–26–36/ 37/38–43 5 % ≤ X &xx; 7 %: T; X45–22–23–36/37/38–43 3 % ≤ X < 5 %: X; X45–22–23–43 1 % ≤ X &xx; 3 %: X; R45–23–43 0,1 % ≤ X < 1 %: X; X45–20 0,01 % ≤ X < 0,1 %:X; X45 |
|
|
016–024–00-X |
xxxxxxxx (ISO) xxx(xxxxxxxxxxxxxxxxxxx)xxxxxxxx |
X,X′-xxxxxxxx-xxxxxxxxxxx(xxxxxxxxxxx)215–993–8 |
1468–37–7 |
Xx; X22 X; X50–53 |
Xx; N R: 22–50/53 X: (2-)60-61 |
|||
|
016–071–00–6 |
3-xxxxx-6,13-xxxxxxx-10-[(3-{[4-xxxxx-6-(2-xxxxxxxxxxxxxxxx)- 1,3,5-xxxxxxx-2-xx]xxxxx}xxxxxx)xxxxx][1,4]xxxxxxxxxxx[2,3-x]xxxxxxxxx-4,11-xxxxxxxxxx xxxxxxxx |
410–130–3 |
136248–03–8 |
X43 |
Xx R: 43 X: (2-)22–24–37 |
|||
|
022–001–00–5 |
chlorid xxxxxxxxxx |
231–441–9 |
7550–45–0 |
X14 X; R34 |
C X: 14-34 X: (1/2-)7/8–26–36/37/39–45 |
X ≥ 10 %: C; X34 5 % ≤ X &xx; 10 %: Xx; X36/37/38 |
||
|
030–004–00–8 |
xxxxxxxxxxxxx [1] xxxxxxxxxxxx [2] |
208–884–1 [1] 209–161–3 [2] |
544–97–8 [1] 557–20–0 [2] |
X14 X; X17 X; X34 X; X50–53 |
X; X; X R: 14–17–34–50/53 X: (1/2-)16–43–45–60–61 |
|||
|
050–002–00–0 |
cyhexatin (XXX) tricyklohexyl(hydroxy)stannan tricyklohexylstannium-hydroxid |
236–049–1 |
13121–70–5 |
Xn; X20/21/22 N; X50–53 |
Xx; X X: 20/21/22–50/53 X: (2-)13–60–61 |
|||
|
050–012–00–5 |
xxxxxxxxxxxxxxxxxxxxxx [1] xxxxx(xxxxxxxxxxxxx)xxxxxxx [2] butyl(tricyklohexyl)stannan [3] |
215–910–5 [1] 221–437–5 [2] 230–358–5 [3] |
1449–55–4 [1] 3091–32–5 [2] 7067–44–9 [3] |
Xx; X20/21/22 X; R50–53 |
Xn; X X: 20/21/22–50/53 X: (2-)26–28–60–61 |
X ≥ 1 %: Xn; R20/21/22 |
1 |
|
|
050–017–00–2 |
fenbutatinoxid (XXX) 1,1,1,3,3,3-hexakis(2-fenyl-2-methylpropyl)distannoxan |
236–407–7 |
13356–08–6 |
T+; R26 Xx; X36/38 X; X50/53 |
X+; X X: 26–36/38–50/53 S: (1/2-)28–36/37–45–60–61 |
|||
|
082–009–00–X |
xxxx (xxxxxxxxxxxx xxxxxxxx) XX Xxxxxxx Xxxxxx 34 (XX 77603) XX xxxxxxxxxx xxxx 34 (XX 77603) |
215–693–7 |
1344–37–2 |
Xxxx. xxx. 3; X40 Repr. xxx. 1; R61 Xxxx. xxx. 3; X62 X33 X; X50–53 |
X; N X: 61–33–40–50/53–62 S: 53–45–60–61 |
1 |
||
|
082–010–00–5 |
xxxxxx (xxxxxxx-xxxxxxxxxx-xxxxx xxxxxxxx) CI Xxxxxxx Red 104 (XX 77605) CI xxxxxxxxxx červeň 104 (XX 77605) |
235–759–9 |
12656–85–8 |
Karc. kat. 3; R40 Xxxx. xxx. 1; X61 Xxxx. xxx. 3; X62 R33 X; X50–53 |
X; X X: 61–33–40–50/53–62 X: 53–45–60–61 |
1 |
||
|
601–024–00-X |
xxxxx [1] xxxxxxxxxxxx [2] |
202–704–5 [1] 203–132–9 [2] |
98–82–8 [1] 103–65–1 [2] |
X10 Xx; R65 Xx; X37 X; X51–53 |
Xx; X X: 10–37–51/53–65 X: (2-)24–37–61–62 |
4 |
||
|
601–032–00–3 |
xxxxx[x]xxxxx benzo[def]chrysen |
200–028–5 |
50–32–8 |
Karc. xxx.2; R45 Xxxx. xxx. 2; R46 Xxxx. xxx. 2; X60–61 X; R50–53 |
T; X R: 45–46–60–61–50/53 X: 53–45–60–61 |
|||
|
601–034–00–4 |
benzo[e]acefenanthrylen |
205–911–9 |
205–99–2 |
Karc. kat.2; X45 N; X50–53 |
X; X X: 45–50/53 X: 53–45–60–61 |
|||
|
602–035–00–2 |
1,4-dichlorbenzen x-xxxxxxxxxxxxx |
203–400–5 |
106–46–7 |
Xx; X36 N; X50–53 |
Xx; X X: 36–50/53 X: (2-)24/25–46–60–61 |
|||
|
602–054–00–6 |
3-xxxxxxx-1-xx xxxxxxxxxx |
209–130–4 |
556–56–9 |
X10 X; X34 |
X X: 10-34 X: (1/2-)7–26–45 |
|||
|
603–076–00–9 |
xxx-2-xx-1,4-xxxx |
203–788–6 |
110–65–6 |
X; X23/25 Xn; X21–48/22 X; X34 |
X X: 21–23/25–34–48/22 S: (1/2-)26–36/37/39–45 |
C ≥ 50 %: X; X21–23/25–34–48/22 25 % ≤ C &xx; 50 %: X; R21–23/25–36/38–48/22 10 % ≤ C &xx; 25 %: Xx; R20/22–48/22 3 % ≤ X &xx; 10 %: Xx; X20/22 |
||
|
603–091–00–0 |
xxx-4-xxxxxxxxx-1-xxxxxx-7-xxxxxxxxxx[2.2.1]xxxxxx-2-xx |
402–470–6 |
87172–89–2 |
X; R8 Xx; X22 Xi; X36 |
X; Xx X: 8–22–36 X: (2-)26 |
|||
|
603–093–00–1 |
xxx-(±)-4-xxxxxxxxx-1-xxxxxx-2-[(2-xxxxxxxxxxxx)xxx]-7-xxxxxxxxxx[2.2.1]xxxxxx |
402–410–9 |
87818–31–3 |
Xx; X20 N; X51–53 |
Xx; X X: 20–51/53 X: (2-)23-61 |
|||
|
603–097–00–3 |
1,1', 1′′-nitrilotripropan-2-ol xxxxxxxxxxxxxxxxxx |
204–528–4 |
122–20–3 |
Xx; X36 X52–53 |
Xx X:36–52/53 S: (2-)26-61 |
|||
|
603–117–00–0 |
propan-2-ol xxxxxxxxxxxxxxxx xxxxxxxxxxx |
200–661–7 |
67–63–0 |
X; X11 Xx; R36 X67 |
X; Xx R: 11–36–67 X: (2-)7–16–24/25–26 |
|||
|
604–020–00–6 |
bifenyl-2-ol 2-xxxxxxxxxxxxxx 2-xxxxxxxxxx (XXX) |
201–993–5 |
90–43–7 |
Xx; R36/37/38 X; X50 |
Xx; X X: 36/37/38–50 S: (2-)22-61 |
|||
|
604–021–00–1 |
2-xxxxxxxxxx, xxxxx sůl xxxxxxx-2-xxxxxxxxxxxx 2-xxxxxxxxx xxxxx xxxxxxx-xxxxxxx-2-xxxx |
205–055–6 |
132–27–4 |
Xx; X22 Xi; X37/38–41 N; X50 |
Xx; X R: 37/38–41–50 X: (2-)22–26–61 |
|||
|
604–024–00–8 |
4,4'-(4-methylpentan-2,2-diyl)difenol 2,2-bis(4-hydroxyfenyl)-4-methylpentan |
401–720–1 |
6807–17–6 |
Repr. xxx. 2; R60 Xx; X36 X; X50–53 |
X; X R: 60–36–50/53 S: 53–45–60–61 |
|||
|
604–041–00–0 |
acifluorfen [1] xxxxxxxxxxx-xxxxxxx [2] 5-[2-xxxxx-4-(xxxxxxxxxxxxxx)xxxxxx]-2-xxxxxxxxxxxxx xxxxxxxx [1] xxxxxxx-5-[2-xxxxx-4-(xxxxxxxxxxxxxx)xxxxxx]-2-xxxxxxxxxxxx [2] |
256–634–5 [1] 263–560–7 [2] |
50594–66–6 [1] 62476–59–9 [2] |
Xx; X22 Xx; R38–41 N; X50–53 |
Xx; X X: 22–38–41–50/53 X: (2-)24–39–60–61 |
|||
|
604–043–00–1 |
xxxxxxxxxxxxxxxx (4-xxxxxxxxxxxx)xxxxx xxxxxxxxxxxxxxxxxxxxxxxxxx 4-(benzyloxy)fenol |
203–083–3 |
103–16–2 |
Xi; X36 R43 |
Xi X: 36-43 X: (2-)24/25–26–37 |
|||
|
604–044–00–7 |
xxxxxxxx 4-xxxxxxxxxxxx xxxxxxxxxxxxxxxxxxxxxxxxxx |
205–769–8 |
150–76–5 |
Xx; X22 Xx; X36 X43 |
Xx X: 22–36–43 S: (2-)24/25–26–37/39–46 |
|||
|
605–016–00–7 |
xxxxxxx… % xxxxxxxxx… % |
X |
203–474–9 |
107–22–2 |
Xxxx. xxx. 3; X40 Xx; X20 Xx; X36/38 X43 |
Xx X: 20–36/38–40–43 S: (2-)36/37 |
X ≥ 10 %: Xn; X20–36/38–40–43 1 % ≤ X &xx; 10 %: Xn; X40–43 |
|
|
606–016–00-X |
xxxxxx (XXX) 2-(trimethylacetyl)indan-1,3-dion |
201–462–8 |
83–26–1 |
T; X25–48/25 X; R50–53 |
T; N X: 25–48/25–50/53 X: (1/2-)37–45–60–61 |
|||
|
606–018–00–0 |
xxxxxxx (ISO) 2,3-dichlor-1,4-naftochinon |
204–210–5 |
117–80–6 |
Xn; X22 Xx; X36/38 X; R50–53 |
Xn; N X: 22–36/38–50/53 X: (2-)26–60–61 |
|||
|
606–019–00–6 |
xxxxxxxxxx (ISO) perchlorpentacyklo[5.3.0.02,6.03,9.04,8]dekan-5-on xxxxxxxxxxxxxxxxxxx[5.2.1.02,6.03,9.05,8]xxxxx-4-xx 1,2,4,5,6,7,8,8,9,10-xxxxxxxxxxxxxxxxxxx[5.3.0.02,6.04,10.05,9]xxxxx-3-xx |
205–601–3 |
143–50–0 |
Xxxx. kat. 3; X40 T; X24/25 N; X50–53 |
X; X R: 24/25–40–50/53 X: (1/2-)22–36/37–45–60–61 |
|||
|
606–034–00–8 |
metribuzin (XXX) 4-xxxxx-6-xxxx-xxxxx-3-(xxxxxxxxxxxxxx)-1,2,4-xxxxxxx-5(4 X)-xx 4-amino-6-terc-butyl-3-(methylsulfanyl)-4,5-dihydro-1,2,4-triazin-5-on |
244–209–7 |
21087–64–9 |
Xn; X22 X; X50–53 |
Xx; X R: 22–50/53 X: (2-)60-61 |
|||
|
606–035–00–3 |
chloridazon (XXX) 5-xxxxx-4-xxxxx-2-xxxxxxxxxxxxxx-3(2X)-xx xxxxxxx |
216–920–2 |
1698–60–8 |
X43 X; X50–53 |
Xx; X R: 43–50/53 S: (2-)24–37–60–61 |
|||
|
606–036–00–9 |
chinomethionát (XXX) 6-methyl-2 X-[1,3]xxxxxxxx[4,5-x]xxxxxxxxxx-2-xx |
219–455–3 |
2439–01–2 |
Xxxx. xxx. 3; X62 Xx; X20/21/22–48/22 Xx; X36 X43 X; X50–53 |
Xx; X X: 20/21/22–36–43–48/22–50/53–62 S: (2-)24–37–60–61 |
|||
|
606–037–00–4 |
xxxxxxxxxxx (XXX) 1-(4-xxxxxxxxxxx)- 3,3-xxxxxxxx-1-(1,2,4-xxxxxxx-1-xx)xxxxx-2-xx |
256–103–8 |
43121–43–3 |
Xx; X22 X; R51–53 |
Xn; X R: 22–51/53 X: (2-)61 |
|||
|
606–044–00–2 |
2,4,6-xxxxxxxxxxxxxxxxxxx xxxxx(2,4,6-xxxxxxxxxxxxxx)xxxxxxxx |
403–150–9 |
954–16–5 |
Xx; X22 Xx; R36 X; X50–53 |
Xx; X X: 22–36–50/53 S: (2-)26–60–61 |
|||
|
607–043–00-X |
xxxxxxx (XXX) 3,6-xxxxxxx-2-xxxxxxxxxxxxxxx xxxxxxxx |
217–635–6 |
1918–00–9 |
Xx; R22 Xx; X41 X52–53 |
Xx; X X: 22–41–52/53 X: (2-)26-61 |
|||
|
607–057–00–6 |
xxxxxxxxx (ISO) 3-[1-(4-chlorfenyl)-3-oxobutyl]-4-hydroxykumarin3-[1-(4-chlorfenyl)-3-oxobutyl]-4-hydroxy-2 X-xxxxxxx-2-xx |
201–378–1 |
81–82–3 |
Xx; X48/22 X52–53 |
Xx X:48/22–52/53 X: (2-)37-61 |
|||
|
607–058–00–1 |
kumafuryl (XXX) xxxxxxx (XX)-3-[1-(2-xxxxx)-3-xxxxxxxx)]-4-xxxxxxxxxxxxxx (XX)-3-[1-(2-xxxxx)-3-xxxxxxxx)]-4-xxxxxxx-2 X -chromen-2-on 3-[1-(2-xxxxx)-3-xxxxxxxx]-4-xxxxxxxxxxxxxx 3-[1-(2-xxxxx)-3-xxxxxxxx]-4-xxxxxxx-2 H -xxxxxxx-2-xx |
204–195–5 |
117–52–2 |
X; R25–48/25 X52–53 |
X X:25–48/25–52/53 X: (1/2-)37–45–61 |
|||
|
607–079–00–6 |
xxxxxxx (XXX) xxxxx-4-xxx-5-(xxxxxxxx-5-xxxxxxxxxxxxxxxxx[5.3.0.02,6.03,9.04,8]xxxxx-5-xx)xxxxxxxxx xxxxx-5-(1,2,3,5,6,7,8,9,10,10-xxxxxxxxx-4-xxxxxxxxxxxxxxxxx[5.2.1.02,6.03,9.05,8]xxxxx-4-xx)-4-xxxxxxxxxxxx xxxxx-5-(1,2,4,5,6,7,8,8,9,10-xxxxxxxxx-3-xxxxxxxxxxxxxxxxx[5.3.0.02,6.04,10.05,9]xxxxx-3-xx)-4-xxxxxxxxxxxx |
— |
4234–79–1 |
X; X24 Xn; X22 N; X51–53 |
X; X X: 22–24–51/53 X: (1/2-)36/37–45–61 |
|||
|
607–097–00–4 |
benzen-1,2,4-trikarbox-1,2-anhydrid 1,2-xxxxxxxx xxxxxx-1,2,4-xxxxxxxxxxxxxx xxxxxxxx xxxxxxxxxxxxxxxxx |
209–008–0 |
552–30–7 |
Xx; X37–41 X42/43 |
Xx X: 37–41–42/43 X: (2-)22–26–36/37/39 |
|||
|
607–143–00–3 |
pentanová xxxxxxxx xxxxxxxx kyselina |
203–677–2 |
109–52–4 |
C; X34 X52–53 |
X X:34–52/53 X: (1/2-)26–36–45–61 |
|||
|
607–152–00–2 |
2,3,6-XXX (ISO) 2,3,6-xxxxxxxxxxxxxxxx xxxxxxxx |
200–026–4 |
50–31–7 |
Xx; R22 X; R51–53 |
Xn; X X: 22–51/53 S: (2-)61 |
|||
|
607–153–00–8 |
xxxxxxxxx (XXX) (4-chlor-2-oxo-2,3-dihydro-1,3-benzothiazol-3-yl)octová xxxxxxxx |
223–297–0 |
3813–05–6 |
Xx; R36/38 X52–53 |
Xx X:36/38–52/53 X: (2-)22-61 |
|||
|
607–156–00–4 |
chlorfenson (XXX) 4-xxxxxxxxxx-4-xxxxxxxxxxx-1-xxxxxxxx |
201–270–4 |
80–33–1 |
Xx; X22 Xx; X38 X; X50–53 |
Xx; X X: 22–38–50/53 S: (2-)37–60–61 |
|||
|
607–158–00–5 |
xxxxx xxx xxxxxxxxxxx xxxxxxxx xxxxxxxxxx sodný |
223–498–3 |
3926–62–3 |
T; X25 Xx; R38 X; X50 |
X; X R: 25–38–50 S: (1/2-)22–37–45–61 |
|||
|
607–159–00–0 |
chlorobenzilát (XXX) xxxxx-2,2-xxx(4-xxxxxxxxxx)-2-xxxxxxxxxxxxx xxxxx-4,4'-xxxxxxxxxxxxxxx |
208–110–2 |
510–15–6 |
Xx; X22 X; X50–53 |
Xx; X R: 22–50/53 X: (2-)60-61 |
|||
|
607–176–00–3 |
Xxxx: α-{3-[3-(2 X-xxxxxxxxxxxx-2-xx)-5-xxxx-xxxxx-4-xxxxxxxxxxxx]xxxxxxxxx}-ω-xxxxxxxxxxx(xxxxxxxxxx);α-{3-[3-(2 X-xxxxxxxxxxxx-2-xx)-5-xxxx-xxxxx-4-xxxxxxxxxxxx]xxxxxxxxx}-ω-({3-[3-(2 X-xxxxxxxxxxxx-2-xx)-5-xxxx-xxxxx-4-xxxxxxxxxxxx]xxxxxxxxx}xxx)xxxx(xxxxxxxxxx) |
400–830–7 |
— |
X43 X; X51–53 |
Xx; X X: 43–51/53 X: (2-)36/37–61 |
|||
|
607–188–00–9 |
xxxxxxx-xxxxxxxx-X-(2-xxxxxxxxxxxx)-X-(xxxxxxx-9-xx-1-xx)xxxxxxxxxx |
402–970–4 |
— |
X43 N; R51–53 |
Xi; X X: 43–51/53 X: (2-)24/37–61 |
|||
|
607–209–00–1 |
Xxxx: X,X′-xxxxxxxxxxx-xxxxxxxxxxxx(xxxxxxxxxxx); X,X′-xxxxxxxxxxx-xxxxxxxxxxxxxx(xxxxxxxxxxx); O,O′-diisopropyl-pentasulfanbis(karbothioát) |
403–030–6 |
— |
Xn; X22 X43 X; R50–53 |
Xn; X X: 22–43–50/ 53 X: (2-)36/37–60–61 |
|||
|
607–213–00–3 |
xxxxx-3,3-xxx(xxxx-xxxxxxxxxxxx)xxxxxxxx |
403–320–2 |
67567–23–1 |
X; X2 X; R7 X10 X; X51–53 |
X; X X: 2–7–10–51/53 X: (2-)3/7–14–33–36/37/39–61 |
|||
|
607–217–00–5 |
2-xxxxxxxxxxx-[4-(7-xxxxx-2,6-xxxxx-2,6-xxxxxxx-1,5-xxxxx-x-xxxxxxx-3-xx)xxxxxx]xxxxxx |
403–960–2 |
— |
X43 X53 |
Xx X: 43-53 X: (2-)24–37–61 |
|||
|
607–243–00–7 |
xxxxxxx-3,6-xxxxxxx-2-xxxxxxxxxxxxxx [1] xxxxxxx-3,6-xxxxxxx-x-xxxxxx [1] xxx(2-xxxxxxxxxxxx)xxxxxxx-3,6-xxxxxxx-2-xxxxxxxxxxxxxx [2] xxx(2-xxxxxxxxxxxx)xxxxxxx-3,6-xxxxxxxxxxxxx [2] (2-hydroxyethyl)amonium-3,6-dichlor-2-methoxybenzoát [3] (2-xxxxxxxxxxxx)xxxxxxx-3,6-xxxxxxxxxxxxx [3] |
217–846–3 [1] 246–590–5 [2] 258–527–9 [3] |
1982–69–0 [1] 25059–78–3 [2] 53404–28–7 [3] |
X52–53 |
X: 52/53 X: 61 |
|||
|
607–248–00–4 |
Xxxxxxxx-xxxxxxx Xxxxxxx-X-(1-xxxxxx)xxxxxxxx |
205–073–4 |
132–67–2 |
Xx; X22 |
Xx X: 22 X: (2) |
|||
|
607–249–00-X |
(xxxxxxxxxxxxx)xxx[xxx(xxxxxxxxxxxxx)]-xxxxxxxxx xxxxxxxxxxxxxxxxx-xxxxxxxxx XXXXX |
256–032–2 |
42978–66–5 |
Xx; X36/37/38 X43 X; X51–53 |
Xx; X R:36/37/38–43–51/53 X: (2-)24–37–61 |
C ≥ 10 %: Xi; X36/37/38–43 1 % ≤ C &xx; 10 %: Xi; X43 |
||
|
607–252–00–6 |
λ-xxxxxxxxxxx (XXX) Směs (1:1): (S)-[(3-fenoxyfenyl)kyanmethyl]-(1 X)-xxx-3-((X)-2-xxxxx-3,3,3-xxxxxxxxxxxx-1-xx-1-xx)-2,2-xxxxxxxxxxxxxxxxxxx-1-xxxxxxxxxx x(X)-[(3-xxxxxxxxxxx)xxxxxxxxxx]-(1 X)-xxx-3-((X)-2-xxxxx-3,3,3-xxxxxxxxxxxx-1-xx-1-xx)-2,2-xxxxxxxxxxxxxxxxxxx-1-xxxxxxxxxx |
415–130–7 |
91465–08–6 |
X+; X26 X; X25 Xn; X21 N; X50–53 |
X+; X X: 21–25–26–50/53 X: (1/2-)28–36/37/39–38–45–60–61 |
|||
|
607–255–00–2 |
xxxxxxxxxx (ISO) [(4-xxxxx-3,5-xxxxxxx-6-xxxxx-2-xxxxxxx)xxx]xxxxxx xxxxxxxx |
— |
69377–81–7 |
X52–53 |
X: 52/53 X: 61 |
|||
|
608–003–00–4 |
akrylonitril |
D X |
203–466–5 |
107–13–1 |
X; Xxx Karc. xxx. 2; X45 X; X23/24/25 Xi; X37/38–41 X43 X; R51–53 |
F; X; X X: 45–11–23-/24/25–37/38–41–43–51/53 S: 9–16–53–45–61 |
X ≥ 20 %: X; X45–23/24/25–37/38–41–43 10 % ≤ X &xx; 20 %: X; R45–23/24/25–41–43 5 % ≤ X &xx; 10 %: X; X45–23/24/25–36–43 1 % ≤ X &xx; 5 %:X; X45–23/24/25–43 0,2 % ≤ X &xx; 1 %:X; X45–20/21/22 0,1 % ≤ X &xx; 0,2 %: X; R45 |
43 |
|
608–016–00–5 |
2,3,5,6-tetrachlor-1,4-dikyanbenzen xxxxxxxxxxxxxxxxxxxxxxxxx |
401–550–8 |
1897–41–2 |
X43 X; R50–53 |
Xi; X X: 43–50/53 X: (2-)24–37–60–61 |
|||
|
609–030–00–4 |
dinoterb (ISO) 2-xxxx-xxxxx-4,6-xxxxxxxxxxxx |
X |
215–813–8 |
1420–07–1 |
Xxxx. kat. 2; X61 X+; X28 X; R24 X44 X; X50–53 |
X+; X X: 61–24–28–44–50/53 X: 53–45–60–61 |
||
|
609–040–00–9 |
xxxxxxxx (ISO) (2,4-xxxxxxxxxxxx)(4-xxxxxxxxxx)xxxxx |
X |
217–406–0 |
1836–75–5 |
Xxxx. xxx. 2; R45 Xxxx. kat. 2; X61 Xn; R22 X; R50–53 |
T; N X: 45–61–22–50/53 X: 53–45–60–61 |
||
|
609–044–00–0 |
xxxxxxxx (XXX) 1,2,4,5-xxxxxxxxxx-3-xxxxxxxxxxx |
204–178–2 |
117–18–0 |
Xx; X22 X43 X; X50–53 |
Xx; X R: 22–43–50/53 X: (2-)24–37–60–61 |
|||
|
611–008–00–4 |
4-aminoazobenzen 4-(xxxxxxxx)xxxxxx |
200–453–6 |
60–09–3 |
Xxxx. xxx. 2; X45 X; X50–53 |
X; X X: 45–50/53 X: 53–45–60–61 |
|||
|
611–013–00–1 |
4-xxxxxxx-3-{4-[2-xxxxxxx-4-(3-xxxxxxxxxxxxxxxxx)xxxxxxxx]-3-xxxxxxxxxxxxxx}-6-(3-xxxxxxxxxxxxxxxx)xxxxxxxx-2-xxxxxxxx trilithný |
403–650–7 |
117409–78–6 |
E; X2 N; X51–53 |
X; X X: 2–51/53 X: (2-)35-61 |
|||
|
611–031–00-X |
4,4'-[(4-xxxxxxxxxxxxxx-2,5-xxxx-1-xxxxxx)xxxxxxxx]xxxxxxxx-xxxxxxxxxxxx CI Xxxxx Xxx 9 XX xxxxxxx červeň 9 |
209–321–2 |
569–61–9 |
Xxxx. xxx. 2; X45 |
X X: 45 X: 53-45 |
|||
|
612–035–00–4 |
2-xxxxxxxxxxxxx o-anisidin |
E |
201–963–1 |
90–04–0 |
Karc. xxx. 2; X45 Xxxx. kat. 3; X40 X; X23/24/25 |
X X: 45–23/24/25 S: 53-45 |
||
|
612–042–00–2 |
xxxxxxxx bifenyl-4,4'-diamin 4,4'-xxxxxxxxxxxxxx xxxxxxx-4,4'-xxxxxxxxxx |
X |
202–199–1 |
92–87–5 |
Xxxx. xxx. 1; X45 Xx; R22 X; X50–53 |
X; X X: 45–22–50/53 S: 53–45–60–61 |
X ≥ 25 %: X; X45–22 0,01 % ≤ X &xx; 25 %: X; X45 |
|
|
612–051–00–1 |
4,4'-xxxxxxxxxxxxxxxxxxxx xxx(4-xxxxxxxxxx)xxxxxx 4,4'-xxxxxxxxxxxxxxxx |
X |
202–974–4 |
101–77–9 |
Xxxx. xxx. 2; R45 Xxxx. xxx. 3; X40 X; R39/23/24/25Xn; X48/20/21/22 X43 X; X51–53 |
X; X R: 45–39/23/24/25–43–48/20/21/22–51/53 X:53–45–61 |
||
|
612–081–00–5 |
3,3'-xxxxxxxxxxxxxxxx, xxxx x-xxxxxxx, xxxx |
X E |
210–322–5 265–294–7 277–985–0 |
612–82–8 64969–36–4 74753–18–7 |
Xxxx. xxx. 2; R45 Xx; R22 X; X51–53 |
X; N X: 45–22–51/53 X: 53–45–61 |
||
|
612–099–00–3 |
4-xxxxxx-x-xxxxxxxxxxxxx4-xxxxxx-1,3-xxxxxxxxxxxxx4-xxxxxxxxxxxx-1,3-xxxxxx 2,4-xxxxxxxxxxxx |
X |
202–453–1 |
95–80–7 |
Xxxx. kat. 2; X45 X; R25 Xx; R21 Xi; X36 X43 N; X51–53 |
X; X X: 45–21–25–36–43–51/53 X: 53–45–61 |
||
|
612–105–00–4 |
2-(xxxxxxxxx-1-xx)xxxxxxxxx2-(xxxxxxxxx-1-xx)xxxxx-1-xxxx |
205–411–0 |
140–31–8 |
Xx; X21/22 X; R34 X43 X52–53 |
X R: 21/22–34–43–52/53 X: (1/2-)26–36/37/39–45–61 |
|||
|
612–111–00–7 |
2-xxxxxx-x-xxxxxxxxxxxxx2-xxxxxx-1,3-xxxxxxxxxxxxx2-xxxxxxxxxxxx-1,3-xxxxxx 2,6-xxxxxxxxxxxx |
212–513–9 |
823–40–5 |
Xxxx. kat. 3; X40 Xx; X21/22 X43 X; X51–53 |
Xx; X R: 21/22–40–43–51/53 X: (2-)24–36/37–61 |
|||
|
612–125–00–3 |
2-xxxxxx-x-xxxxxxxxxxxxx2-xxxxxx-1,4-xxxxxxxxxxxxx2-xxxxxxxxxxxx-1,4-xxxxxx 2,5-xxxxxxxxxxxx |
202–442–1 |
95–70–5 |
X; X25 Xx; R20/21 X43 X; X51–53 |
X; X X: 20/21–25–43–51/53 X: (1/2-)24–37–45–61 |
|||
|
612–144–00–7 |
xxxxxxxxxxx (ISO) X-(2-xxxxx-6-xxxxxxxxxxx)-X-xxxxx-2,6-xxxxxxx-4-(xxxxxxxxxxxxxx)xxxxxx |
— |
62924–70–3 |
Xx; X36/38 R4 3 X; R50–53 |
Xi; X X: 36/38–43–50/53 X: (2-)36/37–60–61 |
|||
|
612–151–00–5 |
xxxxxxxxxxxxx toluendiamin xxxxxxxxxxxxxxxxxxx methylbenzendiamin |
E |
246–910–3 |
25376–45–8 |
Karc. xxx. 2; R45 T; X25 Xn; X20/21 Xx; X36 X43 X; R51–53 |
T; N X: 45–20/21–25–36–43–51/53 X: 53–45–61 |
||
|
613–018–00–4 |
xxxxxxxxxx (XXX) 1,1'-xxx[(3,5-xxxxxxxxxxxxxxxx-4-xxxxxxxx)xxxxxx]-4,4'-xxxxxxxxx-1,1'-xxxxx |
— |
7411–47–4 |
Xx; X22 Xx; X36/37/38 X52–53 |
Xx R: 22–36/37/38–52/53 X: (2-)22–36–61 |
|||
|
613–031–00–5 |
xxxxxxxxx xxxxxxxxxxxxxxxxxxxx xxxxxxxx xxxxxxxx-1,3,5-xxxxxxxxxxxx 1,3,5-xxxxxxxx-1,3,5-xxxxxxx-2(1X), 4(3X), 6(5H)-trion |
201–782–8 |
87–90–1 |
O; X8 Xx; X22 R31 Xx; X36/37 N; X50–53 |
X; Xx; N X: 8–22–31–36/37–50/53 X: (2-)8–26–41–60–61 |
|||
|
613–038–00–3 |
6-xxxxx-1,3,5-xxxxxxx-2,4-xxxxxxxxxx 6-xxxxx-1,3,5-xxxxxxx-2,4-xxxxxx xxxxxxxxxxxxx |
202–095–6 |
91–76–9 |
Xx; X22 R52–53 |
Xn R:22–52/53 X: (2-)61 |
|||
|
613–042–00–5 |
imazalil (ISO) 1-[2-(xxxxxxxx)-2-(2,4-xxxxxxxxxxxx)xxxxx]- 1 X-xxxxxxxx |
252–615–0 |
35554–44–0 |
Xx; X20/22 N; R41 X; X50–53 |
Xx; N X: 20/22–41–50/53 X: (2-)26–39–60–61 |
|||
|
613–043–00–0 |
xxxxxxxx-xxxxxx (XXX) 1-[2-(xxxxxxxx)-2-(2,4-xxxxxxxxxxxx)xxxxx]- 1X -imidazol-1-ium-hydrogensulfát [1] (±)-1-[2-(xxxxxxxx)-2-(2,4-xxxxxxxxxxxx)xxxxx]-1X-xxxxxxxx-1-xxx-xxxxxxxxxxxxxx |
261–351–5 [1] 281–291–3 [2] |
58594–72–2 [1] 83918–57–4 [2] |
Xx; X20/22 Xx; X41 X; X50–53 |
Xx; X X: 20/22–41–50/53 X: (2-)26–39–60–61 |
|||
|
613–066–00–6 |
xxxxxxxxxx (ISO) 2-(xxxx-xxxxxxxxxx)-4-(xxxxxxxxxx)-6-xxxxxxx-1,3,5-xxxxxxx |
251–637–8 |
33693–04–8 |
Xx; X22 X; X50–53 |
Xx; X X: 22–50/53 X: (2-)60-61 |
|||
|
613–091–00–2 |
morfamkvat-dichlorid [1] morfamkvat-sulfát [2] 1,1'-xxx[(3,5-xxxxxxxxxxxxxxxx-4-xxxxxxxx)xxxxxx]-4,4'-xxxxxxxxx-1,1'-xxxxx-xxxxxxxxx [1] 1,1'-xxx[(3,5-xxxxxxxxxxxxxxxx-4-xxxxxxxx)xxxxxx]-4,4'-xxxxxxxxx-1,1'-xxxx-xxxxxxxx [2] |
225–062–8 [1] |
4636–83–3 [1] 29873–36–7 [2] |
Xx; X22 Xx; X36/37/38 R52–53 |
Xn; X: 22–36/37/38–52/53 X: (2-)22–36–61 |
|||
|
613–098–00–0 |
1-xxxxxxxxxxxxxxx-2-xx 1-oktyl-2-pyrrolidon |
403–700–8 |
2687–94–7 |
C; X34 X; R51–53 |
C; N X: 34–51/53 S: (1/2-)23–26–36/37/39–45–61 |
|||
|
613–130–00–3 |
xxxxxxxxxxx (XXX) (XX)-2-(2,4-xxxxxxxxxxxx)-1-(1X-1,2,4-xxxxxxx-1-xx)xxxxx-2-xx |
— |
79983–71–4 |
X43 X; X51–53 |
Xx; N X: 43–51/53 X: (2-)24–37–61 |
|||
|
613–131–00–9 |
xxxxxxxxxx (XXX) 1,2,5,6-xxxxxxxxxx-4 X-xxxxxxx[3,2,1-xx]xxxxxxxx-4-xx |
— |
57369–32–1 |
Xx; X22 X52–53 |
Xx X:22–52/53 X: (2-)61 |
|||
|
613–134–00–5 |
xxxxxxxxxxxx (XXX) 2-(4-xxxxxxxxxx)-2-[(1 X-1,2,4-xxxxxxx-1-xx)xxxxxx]xxxxxxxxxxx |
— |
88671–89–0 |
Xxxx. xxx. 3; X63 Xx; X22 Xx; X36 X; X51–53 |
Xx; X X: 22–36–51/53–63 X: (2-)36/37–46–61 |
|||
|
613–137–00–1 |
xxxxxxxxxxxxxxxxxx (ISO) 1-(1,3-xxxxxxxxxxxx-2-xx)-1,3-xxxxxxxxxxxxxxxx |
242–505–0 |
18691–97–9 |
X; R50–53 |
N X: 50/53 S: 60-61 |
|||
|
613–139–00–2 |
metsulfuron-methyl xxxxxx-2-{X —[X-(4-xxxxxxx-6-xxxxxx-1,3,5-xxxxxxx-2-xx)xxxxxxxxx]xxxxxxxxx}xxxxxxx |
— |
74223–64–6 |
X; X50–53 |
X X: 50/53 X: 60-61 |
|||
|
614–001–00–4 |
xxxxxxx (XXX) 3-(1-xxxxxxxxxxxxxxxx-2-xx)xxxxxxx |
200–193–3 |
54–11–5 |
X+; X27 T; X25 X; X51–53 |
X+; X X: 25–27–51/53 X: (1/2-)36/37–45–61 |
|||
|
614–006–00–1 |
xxxxxx 2,3-dimethoxystrychnidin-10-on |
206–614–7 |
357–57–3 |
T+; X26/28 X52–53 |
X+ X:26/28–52/53 S: (1/2-)13–45–61 |
|||
|
614–007–00–7 |
xxxxxx-xxxxxx [1] xxxxxx-xxxxxx [2] brucin-(R)-(1-methylheptyl)-hydrogen-ftalát [3] xxxxxx-(X)-(1-xxxxxxxxxxxx)-xxxxxxxx-xxxxxx [4] |
225–432–9 [1] 227–317–9 [2] 269–439–5 [3] 269–710–8 [4] |
4845–99–2 [1] 5786–97–0 [2] 68239–26–9 [3] 68310–42–9 [4] |
X+; X26/28 X52–53 |
X+ X: 26/28–52/53 X: (1/2-)13–45–61 |
|||
|
615–006–00–4 |
2-xxxxxx-x-xxxxxxxxxxxxxxxxxx [1] 2-xxxxxx-1,3-xxxxxxxxxxxxxxxxxx [1] 4-xxxxxx-x-xxxxxxxxxxxxxxxxxx [2] 4-xxxxxx-1,3-xxxxxxxxxxxxxxxxxx [2] m-tolylidendiisokyanát [3] 5-xxxxxx-1,3-xxxxxxxxxxxxxxxxxx [3] xxxxxx-2,6-xxxxxxxxxxx [1] toluen-2,4-diisokyanát [2] xxxxxx-3,5-xxxxxxxxxxx [3] |
X |
202–039–0 [1] 209–544–5 [2] 247–722–4 [3] |
91–08–7 [1] 584–84–9 [2] 26471–62–5 [3] |
Xxxx. xxx. 3; X40 T+; X26 Xx; R36/37/38 R42/43 X52–53 |
X+ X: 26–36/37/38–40–42/43–52/53 X: (1/2-)23–36/37–45–61 |
X320 %: X+; X26–36/37/38–40–42/43 7 % ≤ X &xx; 20 %: X+; X26–40–42/43 1 % ≤ X &xx; 7 %: X; X23–40–42/43 0,1 % ≤ X &xx; 1 %:Xx; X20–42 |
2 |
|
616–010–00–9 |
xxxxxxx-xxxxxxxxxxxxxx X-xxxxx-4-xxxxxxxxxxxx-1-xxxxxxxxxx, sodná xxx |
204–854–7 |
127–65–1 |
Xx; X22 X31 X; R34 X42 |
X X: 22–31–34–42 S: (1/2-)7–22–26–36/37/39–45 |
|||
|
616–034–00-X |
xxxxxxxxxxxx (XXX) 6-xxxxxx-3,4-xxxxxxx-2X-xxxxx-5-xxxxxxxxxxxx |
246–419–4 |
24691–76–7 |
X52–53 |
X: 52/53 X: 61 |
|||
|
616–035–00–5 |
xxxxxxxxx X -[(xxxxxxxxxx)xxxxxxxx]-2-xxxx-2-(xxxxxxxxxxxx)xxxxxxxx 1-ethyl-3-[2-kyan-2-(methoxyimino)acetyl]močovina |
261–043–0 |
57966–95–7 |
Xn; X22 X43 X; X50–53 |
Xx; X X: 22–43–50/53 X: (2-)36/37–60–61 |
|||
|
617–004–00–9 |
(1,2,3,4-xxxxxxxxxx-1-xxxxxx)xxxxxxxxxxxx xxxxxxxxxxxxxxxxxxxx |
212–230–0 |
771–29–9 |
X; R7 Xx; X22 X; X34 X; R50–53 |
O; X; X X: 7–22–34–50/53 X:(1/2-)3/7–14–26–36/37/39–45–60–61 |
X325 %: X; X22–34 10 % ≤ C &xx; 25 %: X; X34 5 % ≤ X < 10 %: Xi; X36/37/38 |
||
|
617–006–00-X |
xxx(α, α-dimethylbenzyl)peroxid xxx(2-xxxxxxxxxxx-2-xx)xxxxxxx xxx(1-xxxxx-1-xxxxxxxxxxx)xxxxxxx dikumylperoxid |
201–279–3 |
80–43–3 |
O; R7 Xx; R36/38 X; X51–53 |
X; Xx; N X: 7–36/38–51/53 S: (2-)3/7–14–36/37/39–61 |
|||
|
617–008–00–0 |
xxxxxxxxxxxxxxxx |
202–327–6 |
94–36–0 |
X; X2 Xi; X36 X43 |
X; Xx; X: 2–36–43 X: (2-)3/7–14–36/37/39 |
|||
|
650–007–00–3 |
xxxxxxxxxxxxx (ISO) X2-(4-xxxxx-2-xxxxxxxxxxx)-X1,X1-xxxxxxxxxxxxxxxxxxxx X2-(4-xxxxx-x-xxxxx)-X1,X1-xxxxxxxxxxxxxxxxxx |
228–200–5 |
6164–98–3 |
Xxxx. xxx. 3; X40 Xn; R21/22 X; R50–53 |
Xn; X X: 21/22–40–50/53 X: (2-)22–36/37–60–61 |
|||
|
650–008–00–9 |
xxxxxxxxxx (XXX) 4-[(2-xxxxxxxxxx)xxxxxxxxx]-3-xxxxxxxxxxxxxx-5(4 X)-xx |
227–197–8 |
5707–69–7 |
X; X25 N; X50–53 |
X; X R: 25–50/53 X: (1/2-)22–24–36/37–45–60–61 |
|||
|
650–009–00–4 |
xxxxxxxxxxxxx-xxxxxxxxxxxx X'-(4-xxxxx-x-xxxxx)-X,X-xxxxxxxxxxxxxxxxxx-xxxxxxxxxxxx X2-(4-xxxxx-2-xxxxxxxxxxx)-X1,X1-xxxxxxxxxxxxxxxxxxxx-xxxxxxxxxxxx N2-(4-chlor-o-tolyl)-N1,N1-dimethylformamidin-hydrochlorid |
243–269–1 |
19750–95–9 |
Karc. xxx. 3; X40 Xx; X22 X; X50–53 |
Xx; X X: 22–40–50/53 S: (2-)22–36/37–60–61 |
|||
|
650–033–00–5 |
xxxxxxxxxxxx (XXX) [(S)-(3-fenoxyfenyl)kyanmethyl]-(S)-2-(4-chlorfenyl)-3-methylbutanoát (X)-3-xxxxxx-α-xxxxxxxxxx-(X)-2-(4-xxxxxxxxxx)-3-xxxxxxxxxxxxxx |
— |
66230–04–4 |
X; X23/25 X43 N; X50–53 |
X; X X: 23/25–43–50/53 X: (1/2-)24–36/37/39–45–60–61 |
|||
|
650–041–00–9 |
xxxxxxxxxxxx (XXX) 1-[2-(2-chlorethoxy)benzen-1-sulfonyl]-3-(4-methoxy-6-methyl-1,3,5-triazin-2-yl)močovina |
— |
82097–50–5 |
N; X50–53 |
X X: 50/53 X: 60-61 |
PŘÍLOHA 1X
|
Xxxxxxxx číslo |
Chemický xxxxx |
Xxxxxxxx k xxxxxx |
Xxxxx XX |
Xxxxx CAS |
Klasifikace |
Označení |
Koncentrační limity |
Poznámky x přípravkům |
|
006–090–00–8 |
2-[(3-jodprop-2-yn-1-yl)oxy]ethyl-N-fenylkarbamát |
408–010–0 |
88558–41–2 |
Xn; R20 Xx; X41 X52–53 |
Xx X: 20–41–52/53 S: (2-)22–26–39–61 |
|||
|
014–016–00–0 |
Xxxx: 1,3-xx(xxx-5-xx-1-xx)- 1,1,3,3-xxxxxxxxxxxxxxxxxxxx x 1,3-di(hex-x-en-1-yl)- 1,1,3,3-xxxxxxxxxxxxxxxxxxxx |
406–490–6 |
— |
X; X51–53 |
X X: 51/53 X: 61 |
|||
|
015–164–00–9 |
xxxxxxx-xxxxxxxxxx-(1-xxxxxxxxxxxxxx)xxxxxxxxxxx xxxxxxxx |
400–480–5 |
36669–85–9 |
X52–53 |
X:52/53 X: 61 |
|||
|
015–165–00–4 |
Xxxx: X, X, X', X''-xxxxxxxxxx-4,4'-xxxxxxxxxxxxx(xxxxxxxxxxxxxx)-xxx(xxxxxxxxxxxxxxxx) x xxxxxxx[4-(xxxxxxxxxxxxx)xxxxx]xxxxxxxxx-xxxxxxxxxxxxxxxx |
404–986–7 |
— |
Xx; X41 X; X50–53 |
Xx; X X: 41–50/53 S: (2-)15–26–39–60–61 |
|||
|
015–166–00-X |
3,9-xxx(2,6-xx-xxxx-xxxxx-4-xxxxxxxxxxxx)-2,4,8,10-xxxxxxxx-3,9-xxxxxxxxxxxx[5.5]xxxxxxx |
410–290–4 |
80693–00–1 |
X53 |
X:53 S: 61 |
|||
|
015–167–00–5 |
3-[hydroxy(fenyl)fosfinoyl]propanová xxxxxxxx |
411–200–6 |
14657–64–8 |
Xx; R41 |
Xi X: 41 S: (2-)26-39 |
|||
|
601–050–00–1 |
X10-X13-xxxxxxxxxxxxx xxxxxxx |
267–051–0 |
67774–74–7 |
X; X50 |
X R: 50 S: 61 |
|||
|
601–051–00–7 |
4-xxxxxxxx-1-xx |
405–980–7 |
768–56–9 |
Xx; X38 X; R51–53 |
Xi; X X: 38–51/53 X: (2-)37-61 |
|||
|
602–083–00–4 |
xxxxxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxxxxxxxxxx |
251–084–2 |
32534–81–9 |
Xx; X48/21/22 X64 X; X50–53 |
Xx; X X: 48/21/22–50/53–64 X: (1/2-)36/37–45–60–61 |
|||
|
602–084–00-X |
1,1-xxxxxxx-1-xxxxxxxxxx |
404–080–1 |
1717–00–6 |
X; X52–53–59 |
X R: 52/53–59 X: 59-61 |
|||
|
603–128–00–0 |
2-(fenylmethoxy)naftalen |
405–490–3 |
613–62–7 |
R53 |
R:53 X: 61 |
|||
|
603–129–00–6 |
1-xxxx-xxxxxxxxxxxx-2-xx |
406–180–0 |
57018–52–7 |
X10 Xi; X41 |
Xx R: 10-41 X: (2-)26-39 |
|||
|
603–130–00–1 |
Xxxx xxxxxxx: α-(xxxxxxxxxxxxxxxxx)-ω-xxxxxxxxxxx(xxxxxxxxxx) |
406–325–8 |
— |
Xx; X22 X52–53 |
Xx X:22–52/53 X: (2-)39-61 |
|||
|
603–131–00–7 |
Směs (3:1):1-xxxxx-1-[xxxxxx(1-xxxxxxxxxx)xxxxx]-X-xxxxxxxx; 1-xxxxx-1-[xxxxxx(1-xxxxxxxxxxxxx)xxxxx]-X-xxxxxxxx |
407–290–1 |
— |
Xx; X41 |
Xx X: 41 X: (2-)26-39 |
|||
|
603–132–00–2 |
2-(xxxxxxxxxxxxx)-6-xxxxxxxxx-9-xxxxxx-1,4-xxxxxxxxxx[4.5]xxxxx |
408–200–3 |
63187–91–7 |
Xx; R38–41 X52–53 |
Xx X:38–41–52/53 X: (2-)26–37/39–61 |
|||
|
603–133–00–8 |
Xxxx:3-(4-xxxxx-2-xxxxx-5-xxxxxxxxxxxx)xxxxxx-1,2-xxxx x 3,3'-[(2-xxxxx-5-xxxxx-1,4-xxxxxxx)xxxxxxx]xx(xxxxxx-1,2-xxxx) |
408–240–1 |
— |
Xx; X22 X52–53 |
Xx R:22–52/53 X: (2-)22–36–61 |
|||
|
603–134–00–3 |
Xxxx: xxxxx(X1-X10)-xxxxxxxxxxxxxxxxxxxx x xxxxx(X1-X10)-xxxxxxxxxxxxxxxxxxxxxxx (xxxxxxx x xxxxxxxxxx xxxxxxxxxxxx) |
410–450–3 |
— |
X53 |
X: 53 X: 61 |
|||
|
603–135–00–9 |
xxx[2-(2-xxxxxxxxxxxxx)xxxxxxxxxx]xxx(2,2', 2-xxxxxxxxxxxxxxx-1-xxxxx-X,X)xxxxxxxxxx xxxxxxx |
410–500–4 |
— |
Xx; R41 N; X51–53 |
Xx; X X: 41–51/53 S: (2-)26–39–61 |
|||
|
603–136–00–4 |
3-{4-[xxx(2-xxxxxxxxxxxx)xxxxx]-2-xxxxxxxxxxxx}xxxxxx-1-xx |
410–910–3 |
104226–19–9 |
X43 X52–53 |
Xx X:43–52/53 S: (2-)24–37–61 |
|||
|
603–137–00-X |
Xxxx:1-xxxxx-1-[xxxxxx(1-xxxxxxxxxxxx)xxxxx]-X-xxxxxxxx x 1-deoxy-1-[methyl(1-oxooktadecyl)amino]-D-glucitol |
411–130–6 |
— |
Xi; X41 |
Xx R: 41 X: (2-)26-39 |
|||
|
603–138–00–5 |
3-(2,2-dimethyl-3-hydroxypropyl)toluen 2,2-xxxxxxxx-3-(3-xxxxxxxxxxx)xxxxxx-1-xx |
403–140–4 |
103694–68–4 |
X52–53 |
X:52/53 X: 61 |
|||
|
604–050–00-X |
4-chlor-o-kresol 4-chlor-2-methylfenol |
216–381–3 |
1570–64–5 |
T; X23 C; X 35 N; X50 |
X; X; X X: 23–35–50 X: (1/2-)26–36/37/39–45–61 |
X ≥ 25 %: X; C; X23–35 10 % ≤ X &xx; 25 %: X;X20–35 5 % ≤ X &xx; 10 %: X;X20–34 3 % ≤ C &xx; 5 %: Xx;X20–36/37/38 1 % ≤ X < 3 %:Xx;X36/37/38 |
||
|
604–051–00–5 |
3,5-xxx(3,5-xx-xxxx-xxxxx-4-xxxxxxxxxxxxx)-2,4,6-xxxxxxxxxxxxxx |
401–110–5 |
87113–78–8 |
X52–53 |
X:52/53 X: 61 |
|||
|
604–052–00–0 |
2,2'-xxxxxxxxxxx[6-(2 X - benzotriazol-2-yl)-4-(1,1,3,3-tetramethylbutyl)fenol] 6,6'-xxx(2X -benzotriazol-2-yl)- 4,4'-xxx(1,1,3,3-xxxxxxxxxxxxxxxx)- 2,2'-xxxxxxxxxxxxxxx |
403–800–1 |
103597–45–1 |
X53 |
X:53 S: 61 |
|||
|
604–053–00–6 |
4-xxxx - butyl-2-methyl-6-(1-methylpentadecyl)fenol |
410–760–9 |
157661–93–3 |
Xi; R38 X43 N; X50–53 |
Xx; X R: 38–43–50/53 X: (2-)24–37–60–61 |
|||
|
604–054–00–1 |
Xxxx:2-xxxxxxx-4-(4-xxxxxxxxxxxxxxxxxxxxxxxxx-2-xx)xxxxx x 2-xxxxxxx-4-(4-xxxxxx-3,6-xxxxxxx-2X -pyran-2-yl)fenol |
412–020–0 |
— |
R43 X52–53 |
Xx X:43–52/53 X: (2-)24–37–61 |
|||
|
604–055–00–7 |
4,4'-xxx[(2,3-xxxxxxxxxxx)xxx]-3,3', 5,5'-xxxxxxxxxxxxxxxxxx |
413–900–7 |
85954–11–6 |
Xxxx. Xxx.3; R40 |
Xn X: 40 S: (2-)22–36–37 |
|||
|
605–027–00–7 |
Xxxx:3x, 4,5,6,7,7x-xxxxxxxxx-4,7-xxxxxxx-1X-xxxxx-6-xxxxxxxxxxx x 3x, 4,5,6,7,7a-hexahydro-4,7-methano-1H - xxxxx-5-xxxxxxxxxxx |
410–480–7 |
— |
X43 X; X51–53 |
Xx; X X: 43–51/53 X: (2-)24–37–61 |
|||
|
606–051–00–0 |
4-pentylcyklohexanon xxxxxxxxxxxxxxxx-1-xx |
4–406–670–4 |
61203–83–6 |
X; X51–53 |
X R: 51/53 X: 61 |
|||
|
606–052–00–6 |
4-(X, N-dibutylamino)-2-hydroxy-2'-karboxybenzofenon 2-[4-(xxxxxxxxxxxx)-2-xxxxxxxxxxxxxx]xxxxxxxx xxxxxxxx |
410–410–5 |
54574–82–2 |
X52–53 |
X:52/53 X: 61 |
|||
|
607–272–00–5 |
xxxxxxxxxxx-xxxxxx (XXX) [1] xxxxxxxxxx-xxxxxxxxx (ISO) [2] xxxxxxxxxxxx-[(4-xxxxx-3,5-xxxxxxx-6-xxxxx-2-xxxxxxx)xxx]xxxxxx [1] (2-xxxxxx-1-xxxxxxxxxxx)-[(4-xxxxx-3,5-xxxxxxx-6-xxxxx-2-xxxxxxx)xxx]xxxxxx [2] |
279–752–9 [1] — |
81406–37–3 [1] 154486–27–8 [2] |
X; X50–53 |
X R: 50/53 X: 60-61 |
|||
|
607–273–00–0 |
xxxxxxx-7-{2,6-xxxxxxxx-8-[(2,2-xxxxxxxxxxxxxxxx)xxx]- 1,2,6,7,8,8x-xxxxxxxxx-1-xxxxxx}-3,5-xxxxxxxxxxxxxxxxxx |
404–520–2 |
— |
X52–53 |
X:52/53 X: 61 |
|||
|
607–274–00–6 |
{2-[benzyl(methyl)amino]ethyl}-3-aminobut-2-enoát |
405–350–1 |
54527–73–0 |
R43 X; X51–53 |
Xx; X X: 43–51/53 X: (2-)24–37–61 |
|||
|
607–275–00–1 |
natrium-4-(benzoyloxy)benzen-1-sulfonát |
405–450–5 |
66531–87–1 |
R43 |
Xi X: 43 X: (2-)24-37 |
|||
|
607–276–00–7 |
[xxx(2-xxxxxxxxxxxxxx) bis(1-methylimidazol)]zinečnatý xxxxxxx |
405–635–0 |
— |
Xx; X38–41 X; X50–53 |
Xx; X X: 38–41–50/53 X: (2-)26–37/39–60–61 |
|||
|
607–277–00–2 |
Směs:2-(hexylsulfanyl)ethylamin-hydrochlorid x xxxxxxx-xxxxxxxxx |
405–720–2 |
— |
Xx; R22 Xi; X41 X43 N; X51–53 |
Xx; X R: 22–41–43–51/53 S: (2-)24–26–37/39–61 |
|||
|
607–278–00–8 |
Xxxx:xxxxx(X7-X9 xxxxxxxxxx x xxxxxxxxxxxx)-3-[3-(2 X - xxxxxxxxxxxx-2-xx)-5-xxxx-xxxxx-4-xxxxxxxxxxxx]xxxxxxxxxx |
405–760–0 |
— |
Xx; X41 X43 X52–53 |
Xx X: 41–43–52/53 X: (2-)24–26–37/39–61 |
|||
|
607–279–00–3 |
Xxxx:(xxxxxxxxxxxxxx)xxxxxxxxx-xxx(xxxxxxxx-xxxxxxxx) a (xxxxxxxxxxxxxx)xxxxxxxxx-(xxxxxxxx-xxxxxx)-(xxxxxxxx-xxxxxxxx) |
405–960–8 |
— |
X43 X; X51–53 |
Xx; N X: 43–51/53 S: (2-)24–37–61 |
|||
|
607–280–00–9 |
4-xxxxx-1-xxxxxxxxxxxx-1-xxxxxxxx sodný xxxxxxx-4-xxxxx-1-xxxxxxxxxxxx-1-xxxxxxxx |
406–190–5 |
54322–20–2 |
Xx; X22 Xx; X36 X43 |
Xx R: 22–36–43 X: (2-)22–26–36/37 |
|||
|
607–281–00–4 |
Směs:alkyl(C7-C9 xxxxxxxxxx x lineární)-3-[3-(2H-benzotriazol-2-yl)-5-terc-butyl-4-hydroxyfenyl]propanoáty |
407–000–3 |
127519–17–9 |
N; X51–53 |
X X: 51/53 X: 61 |
|||
|
607–282–00-X |
2-(xxxxxxxxxxxxx)-4-(xxxxxxxxx)xxxxx-xxxxxx |
407–140–5 |
131266–10–9 |
X52–53 |
X: 52/53 X: 61 |
|||
|
607–283–00–5 |
xxxxx-(X)-4-xxxxx-4-xxxxxx-2-xxxxxxxxxx-(X)-4-xxxxx-4-xxxxxxxxxxx |
408–040–4 |
15121–89–8 |
Xx; X21/22 Xi; X38–41 X43 X; X50–53 |
Xx; X X: 21/22–38–41–43–50/53 X: (2-)26–36/37/39–60–61 |
|||
|
607–284–00–0 |
Xxxx (9:1):xxxxxxx-3,3'-{(1,4-xxxxxxx)xxx[(xxxxxxxxxxxxx)(xxxxxx-3,1-xxxx)xxxxx]}xxx(10-xxxxx-6,13-xxxxxxx[1,4]xxxxxxxxxxx[2,3-x]xxxxxxxxx-4,11-xxxxxxxxxx) x xxxxxxx-3,3'-{(1,4-xxxxxxx)xxx[(xxxxxxxxxxxxx)(xxxxxx-3,1-xxxx)xxxxx]}xxx(10-xxxxx-6,13-xxxxxxx[1,4]xxxxxxxxxxx[2,3-x]xxxxxxxxx-4,11-xxxxxxxxxx) |
410–040–4 |
136213–76–8 |
X; X51–53 |
X X: 51/53 X: 61 |
|||
|
607–285–00–6 |
Xxxx:7-(3-xxxxxxxxxxxxxxxxxxxxxx)xxxxxxxx-1,3-xxxxxxxxxxx kyselina, xxxxxx-7-(3-xxxxxxxxxxxxxxxxxxxxxx)xxxxxxxx-1,3-xxxxxxxxxx x natrium-7-(3-aminobenzensulfonamido)naftalen-1,3-disulfonát |
410–065–0 |
— |
R43 |
Xi X: 43 S: (2-)22–24–37 |
|||
|
607–286–00–1 |
Xxxx:xxxxxx- x xxxxxxx-7-[4-({4-[(2-xxxxxxx-1-xxxxxx)xxx]xxxxx}xxx)xxxxxxxxxxxxxxxxx]xxxxxxxx-1,3-xxxxxxxxxx |
410–070–8 |
141880–36–6 |
X43 X52–53 |
Xx X:43–52/53 X: (2-)22–24–37–61 |
|||
|
607–287–00–7 |
xxxxxx-[1-xxxxxx-2-(xxxxxxxxxxxxxxx)xxxxx]-1,2,3,6-xxxxxxxxxxxxxxxx |
410–140–8 |
— |
X52–53 |
X:52/53 X: 61 |
|||
|
607–288–00–2 |
[x-(X -{3-[(1-{3-[(2,6(4,6)-xxxxxxx-5-xxxxxxxxxxxxx-4(2)-xx)xxxxxxxxxxx]xxxxxx}-2-xxxxxxx-4-xxxxxx-6-xxx-1,6-xxxxxxx-3-xxxxxxx)xxx]-4-xxxxxxxxxxxxxx}xxxxxxxxx)-x,x,x -xxxxxxxxxxxxxxxxxxxxxxx]xxxxxxxxx xxxxxxx, xxxxxxxxxx sůl; x = 15, 16, 17 xxxx 18, x = 1, 2, 3 nebo 4, x = 8, 9, 10 xxxx 11, x = 22, 23, 24 xxxx 25 |
410–160–7 |
148732–74–5 |
Xx; X36 R43 X52–53 |
Xx X: 36–43–52/53 X: (2-)22–26–36/37–61 |
|||
|
607–288–00–8 |
3-[(3-{X —[4-(2,4-xx-xxxx-xxxxxxxxxxxx)xxxxx]xxxxxxxxx}-4-xxxxxxx-1-xxxxxx)xxxxxxxx]xxxxxxxxx xxxxxxxx |
410–370–9 |
105488–33–3 |
X53 |
X:53 X: 61 |
|||
|
607–290–00–3 |
Směs (o xxxxxxxx xxxxxx):xxxxxxx-1-xxxxx(X14-X18)-4-[3-(xxxxxxxx)-2-xxxxxxxxxxxxx]-2-xxxxxxxxxxxxxxxxxxx a xxxxxxx-4-xxxxx(X14-X18)-1-[3-(xxxxxxxx)-2-xxxxxxxxxxxxx]-2-xxxxxxxxxxxxxxxxxxx |
410–540–2 |
— |
Xx; X38 X43 X; X50–53 |
Xx; N X: 38–43–50/53 S: (2-)24–37–60–61 |
|||
|
607–291–00–9 |
xxxxxxx-ω-xxxxxxxxxxx(xxxx xxxxxxxxxx)xxxxxxxx |
410–630–1 |
104051–92–5 |
X53 |
X: 53 X: 61 |
|||
|
607–292–00–4 |
Směs:[2-(alkyl(C12)oxy)-1-(methoxymethyl)ethoxy]octová xxxxxxxx x [2-(xxxxx(X14)xxx)-1-(xxxxxxxxxxxxx)]xxxxxx xxxxxxxx |
410–640–6 |
— |
Xx; X38–41 X; X50–53 |
Xx; X X: 38–41–50/53 X: (2-)26–37/39–60–61 |
|||
|
607–293–00-XSměs: |
1-(2-aminoethyl)piperazin-1,4-diium-[(2,4,6-trimethylnonyl)fenoxy]benzendisulfonát x 1-(2-xxxxxxxxxx)xxxxxxxxx-1,4-xxxxx-[xxx(2,4,6-xxxxxxxxxxxxxx)xxxxxx]xxxxxxxxxxxxxxxx |
410–650–0 |
— |
Xx; X41 R43 X; X51–53 |
Xx; X X: 41–43–51/53 X: (2-)26–36/37/39–61 |
|||
|
607–294–00–5 |
xxxxxxx-2-(xxxxxxxxxx)-1-xxxxxxxxxxxx-1-xxxxxxxx |
410–680–4 |
— |
X43 |
Xx R: 43 X: (2-)24-37 |
|||
|
607–295–00–0 |
Xxxx:xxxxxxxxxxxx-xxxxxxxxxxxxxxxxx a xxxxxxxxxxx-xxxxxxxxxxxx-1,2,3,4-xxxxxxxxxxxxxxx |
410–800–5 |
— |
X43 X; X51–53 |
Xx; X X: 43–51/53 X: (2-)24–37–61 |
|||
|
607–296–00–6 |
Xxxx:xxxxxxxxxxx pentaerythritolu, xxxxxxxxx xxxxxxxx a 2-xxxxxxxxxxxxx xxxxxxxx |
410–830–9 |
— |
X53 |
X: 53 X: 61 |
|||
|
607–297–00–1 |
3,3'-(1,4-xxxxxxxxxxxxxxxxxxx)xxx(2-xxxxxxxxx-10-xxxxxxxxx kyselina)2,2'-dioxo-3,3'-(1,4-fenylendimethyliden)bis(1,7,7-trimethylbicyklo[2.2.1]heptan-1-methansulfonová xxxxxxxx) |
410–960–6 |
92761–26–7 |
Xx; R41 |
Xi X: 41 S: (2-)26-39 |
|||
|
607–298–00–7 |
[2-(xxxxxxxxxxxxxxx)xxxxx]-4-xxxxxxxxxxxxxxxx |
411–010–3 |
— |
X43 |
Xx X: 43 X: (2-)22–36/37 |
|||
|
607–299–00–2 |
xxxxxx-3-(xxxxxxxxxxxxxx)-2-xxxxxxxxxxxxxxx |
411–040–7 |
97101–46–7 |
Xx; X22 X43 X; X50–53 |
Xx; X X: 22–43–50/53 X: (2-)24–37–60–61 |
|||
|
607–300–00–6 |
[x-(X-{4-[(5-xxxxx-2,6-xxxxxxxxxxxxxxxx-4-xx)xxxxx]-3-xxxxxxxxxxxxxxxx}xxxxxxxxx)-x-xxxxxxxxx-x, d-sulfonatoftalocyanin]měďnatý komplex, xxxxxxxx sůl; x = 1,2,3 nebo 4, x = 8, 9, 10 xxxx 11, x = 15, 16, 17 xxxx 18, x = 22, 23, 24 nebo 25 |
411–430–7 |
— |
X43 |
Xx X: 43 X: (2-)22–24–37 |
|||
|
607–301–00–1 |
Směs:dodekanová xxxxxxxx x xxxxxxxxxxx oligo(1-7)laktátů |
411–860–5 |
— |
Xi; X38–41 X43 X; X51–53 |
Xx; X X: 38–41–43–51/53 X: (2-)24–26–37/39–61 |
|||
|
607–302–00–7 |
Xxxx:xxxxxxxxxxxxx xxxxxxxx x xxxxxxxxxxxxxx xxxxx(1-7)xxxxxxx |
411–910–6 |
— |
Xx; X38–41 X43 X; R51–53 |
Xi; N X: 38–41–43–51/53 X: (2-)24–26–37/39–61 |
|||
|
607–303–00–2 |
1-xxxxxxxxxxx-6,7-xxxxxxx-4-xxx-1,4-xxxxxxxxxxxxxxx-3-xxxxxxxxxxx kyselina |
413–760–7 |
93107–30–3 |
Repr. xxx.3; X62 R52–53 |
Xn X: 62–52/53 X: (2-)22–36/37–61 |
|||
|
608–023–00–3 |
4-(4-xxxxxxxxxx)-2-xxxxx-2-[(1X- 1,2,4-xxxxxxx-1-xx)xxxxxx]xxxxxxxxxxx |
406–140–2 |
114369–43–6 |
X; X50–53 |
X X: 50/53 X: 60-61 |
|||
|
608–024–00–9 |
2-{4-[xxxxx(xxxxxxxx)xxxxx]xxxxx}xxxxx-1,1,2-xxxxxxxxxxxxxx |
407–650–8 |
97460–76–9 |
X53 |
X:53 X: 61 |
|||
|
608–025–00–4 |
[2-nitro-4,5-bis(benzyloxy)fenyl]acetonitril |
410–970–0 |
117568–27–1 |
R53 |
R:53 S: 61 |
|||
|
609–053–00-X |
xxxxxxxxxxx-xxxxxxxxxxxxxxxx |
414–850–9 |
— |
X; X3 O; X8 Xxxx. xxx. 2; X45 T; X23/25 X43 |
X; X X: 45–3–8–23/25–43 S: 53-45 |
|||
|
610–010–00–2 |
1-xxxx-2-(2-xxxxx)-1-xxxxxxxxxx |
406–110–9 |
35950–52–8 |
Xx; X22–48/22 C; X34 X43 X; X50–53 |
X; N X: 22–34–43–48/22–50/53 X: (1/2-)22–26–36/37/39–45–60–61 |
|||
|
611–043–00–5 |
Xxxx (2:1:1):[xxx(6-{[1-(X-xxxxxxxxxxxxxx)-2-xxxxxxxxxxx-1-xx-1-xx]xxx}-5-xxxxxxxxx-3-xxxxxxxxxxxxxxxxx-2-xxx-1'-xxxxxx-1,2'-xxxxxxx)]xxxxxxxxx trisodný, [bis{6-[(2-amino-4-hydroxyfenyl)azo]- xxxx 6-[(2-xxxxx-6-xxxxxxxxxxxx)xxx]- xxxx 6-[(4-xxxxx-2-xxxxxxxxxxxx)xxx]-5-xxxxxxxxx-3-xxxxxxxxxxxxxxxxx-2-xxx-1'-xxxxxx-1,2'-xxxxxxx}]xxxxxxxxx trisodný x[{6-[(2-xxxxx-4-xxxxxxxxxxxx)xxx]- xxxx 6-[(2-xxxxx-6-xxxxxxxxxxxx)xxx]- nebo 6-[(4-xxxxx-2-xxxxxxxxxxxx)xxx]-5-xxxxxxxxx-3-xxxxxxxxxxxxxxxxx-2-xxx-1'-xxxxxx-1,2'-xxxxxxx}(6-{[1-(X-xxxxxxxxxxxxxx)-2-xxxxxxxxxxx-1-xx-1-xx]xxx}-5-xxxxxxxxx-3-xxxxxxxxxxxxxxxxx-2-xxx-1'-xxxxxx-1,2'-xxxxxxx)]xxxxxxxxx xxxxxxxx |
402–850–1 |
Xx X: 41–52/53 X: (2-)26–39–61 |
|||||
|
611–044–00–0 |
Xxxx:[xxx(5-xxxxxxxxxxx-1-xxx-1'-xxxxxxxx-2,2'-xxxxxxx)]xxxxxxxxx xxxx-xxxxx(X12-X14)xxxxxx, [xxx(4-xxxxxxxxxxx-1-xxx-1'-xxxxxxxx-2,2'-xxxxxxx)]xxxxxxxxx xxxx-xxxxx(X12-X14)xxxxxx, [xxx(5-xxxx-xxxxx-3-xxxxxxxxxxx-1-xxx-1'-xxxxxxxx-2,2'-xxxxxxx)]xxxxxxxxx xxxx-xxxxx(X12-X14)xxxxxx, [(5-xxxx-xxxxx-3-xxxxxxxxxxx-1-xxx-1'-xxxxxxxx-2,2'-xxxxxxx)(5-xxxxxxxxxxx-1-xxx-1'-xxxxxxxx-2,2'-xxxxxxx)]xxxxxxxxx xxxx-xxxxx(X12-X14)xxxxxx x[(4(5)-xxxxxxxxxxx-1-xxx-1'-xxxxxxxx-2,2'-xxxxxxx) (3-nitro-5-pentylbenzen-1-azo-1'-naftalen-2,2'-diolato)]chromitan xxxx-xxxxx(X12-X14)xxxxxx |
403–720–7 |
117527–94–3 |
X; X51–53 |
Xx; X41 X52–53 |
|||
|
611–045–00–6 |
2-({4-[(4-xxxxxxxxxxxx)xxxxxxxxxx]-2-xxxxxxxxxxx}xxx)-3-xxxxxx-5-xxxxxxxxxxxx |
404–830–8 |
— |
X53 |
X:53 S: 61 |
N X: 51/53 X: 61 |
||
|
611–046–00–1 |
4,4'-xxxxxxx-2-xxxxxxxxxxxxxxx2-xxxxxxxxxxxxxxx-4,4'-xxxxxx |
407–590–2 |
43151–99–1 |
X; R25 Xx; X48/22 R43 X; X50–53 |
X; X R: 25–43–48/22–50/53 X: (1/2-)22–28–36/37–45–60–61 |
|||
|
611–047–00–7 |
Směs (1:1):2-({4-[(2-xxxxxxxxxxxx)xxxxxxxxxx]xxxxx}xxx)-5,6-xxxxxxxxxxxxxxxxxxx x 2-({4-[(2-acetoxyethyl)ethylamino]fenyl}azo)-6,7-dichlorbenzothiazol |
407–890–3 |
111381–11–4 |
R53 |
R: 53 S: 61 |
|||
|
611–048–00–2 |
Xxxx (1:1):2-({4-[xxx(2-xxxxxxxxxxxx)xxxxx]xxxxx}xxx)-5,6-xxxxxxxxxxxxxxxxxxx x 2-({4-[xxx(2-xxxxxxxxxxxx)xxxxx]xxxxx}xxx)-6,7-xxxxxxxxxxxxxxxxxxx |
407–900–6 |
111381–12–5 |
X53 |
X: 53 S: 61 |
|||
|
611–049–00–8 |
Xxxx (2:1:1)7-[(4-{[3-(xxxxxxxxxxxx)xxxxxx]xxxxx}-6-{[3-(xxxxxxxxxxxxx)xxxxxx]xxxxx}-1,3,5-xxxxxxx-2-xx)xxxxx]-3-{[4-(xxxxxxxx)xxxxx]xxx}-4-xxxxxxxxxxxxxxx-2-xxxxxxxx, kyselina xxxxxx x mléčná xxxxxxxx (2:1:1) |
408–000–6 |
118658–98–3 |
Xx; X48/22 X43 X52–53 |
Xx X: 43–48/22–52/53 X: (2-(22–36/37–61 |
|||
|
611–051–00–9 |
2-({4-[xxxxx(2-xxxxxxxxxxxx)xxxxx]-2-xxxxxxxxxxx}xxx)-6-xxxxxxx-3-xxxxxxxxxxxxxxxxxxxxx-xxxxxxx |
411–110–7 |
136213–74–6 |
X; R50–53 |
N X: 50/53 X: 60-61 |
|||
|
611–052–00–4 |
[xxxx{4-[(2-xxxxxxx-3,5-xxxxxxxxxxxx) xxx]-6-[(6-xxxxxxxxx-1-xxxxxx)xxx]xxxxxx-1,3-xxxxxxx}]xxxxxxxxx xxxxxxx, xxxxx xxx |
400–720–9 |
— |
X52–53 |
X: 52/53 X: 61 |
|||
|
612–156–00–2 |
Xxxx:xxxxxxxxxxxx(xxxxxx)xxxxxxx-xxxxxxx a xxxxxxxxxxx(xxxxxxxx)xxxxxxx-xxxxxxx |
405–620–9 |
— |
Xx; R41 X; X50–53 |
Xx; X X: 41–50/53 X: (2-)26–39–60–61 |
|||
|
612–157–00–8 |
(X)-1-(1-xxxxxxxxxxxx-2-xx)xxxxx-1-xx-xxxx-xxxxxxxxxxxx |
410–780–8 |
— |
Xx; X22–48/22 Xx; R41 X43 X; X51–53 |
Xx; X X: 22–41–43–48/22–51/53 X: (2-)22–26–36/37/39–61 |
|||
|
612–158–00–3 |
Xxxx:[xxx(5-xxxxx(xxxxxxxxxx X12))-2-xxxxxxxxxxxxxxxxxxxxx)]xxxxxxx xxxxxxx x 4-dodecyl-2-hydroxybenzaldoxim[bis(5-alkyl(rozvětvený X12))-2-xxxxxxxxxxxxxxxxxxxxx)]xxxxxxx komplex a 4-xxxxxxxxxxxxxxxxxxxxx |
410–820–4 |
— |
X53 |
X: 53 X: 61 |
|||
|
612–159–00–9 |
xxxxxxx produkty xxxxx 2,2,4-xxxxxxxxx- a 2,4,4-xxxxxxxxxxxxxx-1,6-xxxxxxx (x xxxxxxx EINECS), xxxxxxxx [(xxxxx(X10-X16)xxx)xxxxxx]xxxxxxx (Epoxid 8) a 4-methylbenzen-1-sulfonové xxxxxxxx |
410–880–1 |
— |
Xx; R22 X; X34 N; X50–53 |
X; X R: 22–34–50/53 X: (1/2-)23–26–36/37/39–45–60–61 |
|||
|
613–149–00–7 |
2-terc-butyl-5-[(4-terc-butylbenzyl)sulfanyl]-4-chlorpyridazin-3(2H)-on |
405–700–3 |
96489–71–3 |
T; X23/25 X; X50–53 |
X; X X: 23/25–50/53 X: (1/2-)36/37–45–60–61 |
|||
|
613–150–00–2 |
2,2'-[xxxxxxxxx-1,4-xxxxxx(xxxxxx-1,3-xxxx)]xxx(xxxxxxxxxxx[2,1-x]xxxxx[xxx][3,8]xxxxxxxxxxxx-1,3,6-xxxxx) |
406–295–6 |
— |
X53 |
X:53 S: 61 |
|||
|
613–151–00–8 |
1-(2-deoxy-3-O-mesyl-5-O-trityl-β-D-threo-pentofuranosyl)-5-methylpyrimidin-2(1H), 4(3 H)-dion |
406–360–9 |
104218–44–2 |
R53 |
R:53 X: 61 |
|||
|
613–152–00–3 |
xxxxx-X-(4,6-xxxxxxxxxxxxxxxxxx-2-xx)xxxxxxxx |
406–600–2 |
89392–03–0 |
X43 X; X51–53 |
Xx; X X: 43–51/53 X: (2-)24–37–61 |
|||
|
613–153–00–9 |
2,3,5-xxxxxxxxxxxxxxx |
407–270–2 |
16063–70–0 |
X52–53 |
X:52/53 S: 61 |
|||
|
613–154–00–4 |
2-xxxxx-4-xxxxx-6-xxxxxxxxxxxxxxxx |
410–050–9 |
5734–64–5 |
Xx; X22 |
Xx X: 22 S: (2-)22 |
|||
|
613–155–00-X |
5-xxxxx-2,3-xxxxxxxxxxxxxx |
410–090–7 |
89402–43–7 |
X10 Xx; R22 X52–53 |
Xx X: 10–22–52/53 X: (2-)23–36–61 |
|||
|
613–156–00–5 |
2-xxxxx-4-xxxxx-5-xxxxxxxxxxxxxx 2-butyl-5-chlorimidazol-4-karbaldehyd |
410–260–0 |
83857–96–9 |
R43 X; X51–53 |
Xx; X X: 43–51/53 S: (2-)24–37–61 |
|||
|
613–157–00–0 |
2,4-xxxxxxx-5-(xxxxxxxxxxxxx)xxxxxxxxx 5-(xxxxxxxxxxxxx)xxxxxxxxx-2,4-xxxxxx |
410–330–0 |
54236–98–5 |
Xx; X22–48/22 Xx; X36 |
Xx X: 22–36–48/22 X: (2-)22–26–36 |
|||
|
613–158–00–6 |
2,3-xxxxxxx-5-(xxxxxxxxxxxxxx)xxxxxxx |
410–340–5 |
69045–84–7 |
Xx; R20/22 Xx; X41 X43 X; R51–53 |
Xn; N X: 20/22–41–43–51/53 S: (2-)24–26–37/39–61 |
|||
|
613–159–00–1 |
4-[2-(4-xxxx-xxxxxxxxxx)xxxxxx]xxxxxxxxxx |
410–580–0 |
120928–09–8 |
X; X25 Xx; X20 N; X50–53 |
X; X X: 20–25–50/53 X: (1/2-)37–45–60–61 |
|||
|
613–160–00–7 |
2-xxxxxx-2,5-xxxxxxxxxxxx[2.2.1]xxxxxx-xxxxxxxxxxxxx |
411–000–9 |
125224–62–6 |
X43 |
Xx X: 43 S: (2-)24-37 |
|||
|
615–022–00–1 |
methyl-3-(isokyanatosulfonyl)thiofen-2-karboxylát |
410–550–7 |
79277–18–2 |
E; X2 R14 Xn; X48/22 X42/43 |
X; Xx X: 2–14–42/43–48/22 S: (2-)22–30–35–36/37 |
|||
|
615–023–00–7 |
xxxxxxxxxxx 2-[(xxxxxxxxxxxxxxxxxx)xxxxxx]xxxxxxxx xxxxxxxxxxxxxx-2-[(xxxxxxxxxxxxxxxxxx)xxxxxx]xxxxxxx |
410–900–9 |
83056–32–0 |
X10 X14 Xxxx. xxx. 3; X40 Xx; X20–48/22 Xx; X41 X42 |
Xx X: 10–14–20–40–41–42–48/22 X: (2-)23–26–36/37/39 |
|||
|
616–044–00–4 |
X-(3,5-xxxxxxx-4-xxxxx-2-xxxxxxxxxxxx)-2-(3-xxxxxxxxxxxxxxxx)xxxxxxxxx |
402–510–2 |
— |
X; R51–53 |
N X: 51/53 S: 61 |
|||
|
616–045–00-X |
2'-[(4-xxxxx-5-xxxxxx-3-xxxx-2-xxxxxxx)xxx]- 5'-(xxxxxxxxxxxx)-2-xxxxxxxxxxxxxxxxx |
405–190–2 |
122371–93–1 |
X43 R53 |
Xi X: 43-53 S: (2-)22–24–37–61 |
|||
|
616–046–00–5 |
X -[2-(6-xxxxx-7-xxxxxxxxxxxxxx[1,5-x][1,2,4]xxxxxxx-4-xx)xxxxxx]-2-(2,4-xx-xxxx-xxxxxxxxxxxx)xxxxxxxxx |
406–390–2 |
— |
X; X50–53 |
X X: 50/53 X: 60-61 |
|||
|
616–047–00–0 |
Xxxx:X,X′,X″,X′′′ - xxxxxxxxxx(X16)-2,2′, 2″, 2′′′ (ethylendinitrilo)tetraacetamid x X, X′,X″,X′′′ - xxxxxxxxxx(X18)- 2,2′, 2′′, 2′′′-(xxxxxxxxxxxxxxxx)xxxxxxxxxxxxx |
406–640–0 |
— |
X43 |
Xx X: 43 X: (2-)24-37 |
|||
|
616–048–00–6 |
3'-(trifluormethyl)isobutyranilid |
406–740–4 |
1939–27–1 |
Xn; X48/22 N; R51–53 |
Xn; X R: 48/22–51/53 X: (2-)22–36–61 |
|||
|
616–049–00–1 |
2-(2,4-xx-xxxx-xxxxxxxxxxx)-X-(3,5-xxxxxxx-4-xxxxx-2-xxxxxxxxxxxx)xxxxxxxxx |
408–150–2 |
99141–89–6 |
X53 |
X:53 X: 61 |
|||
|
616–050–00–7 |
1-[2,5-xxxxxxx-4-(1,1,2,3,3,3-xxxxxxxxxxxxxxxx)xxxxx]-3-(2,6-xxxxxxxxxxxx)xxxxxxxx |
410–690–9 |
103055–07–8 |
X43 X; X50–53 |
Xx; X R: 43–50/53 X: (2-)24–37–60–61 |
|||
|
616–051–00–2 |
Xxxx:3,3'-xxx(4-xxxxxxxxxxx)- 1,1'-(4-methyl-1,3-fenylen)dimočovina x 3,3'-xxx(4-xxxxxxxxxxx)-1,1'-(2-xxxxxx-1,3-xxxxxxx)xxxxxxxxxx Směs:2,4-bis[3-(4-methylfenyl)ureido]toluen x 2,6-xxx[(3-(4-xxxxxxxxxxx)xxxxxx]xxxxxx |
411–070–0 |
— |
X53 |
X: 53 X: 61 |
|||
|
617–015–00–9 |
xxx(4-xxxxxxxxxxxxx)xxxxxxx |
407–950–9 |
895–85–2 |
X; X2 X; X7 N; X50–53 |
X; N X: 2–7–50/53 X: (2-)7–14–36/37/39–47–60–61 |
|||
|
650–032–00-X |
xxxxxxxxxxxx (XXX) (2X, 3X)-, (2 X, 3 X)-, (2 X, 3 X)-, (2 X, 3 R)-2-(4-chlorfenyl)-3-cyklopropyl-1-(1H- 1,2,4-xxxxxxx-1-xx)xxxxx-2-xx |
— |
94361–06–5 |
Xxxx. kat. 3; X63 Xn; R22 X; R50–53 |
Xn; X X: 22–50/53–63 S: (2-)36/37–60–61 |
XXXXXXX 2
POVAHA XXXXXXXXXXXX XXXXX XXXXXXXXX X XXXXXXXXXXXX XXXXXXX A XXXXXXXXX
Xxx xxxxxxxx Xxxxxx 2001/59/XX,
Xx. xxxx. L 332, 28.12.2000, x. 81.
XXXXXXX 3X
XXXXXXXXXX XXXXXX XXX XXXXXXXX ZACHÁZENÍ X XXXXXXXXXXXX LÁTKAMI X XXXXXXXXX
Xxx xxxxxxxx Xxxxxx 2001/59/XX,
Xx. věst. X 332, 28.12.2000, x. 81.
XXXXXXX 3X
XXXXXXXXXX XXXXXX XXX XXXXXXXX XXXXXXXXX X NEBEZPEČNÝMI XXXXXXX X XXXXXXXXX
Xxx xxxxxxxx Xxxxxx 2001/59/ES,
Úř. xxxx. X 332, 28.12.2000, x. 81.
XXXXXXX 4A
"B.10 XXXXXXXXXX — ZKOUŠKA XX XXXXXXXXXXXX XXXXXXX X XXXXX XX XXXXX
1. XXXXXX
Xxxx metoda je xxxxxxxx metody XXXX XX 473 — Xxxxxxx xx xxxxxxxxxxxx xxxxxxx x savců xx xxxxx (1997).
1.1 XXXX
Xxxxxxx na xxxxxxxxxxxx xxxxxxx x savců xx xxxxx xx xxxxxxxxxxxxx činitele, xxxxx xxxxxxxxx xxxxxxxxxx xxxxxxxxxxxx xxxxxxx x kultivovaných xxxxxxx savců (1, 2, 3). Xxxxxxxxx xx xxx xxxx xxxxxxxxxxxx aberací: chromozomové x chromatidové. U xxxxxxx xxxxxxxxxx xxxxxxxx xxxx xxxxxxxxxx aberace xxxxxxxxxxxxxx xxxx, xxxxx xxxxxxxxxxxx aberace xx xxxxxx vyskytují. Nárůst xxxxxxxxxxx může xxxxxxxx, xx xxxxxxxx xxxxx xx schopnost xxxxxxxxx xxxxxxxxx xxxxxxx. Xxxx xxxxxx xxxx xxxx xxxxxx ke xxxxxxxxx xxxxxxxxxxx xxxxxxx x xxxx x tomuto xxxxx xxxxxxx xxxxxxxxx. Xxxxxxxxxxxx xxxxxx x xxxxxxx jevy xxxx xxxxxxxx xxxxx xxxxxxxxx xxxxxxxxxxx xxxxxx x xxxxxxx x existuje xxxxx xxxxxx o xxx, xx chromozomové xxxxxx x x xxxx xxxxxxxxxxx xxxx xxxxxxxxxxx změny x xxxxxxxxxx x x xxxxxx xxxxxxxxxxx xxxxx xxxxxxxxx xxxxxx, xxxx xxxxx xx indukci xxxxxxxx u xxxxxxx x x pokusných xxxxxx.
Xx zkoušce xx xxxxxxxxxxxx aberace in xxxxx xxxxx xxx xxxxxxx xxxxxxxxxxxxx xxxxxxx xxxxx, buněčné xxxxx xxxx primární buněčné xxxxxxx. Xxxxxxx buňky xxxx xxxxxxx xx xxxxxxx xxxxxxxxxx růstu x xxxxxxx, xxxxxxxx xxxxxxxxx, počtu xxxxxxxxxx, xxxxxxxxxxxx xxxxxxxxxx a xxxxxxxxx četnosti chromozomových xxxxxxx.
Xxxxxxx prováděné xx xxxxx xxxxxx vyžadují xxxxxxx vnějšího zdroje xxxxxxxxxxx aktivace. Xxxxx xxxxxxxxxxx xxxxxxxxx xxxxxx xxxxxx zcela xxxxxxxxx xxxxxxxx xx xxxx x savců. Xx xxxxx xx zcela xxxxxxxxx xxxxxxxx, které xx xxxxx x xxxxxxxxxx xxxxxxxxx, jež xxxxxxxxxx xxxxxxx mutagenitu x xxxx k xxx xxxxx xxxxxx xX, xxxxxxxxxx xxxx xxxxxxxx xxxxxx xxxxxxxxxxxx (4, 5).
Xxxx xxxxxxx xx používá ke xxxxxxxx xxxxxxx mutagenů x xxxxxxxxxxx xxx xxxxx. Mnoho sloučenin, xxx xxx je xxxx zkouška xxxxxxxxx, xxxx xxx xxxxx xxxxxxxxxxx; mezi xxxxx xxxxxxxx a karcinogenitou xxxx xxxx xxxxxxxxx xxxxxxxx. Xxxxxxxx xxxxxx xx xxxxxxxx xxxxx x xxxxxxxxx důkazy x xxx, xx xxxxxxxx karcinogeny, které xxxxxx zjištěny xxxxx xxxxxxxx, neboť xxxxxx xxxxxx jinými xxxxxxxxxx xxx xxxxxx xxxxxxxxxx XXX.
Xxx také Xxxxxx xxxx, část X.
1.2 XXXXXXXX
Xxxxxxxxxxxx xxxxxxx : xxxxxxxxxx poškození chromozomu x podobě xxxxx xxxxxxxxxxxx xxxxxxxxx xxxx xxxxx x opětného xxxxxxx xxxxxxxxx.
Xxxxxxxxxxxx aberace : xxxxxxxxxx xxxxxxxxx xxxxxxxxxx x podobě xxxxx xxxx xxxxx x spojení xxxx xxxxxxxxx x xxxxxx xxxxx.
Xxxxxxxxxxxxxxx : xxxxxx, xxx xxxxxx x xxxxx xx X-xxxx xxxxxxxxx XXX xxxxxxx x mitóze, xxxxx xxxxxxxxx další X-xxxx. Xxxxxxxxx jsou chromozomy xx 4, 8, 16… xxxxxxxxxxxx.
Xxx : xxxxxxxxxxxx xxxx xxxxx xxx xxxxx xxxxx xxxxxxxxxx x x xxxxxxxxx xxxxxxxxx xxxxxxxxx.
Xxxxxxxxx xxxxx : xxxxx xxxxx, xxxxx xx xxxxxxxxx x xxxxxxxx, x xxxxxxxxx počtu xxxxx x xxxxxxxx; xxxxx stupeň xxxxxxxxxxx xxxx xxxxxxxx.
Xxxxxxxxx aberace : xxxxxxxx počtu xxxxxxxxxx xx xxxxxxxxxx xxxxx obvyklého u xxxxxxxxx typu xxxxx.
Xxxxxxxxxxx : násobek haploidního xxxxx xxxxxxxxxxxxxx sad (x), jiný xxx xxxxxxxxx (xx. 3 x, 4 x xxx.).
Xxxxxxxxxx xxxxxxx : xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxx xxxxxxxxx xxxxxxxxxx xxx xxxxxxxx xxxxxx xx xxxxxx metafáze; xxxx xx jako xxxxxx x xxxxxxxxx, xxxxxxxxxxxxxxxxxx xxxx interchromozomální xxxxx.
1.3 XXXXXXXX XXXXXXXX XXXXXX
Xxxxxxx xxxxxxx xxxx xxxxxxxxx xxxxxxxx xxxxx, x xx x xxxxxxxxxxxx xxxxxxxx x xxx xx. X xxxxxx xxxxxxxxxxx xxxxxxxxxxx xx xxxxxxxx xxxxx xx xx xxxxxxxxx xxxxxx xxxxx xxxxx xxxxxxxxxxx xxxxxxxx (xxxx. Xxxxxxxx® xxxx xxxxxxxxx), kultury xx xxxxxx, xxxxxx x xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxx xx xxxxxx xxxxxxxxxxxxxx xxxxxxxxxxx buněk.
1.4 XXXXX ZKUŠEBNÍ XXXXXX
1.4.1 Xxxxxxxxx
1.4.1.1 Buňky
Mohou xxx xxxxxxx různé xxxxxxx xxxxx, kmeny xxxx xxxxxxxx xxxxxxx kultury, xxxxxx xxxxxxxx buněčných xxxxx (xxxx. xxxxxxxxxxx xxxxxx xxxxxxxx, xxxxxxxxx xxxxxxxxx xxxx člověka xxxx xxxxxx savců).
1.4.1.2 Xxxxx a kultivační xxxxxxxx
Xxx xxxxxxxxx kultur xx xxxx xxx xxxxxxx xxxxxx xxxxxxxxxx xxxxx a inkubační xxxxxxxx (kultivační xxxxxx, xxxxxxxxxxx XX2, xxxxxxx x vlhkost). X xxxxxxxxxxxxxxx buněčných linií x xxxxx xx xxxx xxx rutinně xxxxxxxxxxxx xxxxxxxxx xxxxxxx xxxxxxx xxxxx chromozomů x xxxx xx xxx kontrolováno, xxx xxxxxx xxxxxxxxxxxxx mykoplasmaty; x xxxxxxx xxxxxxxxxxx xx neměly být xxxxxxx. Pro použité xxxxx x xxxxxxxxx xxxxxxxx xx měla xxx známa normální xxxxx xxxxxxxxx cyklu.
1.4.1.3 Xxxxxxxx kultur
Stabilizované xxxxxxx xxxxx x xxxxx: xxxxx xx xxxxxxx x xxxxxxxxx xxxxxx, xxxxxx se xx xxxxxxxxxxxx xxxxx x xxxxxx xxxxxxx, aby xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx, a xxxxxxxx xx xxx 37 °X.
Xxxxxxxxx: xxxx xxxxxxxx xxxxxxxxxxxxxxx (xxxx. xxxxxxxxx) xxxx oddělené lymfocyty xxxxxxxx probandů se xxxxxxx do xxxxxxxxxxxx xxxxx obsahujícího xxxxxxx (xxxx. xxxxxxxxxxxxxxxx) x xxxxxxxx xx xxx 37 °X.
1.4.1.4 Xxxxxxxxxxx xxxxxxxx
Xxxxx xx xxxx xxx xxxxxxxxx xxxxxxxx xxxxx, x to x xxxxxxx xxxxxxxxxxxx xxxxxxxx x xxx xx. Nejčastěji xxxxxxxxxx xxxxxxxx je kofaktorem xxxxxxxx xxxxxxxxxxxxxxxxxxx xxxxxx (X9) připravená x xxxxx hlodavců xxxxxxxxxx xxxxxxxx indukujícím enzymy, xxxx xx Aroclor 1254 (6, 7, 8 a 9), xxxx xxxx fenobarbitonu x β-naftoflavonu (10, 11 a 12).
Postmitochondriální xxxxxx xx x xxxxxxxx testovacím xxxxx xxxxxxx xxxxxxxxx v xxxxxxxxxxxxx 1 — 10 % xxx. Xxxx xxxxxxxxxxxxx xxxxxxxxxxx xxxxxxx může xxxxxxx xx xxxxx xxxxxxxx xxxxx, která xx xxxxxxxx. X některých xxxxxxxxx xxxx být xxxxxx xxxxxx xxxx xxx jednu koncentraci xxxxxxxxxxxxxxxxxxx xxxxxx.
Xxxx výsledků xxxxxx, včetně xxxxxxxx xxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxx xxxxx xxxxxxxxxxxxx xxxxxxxxxx xxxxxxxxx xxxxxx, xxxxxxxxx xxxxxxxx xxx xxxxxxxxx xxxxxxxx. Xxxxx xxxxxxxxx xxxxxxxxx linií by xxxx xxx xxxxxxx xxxxxxxxxx (např. důležitostí xxxxxxxxx xxxxxxxxxx X450 xxx metabolismus xxxxxxxx xxxxx).
1.4.1.5 Xxxxxxxx látka/příprava
Pevné xxxxxxxx látky xx xxxx xxx xxxx xxxxxxxx xx xxxxx xxxxxxxxxx xxxx xxxxxxxxxxxx xx xxxxxxxx rozpouštědlech xxxx xxxxxxxxxx x xxxxxxxxx xxxxxxx. Xxxxxxx xxxxxxxx xxxxx mohou xxx xxxxxxx xxxxx x testovacím xxxxxxxx x/xxxx xxxxx xxx xxxx xxxxxxxx xxxxxxx. Xxxx xx xxx xxxxxxx čerstvě připravené xxxxxxxx xxxxx, xxxxx xxxxx o xxxxxxxx xxxxxxxxxxx možnost xxxxxxxxxx.
1.4.2 Xxxxxxxx podmínky
1.4.2.1 Rozpouštědlo/vehikulum
Rozpouštědlo/vehikulum xx mělo xxx xxxx xxxxxxxxx, xx xxxxxxx xx xxxxxxxxx xxxxxx, a xxxx xx xxx slučitelné x xxxxxxxx buněk x s aktivitou X9. Xxxx-xx použita xxxx než známá xxxxxxxxxxxx/xxxxxxxx, xxxx xx xxx xxxxxx xxxxxxxx xxxxxxxxx xxxxx x xxxxxx xxxxxxxxxxxxx. Xxxxxxxxxx xx xxxxx možno xxxxxxxx xxxxxx xxxxxxx xxxxxxx xxxxxxxxxxxx/xxxxxxx. Xxx xxxxxxxx xxxxx xxxxxxxxx xx xxxx xx xxxx xxx xxxxxxx xxxxxxxxx rozpouštědla neobsahující xxxx. Vodu xxx xxxxxxxxx přidáním xxxxxxxxxxxx xxxx.
1.4.2.2 Xxxxxxxxx xxxxxxxxxxx
Xxxx xxxxxxxx, která xxxx xxx zohledněna xxx xxxxxxxxx xxxxxxxx koncentrace, xxxxx xxxxxxxxxxxx, xxxxxxxxxxx x xxxxxxxxxx systému x změny pH xxxx xxxxxxxxxx.
Xxxxxxxxxxxx by xxxx xxx stanovena x xxxxxxxxxxxx aktivací x xxx ní x xxxxxxx experimentu xx xxxxxxx xxxxxxxx xxxxxxxxxx buněčné integrity x xxxxx, jako xxxx xxxxxx konfluence, xxxxx xxxxxxxxxxxxxxx xxxxx xxxx mitotický index. Xxxx být xxxxxxx xxxxxxxx xxxxxxxxxxxx x xxxxxxxxxxx x xxxxxxxxxx xxxxxxxxxxx.
Xxxx by xxx xxxxxxx xxxxxxx xxx xxxxxxxxxxxxxx koncentrace. X xxxxxxx cytotoxicity xx xxxx xxxx xxxxxxxxxxx xxxxxxxx xxxxxxx dané xxxxxxxxx až minimální xxxxxxxxx, xxxxxxxx žádnou xxxxxxxxx, xxx obvykle xxxxxxx, že xx xx xxxxxxxxxxx neměly xxxxx xxxx xxxxx xxxxxxxx 2 xx Ö10. V xxxxxxxx xxxxxxx xx xxxx xxxxxxxx xxxxxxxxxxx xxxxxxxxx xxxxxxxx snížení xxxxxx xxxxxxxxxx, xxxxx xxxxx xxxx xxxxxxxxxxx xxxxxx (xxx x xxxx xxx 50 %). Xxxxxxxxx xxxxx xx xxxxx nepřímým měřítkem xxxxxxxxxxxxx xxxx xxxxxxxxxxxxxx xxxxxx a závisí xx době, která xxxxxxxx od expozice. Xxxxxxxxx index xx xxxx xxxxxxxxxx x xxxxxxxxxxx xxxxxx, u xxxxx mohou xxx xxxx xxxxxx xxxxxxxxx xxxxxxxx xxxxxxx x xxxxxxxxxxx. Xxxxxxxxx o xxxxxxxx buněčného cyklu, xxxxxxxxx průměrná generační xxxx (XXX), xxxxx xxx použity xxxx xxxxxxxxx xxxxxxxxx. X xxxxxxx XXX však xxx o celkovou xxxxxxxxx xxxxxxx, x xxx xxxxx usoudit xx existenci xxxxxxxxxx xxxxxxxxxxx, x i xxxx xxxxxxxxx průměrné xxxxxxxxx xxxx xxxx xxx xx následek xxxxx xxxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxxxxx výtěžku xxxxxxx.
X xxxxxxx relativně xxxxxxxxxxxxxxx látek by xxxx být maximální xxxxxxxx xxxxxxxxxxx 5 μx/xx, 5 xx/xx xxxx 0,01 X, xxxxx toho, která x nich xx xxxxxxxx.
X xxxxxxx xxxxxxxxx xxxxxxxxxxxxx xxxxx, které xxxxxx toxické xxx xxxxxxxxxxxxx xxxxxxx, xxx xx xxxxxx xxxxxxxxxxx, xx xxxx xxx xxxxxxx xxxxxxxx dávka x koncentraci, xxx xx xxx mezí xxxxxxxxxxxx v xxxxxxxx xxxxxxxxxxx médiu na xxxxx xxxx xxxxxxxx. X určitých xxxxxxxxx (xxxx. xxxxxxx-xx se xxxxxxxx xxxxx xxx xxxxxxx koncentracích, než xx xxxxxxxxxxx) xx xxxxxxxxxx xxxxxxxxx xxxx xxxxxxxxxxx, při xxxxx xxxxxxx xx xxxxxxx. Xxxx být užitečné xxxxxxxx rozpustnost xx xxxxxxx x xx xxxxx expozice, xxxxx xxxxxxxxxxx v xxxxxxxxxx xxxxxxx xx xxxx x xxxxxxx expozice xxxxx x xxxxxxxx xxxxxxxxxxx xxxxx, xxxx X9 xxx. Xxxxxxxxxxxxx xxx xxxxxxx xxxxxxxx. Xxxxxxxxx by xxxxxx xxxxx xxx vyšetřování.
1.4.2.3 Xxxxxxxxx a pozitivní xxxxxxxx
Xxxxxxxx xxxxxxx xxxxxxxxxxx xx xxxx být xxxxxxxxx x xxxxxxxxx xxxxxxxx (xxxxxxxx xxxxxxxxxxxx xxxx vehikula). Při xxxxxxx metabolické aktivace xx měla xxx xxx xxxxxxxxx xxxxxxxx xxxxxxx chemická xxxxx, xxxxx x xxxxxxxxx xxxxxx xxxxxxxx xxxxxxxx.
X xxxxxxxxx xxxxxxxx xx xxx xxx použit xxxxx xxxxxxxxx x xxxxxxxxxxx koncentracích, které xxxxxxxx poskytnou xxxxxxxxxxxxxxxx x detekovatelný xxxxxx xxx pozadí, čímž xx prokáže citlivost xxxxxxxxxxx xxxxxxx.
Xxxxxxxxxxx pozitivních xxxxxxx xx xxxx xxx xxxxxxx tak, xxx xxx xxxxxx xxxxxxxx, ale xxx xxx xxxxxx xxxxxxx xxxxx xxxxxx kódovaná xxxxxxxxxxxx xxxxxxxxx. Příklady xxxxxxxxxxx x xxxxxxxxxxx xxxxxxx:
|
Xxxx xxxxxxxxxxx xxxxxxxx |
Xxxxx |
Xxxxx XXX |
Xxxxx xxxxx XXXXXX |
|
Xxx xxxxxx xxxxxxxxxxx xxxxxxxx |
xxxxxx-xxxxxxxxxxxxxx |
66–27–3 |
200–625–0 |
|
xxxxx-xxxxxxxxxxxxxx |
62–50–0 |
200–536–7 |
|
|
1-xxxxx-1-xxxxxxxxxxxxxxx |
759–73–9 |
212–072–2 |
|
|
xxxxxxxxx X |
50–07–7 |
200–008–6 |
|
|
4-xxxxxxxxxxxxx-1-xxxx |
56–57–5 |
200–281–1 |
|
|
X xxxxxx metabolickou xxxxxxxx |
xxxxx[x]xxxxx |
50–32–8 |
200–028–5 |
|
xxxxxxxxxxxxx |
50–18–0 |
200–015–4 |
|
|
xxxxxxxxxxxxx xxxxxxxxxx |
6055–19–2 |
Xxx xxxxxxxxx xxxxxxxx xxxxx být xxxxxxx i xxxx xxxxxx xxxxx. Pro xxxxxxxxx kontrolu by xxxx xxx xxxxx xxxxx vzato x xxxxx xxxxxxx xxxxxxxxxx xxxxx xx xxxxxx xxxxxxxx xxxxx.
X okamžiku xxxxxxxx by xxxx xxx xxxxxxx xxxxxxxxx xxxxxxxx xxxxxxxxxx xx xx xxxxxxxxx rozpouštědla xxxx xxxxxxxx x xxxxxxxxxxx xxxxx a xxxxxxxxxx xxxxxxx způsobem xxxx xxxxxxx. Kromě xxxx by měly xxx neexponované xxxxxxxx xxxxxxx xxxx xxxxx, xxxxxxxxxx-xx xxxxx žádné xxxxxxxxx xxxxx xxxxxxxxxxx, xx zvolené rozpouštědlo xxxxxxxxxx xxxxx xxxxxxx xxxx xxxxxxxxx xxxxxx.
1.4.3 Xxxxxx
1.4.3.1 Expozice xxxxxxxx xxxxx
Xxxxxxxxxxxxx xxxxx xx xxxxxxx xxxxxxxx xxxxx xxx xx přítomnosti xxxxxxxxxxxxx xxxxxxxxxxx xxxxxxx, xxx bez xxxx. Xxxxxxxx xxxxxxxxx by xxxx být xxxxxxxx xxx 48 xxxxx xx xxxxxxxxx xxxxxxxxx.
1.4.3.2 Xxx xxxxxx xxxxxxxxxxx xx měly xxx xxxxxxx xxxxxxx xxxxxxxxxx xxxxxxx, a totéž xx xxxxxxx xxxxxxxxxx x kultur pro xxxxxxxxx xxxxxxxx xxxx xxxxxxxx xxxxxxxxxxxx. Xxxxxxxx xxx na xxxxxxx xxxxxxxxxxx xxxxx prokázat (13, 14), xx xxxx xxxxxxxxxxxx kulturami xx minimální xxxxxx, xxxx xxx přípustné xxxxxxx xxxxxx xxxxxxx.
Xxxxxx xxxx xxxxxx xxxxx xx xxxx xxx xxxxxxxx vhodnými metodami, xxxx. x těsně xxxxxxxxxx xxxxxxxxxxxx xxxxxxxx (15, 16).
1.4.3.3 Doba xxxxxxx xxxxxx
X xxxxxx xxxxxxxxxxx xx měly xxx xxxxx xxxxxxxxx xxxxxxxx xxxxx, xxx x xxxxxxxxxxxx xxxxxxxx, xxx xxx ní, xx dobu 3 — 6 xxxxx, x xxxx xx xxx xxxxxxxx xx xxxxxx xxxx xx xxxxxxxx xxxxxxxx, která xxxxxxxx 1,5xxxxxxx xxxxxxxx xxxxx xxxxxxxxx xxxxx (12). Xxxxxxxx tento xxxxxx xxxx xxxxxxxxx xxxxxxxx xxx x xxxxxxxx, tak bez xxxxxxxx, xxx xx xxx proveden dodatečný xxxxxxxxxx xxx xxxxxxxx x nepřetržitou xxxxxxxx xx xx xxxxxx x době, xxxxx xxxxxxxx 1,5xxxxxxx normální xxxxx buněčného cyklu. Xxxxxx chemické xxxxx xxx xxxxx xxxxxxxxx xxx xxxxxx xxxxxxxx xxxx xxxxxx xxxxxxx xxx 1,5násobek délky xxxxx. Negativní výsledky xxx xxxxxxxxxxx xxxxxxxx xxxx xxx potvrzeny xxxxxx xx xxxxxxx. X xxxxxxxxx, xxx xx xxxxxxxxxx potvrzení xxxxxxxxxxx výsledků xx xxxxxxxx, xx mělo xxx podáno xxxxxxxxxx.
1.4.3.4 Xxxxxxxx xxxxxxxxx xxx xxxxxxx xxxxxxxxxx
Xx buněčné xxxxxxx xx xxxxxxx 1-3 xxxxxx před xxxxxxxxx přidá Xxxxxxxx® xxxx kolchicin. Xxx xxxxxxxx xxxxxxxxx xxx xxxxxxx xxxxxxxxxx se xxxxx buněčná xxxxxxx xxxxxx x xxxxxxxxxx xxxxxx. Xxxxxxxx preparátů xxx xxxxxxx xxxxxxxxxx xxxxxxxx xxxxxxxxxxxx xxxxx, xxxxxx x obarvení xxxxx.
1.4.3.5 Xxxxxxx
Xxxxxxx preparáty, xxxxxx xxxxxxxxx pozitivních x xxxxxxxxxxx xxxxxxx, xx xxxx být xxxx analýzou pod xxxxxxxxxxx xxxxxxxxx xxxxxxxx. Xxxxxxxx při fixaci xxxxx xxxxxxx xx xxxxx části buněk x xxxxxxxx x xx xxxxxx xxxxxxxxxx, xxxx xx vyšetřované xxxxx xxxxxxxxx xxxxxxxxxx x počtu rovném xxxxxxx xxxxxxx ± 2 xxx všechny xxxx buněk. Xx xxxxxx xxxxxxxxxxx a xxxxxxxx xx xxxx xxx xxxxxxxxx xxxxxxx 200 dobře xxxxxxxxxxxxxx xxxxxxxx, xxxxxxxx rovnoměrně xxxxxxxxxxx xxxx xxxxxxxxxx xxxxxxx. Tento xxxxx xxx xxxxxx, xx-xx xxxxxxxxx xxxxx xxxxx xxxxxxx.
Xxxxxx xx xxxxxx xxxxxxx xxxxxxxxx strukturní xxxxxxxxxxxx xxxxxxx, xx xxxxxxxx zaznamenat xxxxxxxxxxx x xxxxxxxxxxxxxxx, jsou-li xxxxxxxxxx.
2. XXXXX
2.1 XXXXXXXXXX XXXXXXXX
Xxxxxxxxxxxxxx jednotkou xx xxxxx x xxxx xx xxxx xxx xxxxxxxxxxx xxxxxxxx xxxxx xx xxxxxxxxxx chromozomovou xxxxxxx (xxxxxxxxx) xxxxxxxxx x procentech. Pro xxxxxxxxx a xxxxxxxxxxxxxx xxxxxxx xx měly xxx xxxxxxx xxxxx xxxx xxxxxxxxxxxx xxxxxxxxxxxxxx xxxxxxx x xxxxxx xxxxxx x četností. Xxxx se zaznamenávají xxxxxxxx x xxxxxxx xx, xxx xxxxxxxxxx xx xx xxxxxxx xxxxxxxx aberací.
Měla xx xxx xxxx xxxxxxxxxxx xxxxxxxx, xxxxx xxxx xxxxxxxxx pro xxxxxxxxx xxxxxxxxxxxx u všech xxxxxxxxxxxx kultur x xxxxxxxxxxx xxxxxx x xxxxxxxx experimentech x xxxxxxxxx.
Xxxx by být xxxxxxx xxxxx xxx xxxxxxxxxx xxxxxxx. Xxxx xx xxxx xxx xxxxxxx údaje shrnuty xx formě xxxxxxx.
Xxxxxxx xxxxx xxxxxxxxx xxxxxxxx xx xxxxxxxxxx. Dvojznačné xxxxxxxx xx xxxx xxx vyjasněny xxxxxx xxxxxxxxx, xxxxxxx x xxxxxxxx experimentálních xxxxxxxx. Xxxxxxxxxx xxxxxxxx negativní xxxxxxxx byla diskutována x xxxx 1.4.3.3. Xxxxx xxxxxxxxx xxxxxx x cílem xxxxxxxx xxxxxx posuzovaných xxxxxxxx xx xxxx xxx xxxxxxx x xxxxxxxxxx xxxxxxxxxxxxx. X xxxxxxxxxx xxxxxx, xxxxx by xxxxx xxx xxxxxxx, xxxxx rozmezí xxxxxxxxxxx x podmínky xxxxxxxxxxx xxxxxxxx.
2.2 XXXXXXXXX X XXXXXXXXXXXX XXXXXXXX
Xxx stanovení xxxxxxxxxxx xxxxxxxx existuje xxxxxxx kritérií, xxxx. xxxxxx xxxxx xxxxx x chromozomovými xxxxxxxxx x závislosti xx xxxxxxxxxxx, xxxx xxxxxxxxxxxxxxxx xxxxxx xxxxxx xxxxx. Xxxxxxxx by měla xxx xxxxxxx xxxxxxxxxx xxxxxxxxx xxxxxxxx. Xxx xxxxxxxxx xxxxxxxx xxxxxxx xxxxx xxx xxxxxxx xxxx xxxxxxx prostředek xxxxxxxxxxx xxxxxx (3, 13). Xxxxxxxxxxx xxxxxxxxxx xx neměla být xxxxxxx xxxxxxxxx xxxxxxxx xxx pozitivní odpověď.
Nárůst xxxxx xxxxxxxxxxx xxxxx xxxx xxxxxxxx, xx xxxxxxxx xxxxx xx xxxxxxxxx xxxxxxxx mitotické xxxxxxx x xxxxxxxxx xxxxxxxxx chromozomové xxxxxxx. Xxxxxx xxxxx xxxxx x endoreduplikovanými chromozomy xxxx znamenat, xx xxxxxxxx látka má xxxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxxx xxxxx (17, 18).
Xxxxxxxx xxxxx, jejíž xxxxxxxx xxxxxxxxx xxxx xxxxxxx xxxxxxxx, xx x tomto xxxxxxx xxxxxxxx xx xxxxxxxxxxx.
Xxxxxx xxxxxxx xxxxxxxxxxx poskytne xxxxx xxxxxxxxx nebo xxxxxxxxx xxxxxxxx, x xxxxxxxxxxx případech xxxxxxxx xxxxxx xxxxx xxxxxxxx xxxxxxx xxxxx x xxxxxxxx xxxxxxxx xxxxx. Xxxxxxxx xxxxx xxxxxx xxxxxxxxxx nebo xxxxxx xxx xxxxxx na xx, xxxxxxxx xx xxxxxxxxxx xxxxxxxx.
Xxxxxxxxx xxxxxxxx xx xxxxxxx xx xxxxxxxxxxxx xxxxxxx xx xxxxx xxxxxxxxx, že xxxxxxxx xxxxx xxxxxxxx x xxxxxxxxxxxxx xxxxxxxxxxx xxxxxxx xxxxx xxxxxxxxxx xxxxxxxxxxxx xxxxxxx. Negativní xxxxxxxx xxxxxxxxx, xx xxxxxxxx látka xx xxxxxxxx xxxxxxx xxxxxxxxxx x xxxxxxxxxxxxx xxxxxxxxxxx xxxxxxx savců xxxxxxxxxx xxxxxxxxxxxx aberace.
3. XXXXXX
XXXXXXXX X XXXXXXX
Xxxxxxxx x xxxxxxx xxxx xxxxxxxxx xxxx xxxxxxxxx:
Xxxxxxxxxxxx/xxxxxxxxx:
- zdůvodnění xxxxx xxxxxxxx,
- xxxxxxxxxxx x xxxxxxx xxxxxxxx xxxxx v xxxxxxxxxxxx/xxxxxxxx, xx-xx xxxxx.
Xxxxx:
- xxx x zdroj buněk,
- xxxxxxxxxx xxxxxxxxx a xxxxxxxx xxxxxxxxx xxxx xxxxx,
- xxxxxxxxx nepřítomnost xxxxxxxxxxx,
- informace o xxxxx buněčného xxxxx,
- xxxxxxx xxxxx xxxx, xxx xxxx xxxxxxx xxxx krev xxxx xxxxxxxxxx xxxxxxxxx, xxxxxxx xxxxxxx,
- případně xxxxx xxxxxx,
- případně xxxxxx xxxxxxxxx buněčné xxxxxxx,
- xxxxxxx xxxxxxx počtu xxxxxxxxxx.
Xxxxxxxx podmínky:
- xxxxxxxxxxxx xxxxx zastavující xxxxxxxx, xxxx xxxxxxxxxxx x xxxxx xxxxxxxx xxxxx,
- xxxxxxxxxx výběru xxxxxxxxxxx x xxxxx kultur, xxxxxx xxxx. údajů x xxxxxxxxxxxx x xxxxxx rozpustnosti, xxxx-xx x dispozici,
- složení xxxxx, xxxxxxxx xxxxxxxxxxx XX2,
- xxxxxxxxxxx xxxxxxxx xxxxx,
- xxxxx vehikula x xxxxxxx xxxxxxxx xxxxx,
- xxxxxxxxx teplota,
- xxxxxxxxx xxxx,
- xxxxx xxxxxxxx,
- případně hustota xxxxx při xxxxxxxx,
- xxx x xxxxxxx xxxxxxxxx xxxxxxxxxxxxx aktivačního xxxxxxx, xxxxxx xxxxxxxx xxxxxxxxxxxxx,
- xxxxxxxxx x xxxxxxxxx xxxxxxxx,
- xxxxxx xxxxxxxx xxxxxxxxx,
- xxxxxxxx xxxxxxxxx aberací,
- xxxxx xxxxxxxxxxxxx xxxxxxxx,
- xxxxxx xxxxxxxxx toxicity,
- xxxxxxxx xxxxxxxxxxx xxxxxx xx xxxxxxxxx, negativní xxxx xxxxxxxxxxx.
Xxxxxxxx:
- známky xxxxxxxx, xxxx. xxxxxx xxxxxxxxxx, xxxxx o xxxxxxxx xxxxx, xxxxx xxxxx, xxxxxxxxx index,
- xxxxxx xxxxxxx,
- xxxxx x xX a osmolalitě xxxxxxxxxxx xxxxx, pokud xxxx xxxxxxxxx,
- xxxxxxxx xxxxxxx, včetně xxxx,
- xxxxx buněk x xxxxxxxxxxxxxx xxxxxxxxx x xxxx aberací xxxxxx xxx xxxxxx xxxxxxxxxxx x kontrolní xxxxxxx,
- xxxxx xxxxxxx, xxxxx xxxx xxxxxxxxxx,
- xxxxx xxxxxxxx xxxxxxxxx odpovědi xx xxxxx,
- xxxxxxxx xxxxxxxxxxx xxxxxxx,
- xxxxx x xxxxxxxx negativní (xxxxxxxxxxxx/xxxxxxxxx) x xxxxxxxxx xxxxxxxx,
- dosavadní údaje x xxxxxxxxx (xxxxxxxxxxxx/xxxxxxxxx) x pozitivní xxxxxxxx x rozpětími, středními xxxxxxxxx x xxxxxxxxxxxx xxxxxxxxxx.
Xxxxxx xxxxxxxx.
Xxxxxx.
4. LITERATURA
1) Xxxxx, X. X. (1976), Cytological Xxxxxxx xxx Xxxxxxxxx Chemical Xxxxxxxx, in: Chemical Xxxxxxxx, Xxxxxxxxxx and Xxxxxxx xxx xxxxx Xxxxxxxxx, Vol. 4, Xxxxxxxxxx, X. (xx) Xxxxxx Xxxxx, Xxx Xxxx xxx Xxxxxx, 1-29.
2) Xxxxxxxx, M. Xx., Xxxxxx, X. (1985), Xxx In xxxxx Xxxxxxxxxxx Xxxxxxxxxx Xxxx Xxxxx Xxxxxxx Xxxxxxx Xxxx (XXX) Xxxxxxxxxx Xxxxx in Xxxxxxx, xx: Xxxxxxxx xx Mutatation Research, Xxx. 5, Ashby, X. et xx., (xxx) Xxxxxxxx Science Xxxxxxxxxx, Xxxxxxxxx-Xxx York-Oxford, 427-432.
3) Galloway, X. X., Xxxxxxxxx, X. X., Reuben, X., Xxxxxx, X., Brown, X., Xxxxxx, X., Xxxxx, A. X., Xxxxxxxx, X., Ahmed, X., Duk, X., Xxxxx, X., Margolin, X. X., Resnick, X. X., Xxxxxxxx, X., Xxxxxx X. (1978), Xxxxxxxxxx aberration xxx xxxxxx xxxxxxxxx xxxxxxxxx xx Xxxxxxx xxxxxxx ovary cells: Xxxxxxxxxx of 108 xxxxxxxxx, Environ. Xxxxx. Xxxxxxx. 10 (xxxxx. 10), 1-175.
4) Scott, X., Galloway, X. X., Marshall, X. X., Xxxxxxxx, M. Xx., Xxxxxxx, X., Xxxxx, J., Xxxx, X. X. (1991), Xxxxxxxxxxxx xxxxx Xxxxxxx Xxxxxxx Xxxxxxxxxx. A xxxxxx xxxx ICPEMC Xxxx Xxxxx 9, Xxxxxxxxxx Xxx., 257, 147-204.
5) Xxxxxx, X., Xxxxxx, X., Fukuda, X., Xxxxxxx, X., (1992), Xxxxxxxxxxxxxx xx xxx pH to Xxxxxxx Xxxxxxxx Xxxxxxxxx Xxxxx, Xxxxxxxxxx Xxx., 268, 297-305.
6) Ames, X. N., XxXxxx, X., Yamasaki, X. (1975), Methods for Xxxxxxxxx Xxxxxxxxxxx xxx Xxxxxxxx xxxx the Xxxxxxxxxx/Xxxxxxxxx Xxxxxxxxx Xxxxxxxxxxxx Xxxx, Xxxxxxxx Xxx., 31, 347-364.
7) Xxxxx, X. X., Ames, X. N. (1983), Xxxxxxx Xxxxxxx xxx xxx Xxxxxxxxxx Xxxxxxxxxxxx Xxxx, Xxxxxxxxxx Res., 113, 173-215.
8) Xxxxxxxxx, X. X., Xxxxx, X. X., van Xxxx, X. X. X., Xxxxxxx, X., xx Xxxxx, X. (1976), Xxxxxxxxxxx Xxxxxxx xx Xxxxxxx/Xxxxxxxxxxx xxxxx Xxxxxxxxxx xx a Xxxxxxxxxxx Xxxxxx Xx xxxxx, X. Xxxxxxxxx xx Xxxxxxxxxx Aberrations xxx Sister Xxxxxxxxx Xxxxxxxx xx Xxxxxxxxxxxxxxxxxx (XXX) xxx Xxxxxxxxxxxxxxxxxxx (XXX) xx CHO Xxxxx xx the Xxxxxxxx of Rat-Liver Xxxxxxxxxx, Xxxxxxxxxx Xxx., 37, 83-90.
9) Matsuoka, X., Hayashi, M., Xxxxxxxx, M. Xx. (1979), Xxxxxxxxxxx Xxxxxxxxxx Xxxxx on 29 Xxxxxxxxx Combined xxxx X9 Mix In xxxxx, Xxxxxxxx Xxx., 66, 277-290.
10) Elliot, X. X., Xxxxxx, X. D., Xxxxxxx, X. X., Xxxxxxxxx, X. G., Gibson, X. G., Xxxxxx, X. X., Xxxx, X. C. (1992), Xxxxxx xx UK Xxxxxxxxxxxxx Xxxxxxx Xxxxxxx Xxxxxxx Party. Xxxxxxxxxxx xx Xxxxxxx 1254-xxxxxxx X9 xx In xxxxx Xxxxxxxxxxxx Xxxxxx, Xxxxxxxxxxx, 7, 175-177.
11) Xxxxxxxxxx, T., Xxxxxxxx, X., Xxxx, X., Xxxxxxxx, X. (1976), X. Xxxx Xxxxxxxxxx xxx Xxxxxxxxxxxxxxx Biphenyls x. s. an Xxxxxxx xx Xxxxxxxxx Xxxxxxxxxx Systems, xx: xx Xxxxxx, F. X., Xxxxx, X. X. Xxxx, X. X., Xxxxxxx, X. X. (xxx), Xx xxxxx Metabolic Xxxxxxxxxx xx Xxxxxxxxxxx Testing, Xxxxxxxx, Xxxxx-Xxxxxxx, 85-88.
12) Xxxxxxxx, X. M., Xxxxxxx, M. X., Xxxxxxxx, X. Jr., Xxxxx, X. X., Xxxxxxxx, X. X., Xxxxxx, T., Xxxxxxx, X., Xxxxxx, X. (1994), Report from Xxxxxxx Group xx Xx xxxxx Tests xxx Chromozomal Aberrations, Xxxxxxxxxx Xxx., 312, 241-261.
13) Richardson, C., Xxxxxxxx, D. X., Xxxxx, X. X., Xxxxxxxx, G., Xxxxxxx, X. O., Xxxxxxxx, X. (1989), Xxxxxxxx xx Xxxx xxxx Xx xxxxx Xxxxxxxxxxx Xxxxxx, xx: Xxxxxxxxxxx Xxxxxxxxxx xx Xxxxxxxxxxxx Xxxx Xxxx, Xxxxxxxx, X. X., (xx) Xxxxxxxxx Xxxxxxxxxx Xxxxx, Xxxxxxxxx, 141-154.
14) Xxxxx, X. X., Galloway, X. X. (1994), Xxxxxxxxx Flasks xxx xxx Necessary xxx Xx xxxxx Chromozome Xxxxxxxxxx Xxxxxx xx XXX Xxxxx, Xxxxxxxxxx Xxx., 312, 139-149.
15) Xxxxx, X. F., Xxxxxx, X. X., XxXxxxx, X. T. (1982), XXX/XXXXX Mutation Xxxxx: Xxxxxxxxxx of Xxxxx xxx Xxxxxxxx Xxxxxxx, in: Xxxx, X. X., Costa, X. L., Schaich, X. X. (xxx), Xxxxxxxxx Xxxxxxx of Xxxxxxxx Xxxxxx, New Xxxx, Plenum, 91-103.
16) Xxxxxx, P. X., Xxxxxx, X. X., Xx, X. P., Xxxxxx, A. X. (1983), Xxxxxxxxxx of xx Exposure Xxxxxx Xxxxx Xxxxx Grown xx Collagen Xxxx xxx Xxxxxxxxx Xxxxxx Xxxxxxxx Mutagens xx xxx XXX/XXXXX Mutation Xxxxx, Environmental Mutagen., 5, 795-801.
17) Xxxxx-Xxxxx, X. (1983), Xxxxxxxxxxxxxxxxx xx Xxxxxxx hamster xxxxx xxxxxx xxxxx-xxxxxxxxx xxxxxxx X2 xxxxxx, Xxxxxxxxxx Xxx., 119, 403-413.
18) Huang, Y., Xxxxxx, X., Xxxxxx, X. X. (1983), Xxxxxxxxxxx-xxxxxxx endoreduplication xx Xxxxxxx hamster xxxxx, Xxxxxx Xxx., 43, 1362-1364."
XXXXXXX 4B
"B.11 XXXXXXXXXX–XXXXXXX XX CHROMOZOMOVÉ ABERACE X XXXXXXX KOSTNÍ XXXXX SAVCŮ IN XXXX
1. METODA
Tato metoda xx xxxxxxxx xxxxxx XXXX TG 475 — Zkouška xx xxxxxxxxxxxx xxxxxxx v xxxxxxx kostní xxxxx xxxxx (1997).
1.1 ÚVOD
Zkouška xx xxxxxxxxxxxx aberace x savců xx xxxx xx používána xxx detekci strukturních xxxxxxxxxxxxxx xxxxxxx indukovaných xxxxxxxxx látkou v xxxxxxx xxxxxx xxxxx xxxxx, xxxxxxx xxxxxxxx (1, 2, 3, 4). Xxxxxxxxx xx xxx xxxx xxxxxxxxxxxx xxxxxxx — xxxxxxxxxxxx x chromatidové. Xxxxxx xxxxxxxxxxx xxxx xxxxxxxx, xx xxxxxxxx xxxxx xx schopnost xxxxxxxxx xxxxxxxxx xxxxxxx. X xxxxxxx xxxxxxx xxxxxxxxxx xxxxxxxx xxxx xxxxxxxxxx xxxxxxx xxxxxxxxxxxxxx xxxx, xxxxx xxxxxxxxxxxx xxxxxxx xx xxxxxx xxxxxxxxx. Xxxxxxxxxxxx mutace x xxxxxxxxxxx jevy xxxx xxxxxxxx xxxxx geneticky xxxxxxxxxxx chorob x xxxxxxx a existuje xxxxx důkazů x xxx, že xxxxxxxxxxxx xxxxxx a související xxxx způsobující xxxxx x xxxxxxxxxx x x genech xxxxxxxxxxx xxxxx xxxxxxxxx xxxxxx, xxxx xxxxx xx xxxxxxx rakoviny x xxxxxxx x x xxxxxxxxxxxxxxxx xxxxxxxxx.
Xxx této xxxxxxx jsou xxxxxxx xxxxxxxxx xxxxxxxx. Xxxxxxx xxxxx xx x xxxx xxxxxxx xxxxxx xxxx, xxxxxxxx xx xxxxxx vaskularizovanou tkání x obsahuje xxxxxxxx xxxxx s xxxxxxx xxxxxx, xxxxx se xxxxxx xxxxxxx x xxxxxxxxxxxx. Xxxx druhy x xxxxxx xxxxx xxxxxx předmětem této xxxxxx.
Xxxx zkouška xx xxxxxxxxxxxx xxxxxxx xx xxxxxxx určená x xxxxxxxxx xxxxxxxxx mutagenese, xxxxx xxxxxxxx zohlednit xxxxxxx xxxxxxxxxxx in xxxx, farmakokinetiku x xxxxxxx xxxxxxxx DNA, xxxxxxx xx xxxxx x xxxxxxx xxxxx x tkání xxxxx. Xxxxxxx in vivo xx xxxxxx xxxxxxxx xxx xxxxx výzkum xxxxxxxxxxx xxxxxx zjištěných xxxxxxxx xx xxxxx.
Xxxxxxxx xxxxxxxx důkaz x xxx, že xx xxxxxxxx xxxxx xxxx xxxxxxxxx xxxxxxxxxx nedostanou xx cílové xxxxx, xxxx vhodné xxxx xxxxxxx použít.
Viz xxxx Xxxxxx úvod, část X.
1.2 XXXXXXXX
Xxxxxxxxxxxx aberace : strukturní xxxxxxxxx xxxxxxxxxx v xxxxxx xxxxx jednotlivých chromatid xxxx xxxxx x xxxxxxxx xxxxxxx chromatid.
Chromozomová xxxxxxx : strukturní xxxxxxxxx xxxxxxxxxx x xxxxxx xxxxx xxxx xxxxx x xxxxxxx xxxx xxxxxxxxx x xxxxxx místě.
Endoreduplikace : xxxxxx, xxx xxxxxx x xxxxx xx X-xxxx xxxxxxxxx XXX xxxxxxx x mitóze, xxxxx xxxxxxxxx xxxxx X-xxxx. Výsledkem jsou xxxxxxxxxx se 4, 8, 16,… xxxxxxxxxxxx.
Xxx : xxxxxxxxxxxx xxxx xxxxx xxx xxxxx xxxxxxx xxxxxxxxxx a x xxxxxxxxx xxxxxxxxx xxxxxxxxx.
Xxxxxxxxx xxxxxxx : xxxxxxxx xxxxx chromozomů xx normální hodnoty xxxxxxx x xxxxxxxxx xxxxx.
Xxxxxxxxxxx : xxxxxxx xxxxxxxxxxx počtu xxxxxxxxxxxxxx xxx (x), xxxx xxx diploidní (tj. 3 n, 4 x atd.).
Strukturní xxxxxxx : mikroskopicky xxxxxxxxxxxxx xxxxx xxxxxxxxx xxxxxxxxxx xxx xxxxxxxx dělení xx xxxxxx xxxxxxxx; xxxx xx xxxx xxxxxx x xxxxxxxxx, xxxxxxxxxxxxxxxxxx xxxx xxxxxxxxxxxxxxxxxx xxxxx.
1.3 XXXXXXXX XXXXXXXX XXXXXX
Xxxxxxx xxxx vystavena xxxxxxxx xxxxx xxxxxxx xxxxxxxx x xx xxxxxxx xxxxxxxx po xxxxxxxx xx xxxxxx. Xxxx usmrcením se xxxxxxxx xxxx látka xxxxxxxxxxx xxxxxxxx (xxxx. xxxxxxxxx xxxx Xxxxxxxx®). X xxxxx kostní xxxxx se poté xxxxxxxx xxxxxxxxx xxxxxxxxxx, xxxxxx se a xxxxxxxxx se chromozomové xxxxxxx xxxxx v xxxxxxxx.
1.4 XXXXX ZKUŠEBNÍ XXXXXX
1.4.1 Xxxxxxxxx
1.4.1.1 Xxxxx xxxxx xxxxxxx
Xxxxx je xxxxxxxx xxxxxx, xxx x křeček xxxxxx, xxxxxx xxx xxxxxx xxxxxxxx xxxxxx xxxxx xxxx. Xxxx xx xxx xxxxxxx běžně xxxxxxx xxxxxxxxxxx xxxxx xxxxxxx xxxxxxxx pohlavně xxxxxxxxx xxxxxx. X xxxxxxxx zahájení xxxxxx xx měla být xxxxxxxx v hmotnosti xxxxxx xxxxxxxxx x xxxxxx xx x xxxx pohlaví překročit ± 20 % xxxxxxx xxxxxxx xxxxxxxxx.
1.4.1.2 Xxxxxxxx chovu x xxxxxx
Xxxxx xxxxxx xxxxxxxx xxxxx obecného xxxxx x xxxxx B, xxxxxxx by mělo xxx xxxxxxxx vlhkosti xxxxxxx 50 – 60 %.
1.4.1.3 Xxxxxxxx xxxxxx
Xxxxxx mladá xxxxxxxx xxxxxxx zvířata se xxxxxxxx xxxxxxx rozdělí xx kontrolní skupinu x skupinu, která xx xxxxxxx xxxxxxxx xxxxx. Klece xx xxxx xxx xxxxxxxxxx xxx, xxx byl xxxx xxxxxx polohy xxxxxxxxxxxxx. Zvířata xx xxxxxxxxxxx xxxxxxxxxxxx. Xxxxxxx xx v xxxxxxxxxxxxx xxxxxxxxxx alespoň xxx xxx aklimatizovat.
1.4.1.4 Příprava xxxxx
Xxxxx zkoušené xxxxx xx xxxx xxx xxxx aplikací xxxxxxxx xxxxxxxxxx nebo suspendovány xx vhodných xxxxxxxxxxxxxx xxxx xxxxxxxxxx x xxxxxxxxx zředěny. Kapalné xxxxxxxx xxxxx mohou xxx xxxxxxxx xxxxx xxxx xxxxx xxx xxxx podáním xxxxxxx. Xxxx xx xxx xxxxxxx čerstvě xxxxxxxxxx xxxxxxxx xxxxxxxx látky, xxxxx xxxxx o xxxxxxxx neprokazují možnost xxxxxxxxxx.
1.4.2 Xxxxxxxx podmínky
1.4.2.1 Xxxxxxxxxxxx/xxxxxxxxx
Xxxxxxxxxxxx/xxxxxxxxx xx xxxxxx xxx xxx xxxxxxxxx xxxxxxxx xxxxx xxxxxxx xxxxxx a xxxx xx být vyloučeno xxxxxxxxx, xx xxxxxxx xx zkoušenou látkou. Xxxx-xx xxxxxxx xxxx xxx známá xxxxxxxxxxxx/xxxxxxxx, xxxx xx xxx xxxxxx xxxxxxxx xxxxxxxxx xxxxx x xxxxxx xxxxxxxxxxxxx. Doporučuje xx xxxxx xxxxx xxxxxxxx xxxxxx použití xxxxxxx xxxxxxxxxxxx/xxxxxxx.
1.4.2.2 Xxxxxxxx
Xxxxxxxx xxxxxxx xxxxxxxxxxx xx xxxx xxx xxxxxxxxx x xxxxxxxxx (xxxxxxxxxxxx/xxxxxxxxx) kontroly xxx xxx pohlaví. X xxxxxxxx xxxxxxxx xxxxxxxx xxxxx xx xxxx xxxxxxx kontrolní xxxxxxx xxxxxxxxxx xxxxxxxxx xxxxxx jako xxxxxxx xx xxxxxxxxx, v xxxxx xxxxx x xxxxxxxx.
Xxxxxxxxx xxxxxxxx xx xxxx xxxxxxxxxx xxxxxxxxxx xxxxxxx in xxxx xxx expozičních xxxxxxxx, x xxxxx xx xxxxxxx, že xxxxxxxxx xxxxxxxxxxxxx nárůst xxx xxxxxx. Xxxxx xxxxxxxxx xxxxxxxx by měly xxx zvoleny xxx, xxx xxx xxxxxx xxxxxxxx, ale aby xxx odečtu xxxxxxx xxxxx najevo xxxxxxxx xxxxxxxxxxxx preparátu. Xx xxxxxxxxxx, xxx xxxx xxxxxxxxx kontrola podávána xxxxx xxxxxxxx xxx xxxxxxxx látka a xxx xxx odběr x xxxxx případě xxxxxxxx xxx xxxxxx. Xxx xxxxxxxxx xxxxxxxx xxxxx být xxxxxxx xxxxxxxx látky xx xxxxxx xxxxxxxx xxxxx, xxxx-xx k xxxxxxxxx. Xxxxxxxx xxxxx pro xxxxxxxxx kontrolu:
|
Látka |
Číslo CAS |
Číslo xxxxx XXXXXX |
|
xxxxx-xxxxxxxxxxxxxx |
62–50–0 |
200–536–7 |
|
1-xxxxx-1-xxxxxxxxxxxxxxx |
759–73–9 |
212–072–2 |
|
xxxxxxxxx X |
50–07–7 |
200–008–6 |
|
xxxxxxxxxxxxx |
50–18–0 |
200–015–4 |
|
xxxxxxxxxxxxx xxxxxxxxxx |
6055–19–2 |
|
|
2,4,6-xxxx(xxxxxxxx-1-xx)- 1,3,5-xxxxxxx |
51–18–3 |
200–083–5 |
X xxxxxxxx xxxxxxx xxxxxx xx xxx být xxxxxxxx xxxxx u xxxxxxxxxxx xxxxxxx, xxxx je xxxxxxxxxx xxxxx xxxxxxxxxxxx xxxx vehikulum a xxx jinak xxxxxxxxxx xxxxxx proces xxxx xxxxxxxxxx xxxxxxx, xxxxx xxxxxx x xxxxxxxxxxx xxxxxxxxxxx údajů x xxxxxxxxx xxxxxxxxxx xxxxx x variabilitě xxxxxx x četnosti buněk x xxxxxxxxxxxxxx aberacemi. Xxxxxxx-xx xx pro xxxxxxxxx xxxxxxxx xxxxx xxxxx, xx xxxxxxxxxxxxx xxxxxxxxx doba prvního xxxxxx. Xxxxx xxxx xx měly být xxxxxxxxxxxx kontroly xxxxxxx xxxx xxxxx, neexistují-li xxxxx kontrolní údaje xxxxxxxxxxx, xx zvolené xxxxxxxxxxxx/xxxxxxxxx nevyvolává žádné xxxxxxx xxxx xxxxxxxxx xxxxxx.
1.5 XXXXXX
1.5.1 Xxxxx x pohlaví zvířat
Každá xxxxxxxxxx x kontrolní xxxxxxx xx xxxxxx x xxxxxxx xxxx xxxxxxxxxxxxxxxx zvířat xxx xxxxx xxxxxxx. Xxxxxxxx xxxx x době xxxxxx x dispozici xxxxx xx xxxxxx xx stejným druhem x xx použití xxxxxxxx způsobu expozice, xxx xxxxxxxxx, xx xxxxxxxxxx mezi xxxxxxxxx xxxxxx x xxxxxxxx, xxxx postačující zkoušení xxxxxxx xxxxxxx. Xx-xx xxxxxxxx xxxxxxx xxxxxxxxxx xxx určité xxxxxxx, xxxx xx xxxx xxxxxxxxx u xxxxxxxxx xxxxxxxxxxxxxxx látek, xxxx xx být zkouška xxxxxxxxx xx zvířaty xxxxxxxxxxxxxx xxxxxxx.
1.5.2 Xxxx xxxxxxxx
Xxxxxxxx xxxxx xx xxxx xxx xxxxx xxxxx xxxxxxxx xxxxxxxxxxx. Xxxxxxxx látky xxxxx xxx podávány xxxx xx xxxx xxxxxxx, xxx. dvě xxxxx x xxx xxx x rozmezí xx xxxx než několika xxxxx, xxx xxxx xxxxxxxxx xxxxxxxx velkých xxxxxx materiálu. Xxxx xxxxxx xxxxxxxx xx xxxx být vědecky xxxxxxxxxx.
Xxxxxx xx xxxx xxx xxxxxxxx ve xxxx xxxxxxx xxxxxxxxxxx xx aplikace podané x xxxxxx dni. X hlodavců xx xxxxx provádí xx xxxxxx xxxx xx xxxxxxxx, xxxxx odpovídá 1,5xxxxxxx xxxxxxxx délky xxxxxxxxx xxxxx (xxxx xxxx obvykle 12 — 18 h). Xxxxxxxx xxxx xxxxxxxx xxx příjem a xxxxxxxxxxxx xxxxxxxx látky x rovněž xxx xxxxxx xx kinetiku xxxxxxxxx cyklu xxxx xxx vliv xx xxxxxxxxx xxxxxxx xxx xxxxxxxxx chromozomových xxxxxxx, xxxxxxxxxx xx xxxxxxx xxxxx xxxxx po 24 h od xxxxxxx xxxxxx. Je-li xxxxxxxx xxxxxxxxx xx xxxx xxx jednoho xxx, xxx by xxx xxxxx xxxxxxxx xx xxxxxx době xx poslední xxxxxxxx, xxxxx odpovídá 1,5xxxxxxx xxxxxxxx délky xxxxxxxxx xxxxx.
Xxxx xxxxxxxxx se xxxxxxxx xxxxxxxxxxxxxxxxx xxxx xxxxxx xxxxx xxxxx xxxxxxxxxxx metafázi (např. Xxxxxxxx® nebo xxxxxxxxx). Xxxx xx xx xxxxxx době xxxxxxx x zvířat xxxxx. X myši je xxxx xxxx přibližně 3 — 5 x; x xxxxxx xxxxxxxx xx xxxx xxxx xxxxxxxxx 4 — 5 x. X xxxxxx xxxxx xx xxxxxxxx xxxxx x xxxxxxxxx se xx chromozomové aberace.
1.5.3 Xxxxxxxxx
Xxxxxxx-xx xx xxxxx xxxxxxxxxxx vhodných dostupných xxxxx xxxxxx xxx xxxxxxxx xxxxxxx dávek, xxxx by xxx xxxxxxxxx ve stejné xxxxxxxxxx, xx xxxxxxx xxxxxx, xxxxxx, pohlavím x xx xxxxxxxx xxxxxx xxxxxxxx, jež xx xxxxxxx x xxxxxx xxxxxx (5). X případě toxicity xx pro xxxxx xxxxx xxxxxxx tři xxxxxx xxxxx. Tyto xxxxxx dávky xx xxxx pokrývat xxxxxxx xxxx xxxxxxxxx x xxxxxxxxx xxxxxxxxx, xxxxxxxx xxxxxx toxicitou. Xxx xxxxxxxxx xxxxxx xxxxx, xxxx xxxx xxxxxxx xxxxx nejvyšší xxxxx. Xxxxxxxx xxxxx xx xxxxxxxxxx xxxx xxxxx xxxxxxxxxxxx xxxxxx xxxxxx xxxxxxxx, xx xxxxx xxxxx xx xxxxx xxx xxxxxxx xxxxxx xxxxxxxxx xxxxx očekávání x xxxxxxxx. Xxxxx xx specifickou xxxxxxxxxxx xxxxxxxxx xxx xxxxxxx xxxxxxxxxxx xxxxxxx (např. xxxxxxx a xxxxxxxx) xxxxxx xxxxxxxxx xxxxxxxxx xxxxx xxxxxxxxx a xxxx by být xxxxxxxxx případ xx xxxxxxx. Xxxxxxxx xxxxx xxxx xxx také xxxxxxxxxx xxxx dávka xxxxxxxxxxxx x kostní xxxxx xxxxxxx xxxxxx xxxxxxxx (xxxx. xxxx xxx 50 % xxxxxxx mitotického xxxxxx).
1.5.4 Xxxxxxx xxxxxxx
Xxxxxxxx xxxxxxx x xxxxxx xxxxxx xxxxxxx 2000 mg/kg xxxxxxx xxxxxxxxx xxxxxxx xxxxxxxxxxx xxxx xx xxxx dávkách v xxxxxx xxx xxxxxxxxxx xxxxx xxxxxxxxxxxxx xxxxxxx xxxxxx a není-li xx xxxxxxx údajů x xxxxxxx, xxxxx xxxx xxxxxxxx strukturu, xxxxxxxxx genotoxicita, nepovažuje xx xxxxx xxxxxx xx xxxxx úrovněmi xxxxx xx nezbytnou. X déle xxxxxxxxxx xxxxxx xx xxxxxxx xxxxxx pro 14xxxxx xxxxxxxx 2000 mg/kg xxxxxxx hmotnosti/den x xxx xxxxx než 14xxxxx xxxxxxxx xx xxxxxxx dávkou 1000 xx/xx tělesné xxxxxxxxx/xxx. Xxxxxxxxx expozice xxxxxxx xxxx xxxxxxxx xxxxxxx xxxxxx x xxxxxxx xxxxxxx xxxxx xxxxxx xxxxx.
1.5.5 Xxxxxxxx xxxxx
Xxxxxxxx xxxxx xx xxxxxxx xxxxxx xxxxxxxxxxxxxx, xxxxxxxxx xxxxxx xxxx vhodnou xxxxxxxxx kanylou, nebo xxxxxxxxxxxxxxxxx xxxxxxx. Xxxx xxxxxxx xxxxxxxx xxxx x xxxxxxxxxxxx xxxxxxxxx xxxxxxxxxx. Xxxxxxxxx xxxxx xxxxxxxx, který může xxx xxxxxxxx xxxxx xxxxxxxxxxxxxx nebo xxxxxxxx, xxxxxx xx xxxxxxxxx xxxxxxxxxxx xxxxxxx. Objem xx xxxxx xxxxxxxxx 2 xx/100 g xxxxxxx xxxxxxxxx. Xxxxxxx xxxxxxx objemů, xxx xx uvedený objem, xxxx xxx xxxxxxxxxx. Xx xx xxxxxxxx x xxxxxx látky, xxxxx xxxxxxx při xxxxxxx xxxxxxxxxxxxx xxxxxxxx xxxxxxxx xxxxxx, by xxxx xxx variabilita xxxxxxxxxx xxxxxx xxxxxxxxxxxxxx xxxxxxxxxx koncentrace xxxxxxxxxxx xxxxxxxxxx objem při xxxxx xxxxxxxx dávky.
1.5.6 Xxxxxxxx preparátů xxx xxxxxxx xxxxxxxxxx
Xxxxx po xxxxxxxx xx xxxxxxx xxxxxx dřeň, xxxxxxxxxxxx xx a fixuje. Xxxxx xx xxxxxxx xx xxxxxxxx xxxxxxx x obarví xx.
1.5.7 Xxxxxxx
Xxxx měřítko xxxxxxxxxxxx xx měl xxx x xxxxx xxxxxxxxxxxx xxxxxx (xxxxxx pozitivních xxxxxxx) x x xxxxxxxxxxxxxx zvířat xxx xxxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxxx xxxxx, a xx xxxxxxx u 1000 xxxxx xx xxxxx xxxxx.
X xxxxxxx xxxxxxx xx xxxx xxx xxxxxxxxxxx xxxxxxx 100 buněk. Xxxxx xxxxx xxx xxxxxx, xx-xx xxxxxxxxx velký xxxxx xxxxxxx. Xxxxxxx xxxxxxxxx pozitivních x xxxxxxxxxxx xxxxxxx xx xxxx xxx xxxx xxxxxxxxxxxxxx xxxxxxxx xxxxxxxxx xxxxxxxx. Protože xxx xxxxxx xxxxx xxxxxxx xx chromozomálním zlomům xxxx xx xxxxxx xxxxxxxxxx u části xxxxx x xxxxxxxx, xxxx xx vyšetřované xxxxx xxxxxxxxx xxxxxxxxxx x počtu odpovídajícímu xxxxx 2 x ± 2.
2. ÚDAJE
2.1 XXXXXXXXXX VÝSLEDKŮ
Údaje xxx xxxxxxxxxx xxxxxxx xx xxxx xxx xxxxxxxxxx xx xxxxx xxxxxxx. Xxxxxxxxxxxxxx xxxxxxxxx je xxxxx. Pro xxxxx xxxxx xx xxx xxx vyhodnocen xxxxx xxxxx, počet xxxxxxx xx xxxxx x xxxxx xxxxx s xxxxxxxxxxxxx xxxxxxx (xxxxxxxxxxxxxx xxxxxxxxx) vyjádřený v xxxxxxxxxx. Pro xxxxxxxxxx x xxxxxxxxx skupiny xx xxxx xxx xxxxxxx xxxxx typy xxxxxxxxxxxx xxxxxxxxxxxxxx aberací x xxxxxx xxxxxx x četností. Gapy xx xxxxxxxxxxxxx xxxxxxxx x xxxxxxx xx, xxx obecně xx xxxxxxxxxx do xxxxxxx xxxxxxxx xxxxxxx. Xxxxxxxxxx-xx xxxxx x rozdílu x xxxxxxxx xxxx xxxxxxxxx, mohou xxx xxx xxxxxxxxxxxx xxxxxxx xxxxx xxx xxx xxxxxxx xxxxxxxxxxxx.
2.2 XXXXXXXXX X XXXXXXXXXXXX VÝSLEDKŮ
Pro xxxxxxxxx pozitivního xxxxxxxx xxxxxxxx několik xxxxxxxx, xxxx. xxxxxx relativního xxxxx xxxxx x xxxxxxxxxxxxxx xxxxxxxxx x xxxxxxxxxx xx xxxxx xxxx jasný nárůst xxxxx buněk x xxxxxxxxx pro skupinu x určitou xxxxxx x k určitému xxxxxxxx xxxxxx. Xxxxxxxx xx xxxx být xxxxxxx xxxxxxxxxx xxxxxxxxx xxxxxxxx. Při xxxxxxxxx xxxxxxxx xxxxxxx xxxxx xxx použity xxxx xxxxxxx prostředek statistické xxxxxx (6). Xxxxxxxxxxx xxxxxxxxxx xx xxxxxx xxx jediným xxxxxxxxx xxxxxxxx pro xxxxxxxxx xxxxxxx. Xxxxxxxxxx výsledky xx měly xxx xxxxxxxxx dalším xxxxxxxxx, xxxxxxx x xxxxxxxx xxxxxxxxxxxxxxxx podmínek.
Nárůst xxxxxxxxxxx xxxx znamenat, že xxxxxxxx látka xx xxxxxxxxx xxxxxxxxx numerické xxxxxxxxxxxx xxxxxxx. Xxxxxx xxxxx xxxxx x xxxxxxxxxxxxxxxxxxx xxxxxxxxxx může xxxxxxxx, xx zkoušená xxxxx xx potenciál xxxxxxxx progresi xxxxxxxxx xxxxx (7, 8).
Zkoušená xxxxx, jejíž xxxxxxxx xxxxxxxxx xxxx xxxxxxx xxxxxxxx, xx xxxxxxxx x xxxxx systému xx xxxxxxxxxxx.
Xxxxxx xxxxxxx xxxxxxxxxxx xxxxxxxx xxxxx xxxxxxxxx xxxx negativní xxxxxxxx, x ojedinělých xxxxxxxxx neumožní soubor xxxxx vyslovit xxxxxxx xxxxx o xxxxxxxx xxxxxxxx látky. Xxxxxxxx xxxxx xxxxxx dvojznačné xxxx sporné xxx xxxxxx xx xx, xxxxxxxx je experiment xxxxxxxx.
Xxxxxxxxx výsledky xxxxxxx xx xxxxxxxxxxxx xxxxxxx xx xxxx xxxxxxxxx, xx xxxxxxxx xxxxx xxxxxxxx x xxxxxx xxxxx xxxxxxxxxxx xxxxx xxxxxxxxxxxx xxxxxxx. Xxxxxxxxx xxxxxxxx xxxxxxxxx, že xxxxxxxx látka xx xxxxxxxx xxxxxxx xxxxxxxxxx x xxxxxx dřeni xxxxxxxxxxx xxxxx chromozomové xxxxxxx.
Xxxx xx xxx xxxxxxxxxxx xxxxxxxxxxxxxxx, x xxxxx xx xxxxxxxx xxxxx nebo xxxx xxxxxxxxxx xxxxxxxx do xxxxxxxx xxxxx, xxxx xxxxxxxxxx do xxxxxx xxxxx (xxxx. xxxxxxxxx xxxxxxxx).
3. XXXXXX
XXXXXXXX O XXXXXXX
Xxxxxxxx o zkoušce xxxx obsahovat xxxx xxxxxxxxx:
Xxxxxxxxxxxx/xxxxxxxxx:
- zdůvodnění volby xxxxxxxx,
- xxxxxxxxxxx x xxxxxxx zkoušené xxxxx x xxxxxxxxxxxx/xxxxxxxx, xx-xx xxxxx.
Xxxxxxxxx xxxxxxx:
- xxxxxxx xxxx/xxxx,
- xxxxx, xxxxx x xxxxxxx zvířat,
- xxxxx, podmínky xxxxx, xxxxxx xxx.,
- individuální xxxxxxxx xxxxxx xx xxxxxxx xxxxxxx, xxxxxx xxxxxxx tělesné hmotnosti, xxxxxxx xxxxxxx a xxxxxxxxxx xxxxxxxx xxx xxxxxx xxxxxxx.
Xxxxxxxx podmínky:
- xxxxxxxxx x xxxxxxxxx (xxxxxxxxx/xxxxxxxxxxxx) xxxxxxxx,
- xxxxx xx xxxxxx xxx xxxxxxxx xxxxxxx, pokud xxxx xxxxxxxxx,
- zdůvodnění xxxxxxxxx úrovní xxxxx,
- xxxxx o přípravě xxxxxxxx xxxxx,
- xxxxx x podávání zkoušené xxxxx,
- zdůvodnění xxxxxxx xxxxxxxx,
- xxxxxxxxx metody xxxxxxx, zda se xxxxxxxx látka xxxxxxx xx krevního xxxxx xxxx do xxxxxx xxxxx,
- xxxxxxxx přepočet xxxx koncentrací zkoušené xxxxx x xxxxxx xxxx xxxx (xxx) xx xxxxxxxxxxxx dávku (xx/xx tělesné xxxxxxxxx/xxx),
- xxxxxxxx xxxxx x xxxxxxx krmiva x xxxx,
- xxxxxxxx xxxxx xxxxxxx expozice a xxxxxx,
- xxxxxx stanovení xxxxxxxx,
- xxxxxxxxxxxx xxxxx xxxxxxxxxxx metafázi, xxxx xxxxxxxxxxx x délka xxxxxxxx,
- metody xxxxxxxx xxxxxxxxx,
- xxxxxxxx xxxxxxxxx xxxxxxx,
- počet xxxxxxxxxxxxx xxxxx xx xxxxx xxxxx,
- kritéria klasifikace xxxxxx xx xxxxxxxxx, xxxxxxxxx xxxx dvojznačnou.
Výsledky:
- xxxxxx xxxxxxxx,
- xxxxxxxxx xxxxx,
- xxx x xxxxx xxxxxxx uvedený xxxxxxxxxx pro xxxxx xxxxx,
- xxxxxxx počet xxxxxxx ve skupině xx středními xxxxxxxxx x směrodatnými xxxxxxxxxx,
- xxxxx buněk x xxxxxxxxx ve skupině xx xxxxxxxxx xxxxxxxxx x xxxxxxxxxxxx xxxxxxxxxx,
- xxxxx xxxxxxx, xxxxx xxxx xxxxxxxxxx,
- podle xxxxxxxx xxxxxxxxx xxxxxxxx xx xxxxx,
- případné xxxxxxxxxxx xxxxxxx,
- xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxx,
- dosavadní xxxxx x xxxxxxxxx xxxxxxxx x xxxxxxxxx, středními xxxxxxxxx a xxxxxxxxxxxx xxxxxxxxxx,
- xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxx.
Xxxxxx xxxxxxxx.
Xxxxxx.
4. XXXXXXXXXX
1) Xxxxx, X. X. (1984), Xxxxxxxxxxx Xxxxx xx Xxxxxxx, xx: Xxxxxxxxxxxx Xxxxxxx: x Practical Xxxxxxxx, X. Venitt, X. M. Xxxxx (xxx), XXX Press, Xxxxxx, Washington X. X., 275-306.
2) Preston, X. X., Dean, X. X., Xxxxxxxx, X., Holden, X., XxXxx, X. X., Xxxxxx, M. (1987), Xxxxxxxxx In vivo Xxxxxxxxxxx Assays: Xxxxxxxx xx Chromozome Xxxxxxxxxxx xx Bone Marrow Xxxxx, Xxxxxxxxxx Xxx., 189, 157-165.
3) Richold, X., Chandley, X., Xxxxx, J., Xxxxxxxxx, X. G., Xxxxxxx, X., Henderson, X. (1990), Xx xxxx Xxxxxxxxxxx Xxxxxx, xx: X. X. Kirkland (xx.), Xxxxx Mutagenicity Xxxxx, UKEMS Xxxxxxxxxxx Xxxxxxxxxx. UKEMS Xxx-Xxxxxxxxx xx Guidelines xxx Xxxxxxxxxxxx Xxxxxxx. Report, Xxxx X revised, Xxxxxxxxx Xxxxxxxxxx Xxxxx, Xxxxxxxxx, Xxx York, Xxxx Xxxxxxx, Xxxxxxxxx, Xxxxxx, 115-141.
4) Tice, X. X., Xxxxxxx, X., XxxXxxxxxx, J. X., Anderson, D., Xxxxxx, D. X., Xxxxxx, X. X., Xxxxxx-Xxxxxxx, X., Oleson Xx., X. X., Xxxxxxxxxxxx, X., Xxxxxxx, X. J., Romagna, X., Xxxxxxx, X., Xxxxx, S., Xxxxxxx, X. (1994), Xxxxxx xxxx xxx Xxxxxxx Xxxxx xx xxx xx xxxx Xxxxxxxxx Xxxx Xxxxxx Chromozomal Xxxxxxxxxx Test, Xxxxxxxxxx Xxx., 312, 305-312.
5) Xxxxxxx, X. X., Xxxxx, X. X., Xxxxxx, A. X., Xxxxxx, X. X., Xxx, X., Xxxxxxx, X. X., Xxxxxxxxx, X. X., Hodson-Walker, X., Xxxxxx, X. X., Xxxxxxxx, X. X., Xxxxxxx, X. (1992), Report xx Xxxxxxx Xxxxxxxxxx Xxxxxxx/XX Xxxxxxxxxxxxx Xxxxxxx Xxxxxxx Xxxxxxx Xxxxx: Dose Xxxxxxx in Xx xxxx Xxxxxxxxxxxx Assays, Xxxxxxxxxxx, 7, 313-319.
6) Xxxxxx, X. X., Xxxxxxxx, X., Xxxxxxxx, X., Xxxxxxxx, X. X., Xxxxx, G., Xxxxxxxx, X., Xxxxxxx, X., Xxxxxxxx, D. X., Xxxxxx, X. X. K. (1989), Xxxxxxxxxxx Xxxxxxxx xx Xx vivo Xxxxxxxxxxx Xxxxxx, in: UKEMS Xxx-Xxxxxxxxx on Guidelines xxx Xxxxxxxxxxxx Xxxxxxx, Xxxxxx Part III. Xxxxxxxxxxx Xxxxxxxxxx xx Xxxxxxxxxxxx Test Xxxx, X. X. Kirkland (xx.) Xxxxxxxxx University Xxxxx, Cambridge, 184-232.
7) Xxxxx-Xxxxx, X. (1983), Xxxxxxxxxxxxxxxxx xx Chinese xxxxxxx xxxxx during xxxxx-xxxxxxxxx-xxxxxxx G2 xxxxxx, Xxxxxxxxxx Xxx., 119, 403-413.
8) Huang, X., Xxxxxx, X., Xxxxxx, X. X. (1983), Xxxxxxxxxxx-xxxxxxx xxxxxxxxxxxxxxxxx xx Xxxxxxx xxxxxxx xxxxx, Xxxxxx Xxx., 43, 1362-1364."
PŘÍLOHA 4C
"B.12 MUTAGENITA–TEST XXXXXXX XXXXXXXXXXXXXXX MIKROJADER XX XXXX
1. METODA
Tato xxxxxx xx replikou xxxxxx XXXX XX 474 — Xxxx xxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxx xx vivo (1997).
1.1 XXXX
Xxxx xxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxx xx xxxx xx používán pro xxxxxxx poškození xxxxxxxxxx xxxx xxxxxxxxxxx xxxxxxx xxxxxxxxxxxx, které xx xxxxxxxxxx xxxxxxxxx látkou, x xx pomocí xxxxxxx xxxxxxxxxx xxxxxxxxxx x xxxxxx xxxxx x/xxxx buněk xxxxxxxxx xxxx, obvykle xxxxxxxx.
Xxxxxx xxxxx savčích xxxxxxxxxxxxxxx xxxxxxxxxx je xxxxxxxxxxxxx xxxxx, které xxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx, xxxxx xxxxxxxxx xx xxxxxx xxxxxxxxxx xxxxxxxxxxxx xxxxxxxxxxxxx xx (xxxxxxx) xxxxxxxxxxxx xxxxxxxxx nebo xxxx xxxxxxxxxx.
Xxxx se xxxxxxxxxxx xxxxxx xxxxx mění xx xxxxxxxxxxxxxxx erytrocyt, xxxxxx jádro je xxxxxxxx x xxxxxxxxxx, xxxxx při tom xxxxx xxxxxxxxx, xxxxxxxxx x cytoplasmě, xxxxx xxxxx xxxxx xxxxxxxxxx. Xxxxxxxxxxxx xxxxxxxxxx je x těchto buňkách xxxxxxxxx xxx, xx xxxxxxxxxx xxxxxx xxxxx. Xxxxxx výskytu xxxxxxxxxxxxxxxxx xxxxxxxxxx x xxxxxxxxxx x exponovaných xxxxxxxxx xx xxxxxxx indukovaného xxxxxxxxxxxxxx poškození.
V tomto xxxxx xx rutinně xxxxxxxxx kostní xxxx xxxxxxxx, xxxxxxxx xxxx xxxx produkuje xxxxxxxxxxxxxxx xxxxxxxxxx. Xxxxxxxxx xxxxxxxxx (xxxxxxxxxxxxxxxxx) xxxxxxxxxx s xxxxxxxxxx x periferní xxxx xx rovnocenně xxxxxxxxxx x xxxxxxxxxxx xxxxx, u xxxxx xxxx prokázána xxxxxxxxxxx xxxxxxx xxxxxxxxxxx xxxxxxxxxx x xxxxxxxxxx, xxxx xxxxxxxxxx citlivost xxxxxxxxx xxxxxxxx, xxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxxx. Mikrojádra xxx rozlišit xxxxx xxxxxxxx. Ta xxxxxxxx xxxxxxxxxxxx přítomnosti nebo xxxxxxxxxxxxx xxxxxxxxxxx (kinetochorní) XXX v xxxxxxxxxx. Xxxxxxxxx se zejména xxxxxxx xxxxxxxxx (xxxxxxxxxxxxxxxxx) xxxxxxxxxx x mikrojádry. Xxxxx zralých (xxxxxxxxxxxxxxxxxx) xxxxxxxxxx x xxxxxxxxx xxxx, které xxxxxxxx xxxxxxxxxx, xxxxxxxxxxx na xxxxxx počet xxxxxxx xxxxxxxxxx xxx rovněž xxxxxx xxxx konečný xxxxxxxx xxxxxxx, xxxxxxxx xxxx zvířata xxxxxxxxxx xxxxx xxxxx xxxx xxxx.
Xxxxx test xxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxx in xxxx xx xxxxxxx xxxxxx k posouzení xxxxxxxxx xxxxxxxxxx, xxxxx xxxxxxxx zohlednit faktory xxxxxxxxxxx xx xxxx, xxxxxxxxxxxxxxx a xxxxxxx xxxxxxxx XXX, xxxxxxx xx xxxxx xxxxx x různých xxxxx x xxxxx, xxxxx x x xxxxxxxxxxx xxxxxxxx. Zkouška xx xxxx je xxxxxx xxxxxxxx xxx xxxxx xxxxxx mutagenních xxxxxx xxxxxxxxxx x xxxxxxxxx xx xxxxx.
Xxxxxxxx existuje xxxxx x xxx, xx xx xxxxxxxx xxxxx nebo reaktivní xxxxxxxxxx xxxxxxxxxx xx xxxxxx tkáně, xxxx xxxxxx tuto zkoušku xxxxxx.
Xxx xxxx Obecný xxxx, xxxx B.
1.2 XXXXXXXX
Xxxxxxxxxx (xxxxxxxxxx) : xxxxxx (oblasti) xxxxxxxxxx, x xxx (x xxxx) se xxxxx xxxxxx buněk xxxxxxx xxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxxxx xxxxx dceřiných xxxxxxxxxx k xxxxx xxxxxxxxx xxxxx.
Xxxxxxxxxx : xxxx xxxxx existující xxxxxxxx od xxxxxxxx xxxxx a xxxxx xxxx, xxxxxxxxx xxxxx xxxxxxxx xxxxxx (xxxxxx) xxxxxxxxxxxxxxx xx (lagging) xxxxxxxxxxxxxx fragmenty xxxx xxxxxx xxxxxxxxxx.
Xxxxxxxxxxxxxxxx xxxxxxxxx : zralý erytrocyt xxxxxxxxxxxx xxxxxxxx, xxxxx xxx xxxxxxxx xx xxxxxxxxx xxxxxxxxxxxxxxxxx xxxxxxxxxx xxxxxxxx xxxxxxxxxxx xxx xxxxxxxx.
Xxxxxxxxxxxxxxx xxxxxxxxx : xxxxxxx xxxxxxxxx ve xxxxxxxxx xxxxxxxxxx, xxxxx xxxxx xxxxxxxx xxxxxxxx, x xxxx xxx xxxx xxxxxxxx od xxxxxxx normochromatických erytrocytů xxxxxxxx xxxxxxxxxxx xxx xxxxxxxx.
1.3 PODSTATA ZKUŠEBNÍ XXXXXX
Xxxxxxx xx vhodným xxxxxxxx xxxxxxx zkoušené xxxxx. Xxx xxxxxxx xxxxxx xxxxx xx xxxxxxx xx vhodném xxxxxxxx xx xxxxxxxx xxxxxx, xxxxxxx xx xxxxxx xxxx, xxxxxxxx xx xxxxxxxxx a xxxxxx se (1, 2, 3, 4, 5, 6, 7). Xxx xxxxxxx xxxxxxxxx xxxx se xxxx xx xxxxxxx xxxxxxxx xx xxxxxxxx xxxxxxx, xxxxxxxxxx xx xxxxxxxx xxxxxxxx x xxxxxx xx (4, 8, 9, 10). Xxx xxxxxxxx s periferní xxxx by měla xxxx xxxxxxxx xxxxxxxx x xxxxxxxxx buněk xxxxxxxx co xxxxxxxxx xxxx. Xxxxxxxxx jsou xxxxxxxxxxx xx přítomnost xxxxxxxxxx.
1.4 POPIS ZKUŠEBNÍ XXXXXX
1.4.1 Přípravky
1.4.1.1 Výběr xxxxx xxxxxxx
Xxx xxxxxxx xxxxxx dřeně xx xxxx testovací zvíře xxxxxxxxxx myš xxxx xxxxxx, xxxxxx lze xxxxxx jakýkoli vhodný xxxxx druh. Při xxxxxxx xxxxxxxxx xxxx xx doporučuje xxx. Xxx však xxxxxx xxxxxxxx xxxxxx xxxx xxxxx xx xxxxxxxxxxx, xx jde x xxxx, x xxxxx xxxxxxx xxxxxxxxxxxx xxxxxxxxxx x mikrojádry, nebo xxxx vykazující dostatečnou xxxxxxxxx xxxxxxxxx činitele, xxxxx způsobují strukturní xxxx xxxxxxxxx chromozomové xxxxxxx. Xxxx xx xxx použity xxxxx xxxxxxx xxxxxxxxxxx xxxxx xxxxxxx xxxxxxxx xxxxxxxx xxxxxxxxx zvířat. X xxxxxxxx zahájení xxxxxx xx měla xxx xxxxxxxx v xxxxxxxxx xxxxxx minimální x xxxxxx xx x xxxx xxxxxxx xxxxxxxxx ± 20 % xxxxxxx xxxxxxx xxxxxxxxx.
1.4.1.2 Xxxxxxxx chovu a xxxxxx
Xxxxx xxxxxx podmínky xxxxx xxxxxxxx úvodu x části X, xxxxxxx xx xxxx xxx xxxxxxxx xxxxxxxx xxxxxxx 50 – 60 %.
1.4.1.3 Xxxxxxxx xxxxxx
Xxxxxx mladá pohlavně xxxxxxx xxxxxxx xx xxxxxxxx xxxxxxx rozdělí xx kontrolní xxxxxxx x skupinu, x xxx xx xxxxxxx xxxxxxxx. Xxxxxxx se xxxxxxxxxxx xxxxxxxxxxxx. Xxxxxxx xx x xxxxxxxxxxxxx xxxxxxxxxx alespoň pět xxx xxxxxxxxxxxxx. Xxxxx xx uspořádají xxx, xxx xxx xxxx xxxxxx xxxxxx minimalizován.
1.4.1.4 Xxxxxxxx xxxxx
Xxxxx xxxxxxxx xxxxx xx měly xxx xxxx xxxxxxxx xxxxxxxx xxxxxxxxxx xxxx xxxxxxxxxxxx xx vhodných xxxxxxxxxxxxxx xxxx xxxxxxxxxx x xxxxxxxxx zředěny. Xxxxxxx xxxxxxxx látky xxxxx xxx xxxxxxxx xxxxx xxxx xxxxx xxx xxxx xxxxxxx xxxxxxx. Měly by xxx xxxxxxx xxxxxxx xxxxxxxxxx xxxxxxxx xxxxxxxx xxxxx, xxxxx xxxxx x xxxxxx stálosti xxxxxxxxxxx možnost xxxxxxxxxx.
1.4.2 Xxxxxxxx podmínky
1.4.2.1 Rozpouštědlo/vehikulum
Rozpouštědlo/vehikulum xx nemělo xxx xxx xxxxxxxxx xxxxxxxx xxxxx xxxxxxx xxxxxx x mělo xx xxx vyloučeno xxxxxxxxx, xx xxxxxxx xx xxxxxxxxx xxxxxx. Jsou-li xxxxxxx xxxx xxx xxxxx rozpouštědla/vehikula, mělo xx xxx xxxxxx xxxxxxxx podloženo xxxxx x xxxxxx kompatibilitě. Xxxxxxxxxx xx xxxxx xxxxx xxxxxxxx zvážit xxxxxxx xxxxxxx rozpouštědel/vehikul.
1.4.2.2 Xxxxxxxx
Xxxxxxxx xxxxxxx xxxxxxxxxxx xx xxxx xxx xxxxxxxxx x negativní (xxxxxxxxxxxx/xxxxxxxxx) xxxxxxxx xxx xxx xxxxxxx. S xxxxxxxx xxxxxxxx xxxxxxxx xxxxx xx xxxx xxxxxxx xxxxxxxxx skupiny xxxxxxxxxx identický xxxxxx xxxx xxxxxxx xx xxxxxxxxx, v nichž xxxxx x xxxxxxxx.
Xxxxxxxxx xxxxxxxx xx xxxx xxxxxxxxxx mikrojádra xx xxxx xxx xxxxxxxxxxx xxxxxxxx, u nichž xx očekává, xx xxxxxxxxx detekovatelný xxxxxx xxx xxxxxx. Xxxxx xxxxxxxxx xxxxxxxx by xxxx xxx zvoleny xxx, xxx xxx xxxxxx zřetelný, ale xxx xxx xxxxxx xxxxxxx xxxxx najevo xxxxxxxx identifikace xxxxxxxxx. Xx přijatelné, xxx xxxxxxxxx xxxxxxxx xxxx xxxxxxxx xxxxx xxxxxxxx xxx xxxxxxxx látka x xxx xxx xxxxx v tomto xxxxxxx xxxxxxxx xxx xxxxxx. Pro pozitivní xxxxxxxx xxxxx xxxx xxx vzato x xxxxx xxxxxxx chemických xxxxx xx xxxxxx xxxxxxxx xxxxx, xxxx-xx x dispozici. Příklady xxxxx xxx xxxxxxxxx xxxxxxxx:
|
Xxxxx |
Xxxxx XXX |
Xxxxx xxxxx XXXXXX |
|
xxxxx-xxxxxxxxxxxxxx |
62–50–0 |
200–536–7 |
|
1-xxxxx-1-xxxxxxxxxxxxxxx |
759–73–9 |
212–072–2 |
|
xxxxxxxxx C |
50–07–7 |
200–008–6 |
|
cyklofosfamid |
50–18–0 |
200–015–4 |
|
cyklofosfamid monohydrát |
6055–19–2 |
|
|
2,4,6-tris(aziridin-1-yl)- 1,3,5-xxxxxxx |
51–18–3 |
200–083–5 |
X okamžiku xxxxxx xx měl být xxxxxxxx xxxxx u xxxxxxx xxxxxxxxx xxxxxxxx, xxxxx xx xxxxxxxxxx xxxxx xxxxxxxxxxxx xxxx xxxxxxxxx x xxxxx xxxxx xxxxxxxxxx xxxxxx xxxxxx xxxx xxxxxxxxxx xxxxxxx, xxxxx xxxxxx x dosavadních xxxxxxxxxxx xxxxx x dispozici xxxxxxxxxx údaje o xxxxxxxxxxx xxxxxx x xxxxxxxx xxxxx x xxxxxxxxxx. Xxxxxxx-xx se xxx xxxxxxxxx xxxxxxxx xxxxx xxxxx, xx xxxxxxxxxxxxx xxxxxxxxx doba xxxxxxx odběru. Xxxxx xxxx by xxxx xxx neexponované xxxxxxxx xxxxxxx xxxx xxxxx, xxxxxxxxxx-xx dosud xxxx xxxxxx-xx xxxxxxxxxxx kontrolní xxxxx xxxxxxxxxxx, že xxxxxxx xxxxxxxxxxxx/xxxxxxxxx xxxxxxxxxx xxxxx xxxxxxx xxxx xxxxxxxxx účinky.
Při použití xxxxxxxxx xxxx xxxx xxx xxxx xxxxxxxxx xxxxxxxx xxxxxxxxxx xxxx xxxxxx xxxx odebraný xxxx xxxxxxxx, xxxxx xxxx u xxxxxxxx xxxxxx s periferní xxxx (např. 1 — 3 xxxxxxxx) xx xxxxxxxxxxx, xx xxxxxxxx xxxxx budou x xxxxxxx, xxxxx xx xx xxxxxxx xxxxxxxxxxx xxxxxxx očekává.
1.5 XXXXXX
1.5.1 Xxxxx a xxxxxxx xxxxxx
Xxxxx xxxxxxxxxx x kontrolní xxxxxxx xx xxxx xxxxxxx x alespoň xxxx xxxxxxxxxxxxxxxx zvířat pro xxxxx xxxxxxx (11). Xxxxxxxx jsou v xxxx studie x xxxxxxxxx údaje ze xxxxxx se stejným xxxxxx x za xxxxxxx xxxxxxxx xxxxxxx xxxxxxxx, jež prokazují, xx neexistuje mezi xxxxxxxxx xxxxxx x xxxxxxxx, xxxx xxxxxxxxxxx xxxxxxxx xxxxxxx pohlaví. Xx-xx xxxxxxxx xxxxxxx xxxxxxxxxx pro xxxxxx xxxxxxx, xxxx xx xxxx xxxxxxxxx u xxxxxxxxx farmaceutických xxxxx, xxxx xx xxx xxxxxxx provedena xx xxxxxxxx xxxxxxxxxxxxxx xxxxxxx.
1.5.2 Xxxx xxxxxxxx
Xxxxx doporučit xxxxx xxxxxxxxxx xxxx (xx. xxxxx, xxx xxxx tři xxxxxxxx x xxxxxxxxx 24 xxxxx). Xxxxxx xx xxxxxx s xxxxxxxxxxxx xxxxxxx xxxxxxxx xxxx xxxxxxxxxx, xxxxx se x těchto xxxxxx xxxxxxx xxxxxxxxx xxxxxxxx, xxxx –x xxxxxxx xxxxxxxxxxx xxxxxx — xxxxx byla xxxxxxxxx xxxxxxxx nebo xxxx xxxxxxxxx limitní xxxxx x xxxxxxxx pokračuje xx do xxxxxxxx xxxxxx. Xxxxxxxx látky xxxxx xxx podávány xxxx xx dvou xxxxxxx, xxx. dvě xxxxx v xxx xxx v rozmezí xx více než xxxxxxxx xxxxx, xxx xxxx xxxxxxxxx podávání xxxxxxx xxxxxx materiálu.
Test xxxx xxx xxxxxxxx xxxxx xxxxxxx:
x) xxxxxxxx xxxxx xx aplikuje xxxxxxxx xxxxxx. Xxxxxx xxxxxx xxxxx xx xxxxxxxx xxxxxxx dvakrát, xxxxxxx xxxxx xxxxx xx xxxxxxx nejdříve 24 xxxxx po xxxxxxxx a poslední xxxxxxxxxx 48 xxxxx xx aplikaci x x přiměřeným xxxxxxxx xxxx xxxxxx. Odběr xxxxx xxx 24 xxxxx po xxxxxxxx xxxx xxx zdůvodněn. Xxxxxx periferní xxxx xx xxxxxxxx alespoň xxxxxxx, xxxxxxx xxxxx xxxxx se xxxxxxx xxxxxxxx 36 xxxxx xx xxxxxxxx x xxxxxxxx nejpozději 72 xxxxx xx aplikaci x po xxxxxxxxxxxx xx xxxxxx odpovídající xxxxxx. Je-li po xxxxxx xxxxxx pozorována xxxxxxxxx xxxxxxx, není xxxxx xxxxx nutný;
b) xxxx-xx xxxxxxxx xxx xxxx xxxx dávek xxxxx (xxxx. xxx xxxx více xxxxx x xxxxxxxxx 24 xxxxx), měly by xxx vzorky xxx xxxxxxx xxxxxx dřeně xxxxxxxx jednou xx 18 xx 24 xxxxxxxx po xxxxxxxx xxxxxxxx x xxx xxxxxxx xxxxxxxxx krve xxxxxx xx 36 xx 48 xxxxxxxx xx xxxxxxxx xxxxxxxx (12).
Xxxxx xxxxxxx mohou xxx navíc xxxxxxx xxxx xxxx xxxxxx.
1.5.3 Xxxxxxxxx
Xxxxxxx-xx se xxxxx xxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxx xxxxxx xxx xxxxxxxx rozsahu xxxxx, xxxx xx být xxxxxxxxx xx xxxxxx xxxxxxxxxx, xx stejným xxxxxx, kmenem, xxxxxxxx x xx xxxxxxxx xxxxxx xxxxxxxx, xxx xx xxxxxxx x xxxxxx xxxxxx (13). X případě xxxxxxxx xx xxx první xxxxx xxxxxxx xxx xxxxxx dávky. Xxxx xxxxxx xxxxx xx xxxx xxxxxxxx xxxxxxx xxxx maximální xx xxxxxxxxx toxicitou, případně xxxxxx xxxxxxxxx. Xxx xxxxxxxxx odběru xxxxx, xxxx xxxx xxxxxxx xxxxx xxxxxxxx dávka. Xxxxxxxx xxxxx xx xxxxxxxxxx xxxx xxxxx xxxxxxxxxxxx xxxxxx známky xxxxxxxx, že vyšší xxxxx by vedly xxx stejném režimu xxxxxxxxx xxxxx xxxxxxxxx x letalitě. Xxxxx xx specifickou xxxxxxxxxxx xxxxxxxxx při nízkých xxxxxxxxxxx xxxxxxx (xxxx. xxxxxxx a xxxxxxxx) xxxxxx xxxxxxxxx xxxxxxxxx xxxxx vyhovovat x xxxx by xxx xxxxxxxxx xxxxxx od xxxxxxx. Xxxxxxxx xxxxx xxxx xxx také xxxxxxxxxx xxxx dávka xxxxxxxxxxxx x xxxxxx xxxxx xxxxxxx známky xxxxxxxx (xxxx. snížení xxxxxx nezralých erytrocytů x celkového xxxxxxxx xxxxxxxxxx v xxxxxx xxxxx nebo x xxxxxxxxx xxxx).
1.5.4 Limitní xxxxxxx
Xxxxxxxx xxxxxxx x xxxxxx xxxxxx x xxxxxxx 2000 mg/kg xxxxxxx hmotnosti xxxxxxx xxxxxxxxxxx xxxx ve xxxx dávkách v xxxxxx xxx xxxxxxxxxx xxxxx pozorovatelné xxxxxxx xxxxxx a xxxx-xx xx základě údajů x látkách, xxxxx xxxx podobnou xxxxxxxxx, xxxxxxxxx genotoxicita, xxxx xxxxxxxxxx úplná xxxxxx xx třemi xxxxxxxx xxxxx za nezbytnou. X xxxx xxxxxxxxxx xxxxxx je xxxxxxx xxxxxx xxx 14xxxxx xxxxxxxx 2000 mg/kg xxxxxxx xxxxxxxxx/xxx a xxx xxxxx xxx 14xxxxx xxxxxxxx xx xxxxxxx xxxxxx 1000 xx/xx xxxxxxx xxxxxxxxx/xxx. Xxxxxxxxx xxxxxxxx člověka xxxx xxxxxxxx xxxxxxx xxxxxx x xxxxxxx xxxxxxx vyšší xxxxxx xxxxx.
1.5.5 Podávání dávek
Zkoušená xxxxx xx xxxxxxx xxxxxx xxxxxxxxxxxxxx, xxxxxxxxx xxxxxx nebo vhodnou xxxxxxxxx kanylou, xxxx xxxxxxxxxxxxxxxxx xxxxxxx. Jiné xxxxxxx podávání xxxx xxxxxxxxxx x xxxxxxxxxxxxxxx xxxxxxxxx. Maximální xxxxx xxxxxxxx, xxxxx xxxx xxx xxxxxxxx xxxxx xxxxxxxxx xxxxxx nebo xxxxxxxx, xxxxxx xx xxxxxxxxx xxxxxxxxxxx xxxxxxx. Xxxxx xx neměl xxxxxxxxx 2 xx/100 x xxxxxxx xxxxxxxxx. Xxxxxxx xxxxxxx objemů, xxx xx uvedený xxxxx, xxxx xxx xxxxxxxxxx. Až xx xxxxxxxx x žíravé xxxxx, xxxxx xxxxxxx xxx xxxxxxx koncentracích xxxxxxxx xxxxxxxx xxxxxx, xx xxxx být xxxxxxxxxxx xxxxxxxxxx xxxxxx xxxxxxxxxxxxxx xxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxx konstantní objem xxx xxxxx xxxxxxxx xxxxx.
1.5.6 Příprava xxxxxx xxxxx xxxx xxxx
Xxxxx xxxxxx xxxxx xx xxxxxxx získávají x xxxxxx xxxx tibie xxxxx po xxxxxxxx. Xxxxx se odeberou x xxxxxx xxxx xxxxx x zavedenými xxxxxxxx se xxxxxxxxx x xxxxxx. Xxxxxxxxx xxxx xx získává x xxxxxx xxxx xxxx xxxx vhodné xxxxxx xxxx. Xxxxxx xxxxx xx xxxxx xxxxxxxxxxxx xxxxxx (8, 9, 10), xxxx xx xxxxxxxx xxxxxxxxx xxxxxxxx x poté xx xxxxxx. Xxxxxxxx xxxxxxx xxxxxxxxxxxx pro XXX (xxxx. xxxxxxxxxx xxxxx (14) xxxx Xxxxxxx 33258 a xxxxxxx-X (15)) se xxx vyhnout xxxxxxxx xxxxxxxxxx xxxxxxxx s xxxxxxxx xxxxxxx xxxxxxxxxxxxxx xxx XXX. Tato xxxxxx nebrání xxxxxxx xxxxxxxxxxx xxxxxx (xxxx. Xxxxxx). Xxxxxxxx systémy (xxxx. celulosová xxxxxx x xxxxxxxxxx buněk xxxxxxxxxxxx xxxxx (16)) xxx xxxxxx za xxxxxxxxxxx, xx se xxxxxxxxx xxxxxxxxxxxx xxxxxxxxx xxxxxx xxxxxxx pro xxxxxxxxx xxxxxxxxxx x xxxxxxxxxx.
1.5.7 Analýza
Pro xxxxx xxxxx xx xxxxxxx xxxxx xxxxxxxxx erytrocytů x celkového (xxxxxxx + xxxxx) xxxxxxxx xxxxxxxxxx, xxxxxxx se x xxxxxxx xxxxxx xxxxx xxxxxxx celkově xxxxxxx 200 xxxxxxxxxx x x xxxxxxx xxxxxxxxx xxxx xxxxxxx 1000 xxxxxxxxxx (17). Xxxxxxx xxxxxxxxx xxxxxx xxxxxxxxx xxxxxxxxxxx x xxxxxxxxxxx xxxxxxx, xx xxxx být xxxx xxxxxxxx xxx xxxxxxxxxxx xxxxxxxxx xxxxxxxx. X xxxxxxx zvířete xx xxxxxxx alespoň 2000 xxxxxxxxx xxxxxxxxxx na xxxxxx xxxxxxxxxx x xxxxxxxxxxxxxxxxxxxxx. Xxxxx xxxxxxxxx xxxxx xxx získány xxxxxxxxxx xxxxxxx xxxxxxxxxx xx xxxxxx xxxxxxxxxx. Xxx xxxxxxxxxxxxx xxxxxxx xx xxxxx xxx xxxxx xxxxxxxxx xxxxxxxxxx x xxxxxxxxx xxxxxxxx xxxxxxxxxx menší než 20 % xxxxxxxxx xxxxxxx. Jestliže jsou xxxxxxx xxxxxxxxxx xxxxxxxxxxx xxxxx týdny xxxx xxxx, xxx xxxx xxxxxxxx na výskyt xxxxxxxxxx alespoň 2000 xxxxxxx xxxxxxxxxx xx xxxxx xxxxx. Systémy xxx xxxxxxxxxxxx analýzu (xxxxxxx xxxxxx x xxxxxxxxx xxxxxxxxxxxx xxxxxxx xxxxxxx xxxxxxxx) xxxx xx xxxxxxxxxxxxx xxxxxxxxxx x validaci přijatelnými xxxxxxxxxxxxx xxxxxxxxxx hodnocení.
2. XXXXX
2.1 XXXXXXXXXX VÝSLEDKŮ
Údaje xxx xxxxxxxxxx zvířata xx xxxx xxx xxxxxxxxxx ve xxxxx xxxxxxx. Xxxxxxxxxxxxxx xxxxxxxxx xx xxxxx. Xxx xxxxx xxxxxxxxxxx xxxxx xx xxx být xxxxxx počet xxxxxxxxxxx xxxxxxxxx xxxxxxxxxx, počet xxxxxxxxx xxxxxxxxxx x xxxxxxxxxx a počet xxxxxxxxx xxxxxxxxxx x xxxxxxxxx xxxxxxxx xxxxxxxxxx. Xxxxxxxx xxxx zvířata xxxxxxxxxx nepřetržitě xxxxx xxxxx xxxx xxxx, xxxx xx být xxxx uvedeny údaje x xxxxxxx xxxxxxxxxxxx, xxxx-xx xxxxxxxxxxxxx. Xxx xxxxx zvíře xx xxxxx xxxxx xxxxxxxxx xxxxxxxxxx x xxxxxxxxx xxxxxxxx xxxxxxxxxx a xxxxxxxx množství erytrocytů x mikrojádry xxxxxxxxx x xxxxxxxxxx. Neexistuje-li xxxxx x xxxxxxx x xxxxxxxx mezi xxxxxxxxx, mohou být xxx xxxxxxxxxxxx xxxxxxx xxxxx xxx obě xxxxxxx zkombinována.
2.2 XXXXXXXXX X XXXXXXXXXXXX XXXXXXXX
Xxx xxxxxxxxx pozitivního xxxxxxxx xxxxxxxx xxxxxxx kritérií, xxxx. xxxxxx počtu xxxxx x xxxxxxxxxx x závislosti xx xxxxx nebo xxxxx xxxxxx xxxxx xxxxx x xxxxxxxxxx pro xxxxxxx x xxxxxxx xxxxxx x k xxxxxxxx xxxxxxxx xxxxxx. Xxxxxxxx xx xxxx xxx uvážena xxxxxxxxxx xxxxxxxxx xxxxxxxx. Xxx xxxxxxxxx výsledků xxxxxxx xxxxx xxx použity xxxx xxxxxxx xxxxxxxxxx xxxxxxxxxxx xxxxxx (18, 19). Xxxxxxxxxxx xxxxxxxxxx xx neměla být xxxxxxx určujícím xxxxxxxx xxx xxxxxxxxx odpověď. Xxxxxxxxxx výsledky by xxxx xxx vyjasněny xxxxxx zkoušením, nejlépe x úpravou xxxxxxxxxxxxxxxx xxxxxxxx.
Xxxxxxxx látka, jejíž xxxxxxxx xxxxxxxxx xxxx xxxxxxx kritéria, xx xxxxxxxx v xxxxx xxxxxxx xx xxxxxxxxxxx.
Xxxxxx xxxxxxx xxxxxxxxxxx xxxxxxxx xxxxx xxxxxxxxx nebo xxxxxxxxx xxxxxxxx, x xxxxxxxxxxx xxxxxxxxx xxxxxxxx xxxxxx údajů xxxxxxxx xxxxxxx xxxxx x xxxxxxxx xxxxxxxx xxxxx. Xxxxxxxx xxxxx xxxxxx xxxxxxxxxx xxxx xxxxxx xxx xxxxxx xx xx, xxxxxxxx je xxxxxxxxxx xxxxxxxx.
Xxxxxxxxx xxxxxxxx xxxxx na xxxxxxxxxx xxxxxxxxx, že zkoušená xxxxx xxxxxxxx xxxxxxxxxx, xxx xxxx xxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxx nebo xxxxxxxxx mitotického xxxxxxx xxxxxxxxxxxx testovacího xxxxx. Xxxxxxxxx xxxxxxxx xxxxxxxxx, xx zkoušená látka xx xxxxxxxx xxxxxxx xxxxxxxxxxx xxxxxxxxxx v xxxxxxxxx xxxxxxxxxxxx testovacího xxxxx.
Xxxx xx xxx xxxxxxxxxxx pravděpodobnost, x xxxxx se zkoušená xxxxx xxxx xxxx xxxxxxxxxx xxxxxxxx xx xxxxxxxx xxxxx, nebo xxxxxxxxxx xx cílové xxxxx (např. xxxxxxxxx xxxxxxxx).
3. XXXXXX
XXXXXXXX X XXXXXXX
Xxxxxxxx x xxxxxxx xxxx xxxxxxxxx xxxx xxxxxxxxx:
Xxxxxxxxxxxx/xxxxxxxxx:
- zdůvodnění xxxxx xxxxxxxx,
- xxxxxxxxxxx x xxxxxxx xxxxxxxx látky x rozpouštědle/vehikulu, xx-xx xxxxx.
Xxxxxxxxx xxxxxxx:
- xxxxxxx xxxx/xxxx,
- počet, stáří x xxxxxxx xxxxxx,
- xxxxx, xxxxxxxx chovu, xxxxxx atd.,
- xxxxxxxxxxxx xxxxxxxx xxxxxx xx xxxxxxx zkoušky, xxxxxx xxxxxxx xxxxxxx xxxxxxxxx, xxxxxxx xxxxxxx x xxxxxxxxxx xxxxxxxx xxx xxxxxx xxxxxxx.
Xxxxxxxx podmínky:
- xxxxx k pozitivní x xxxxxxxxx (vehikulum/rozpouštědlo) xxxxxxxx,
- údaje xx xxxxxx xxx zjištění xxxxxxx, xxxxx xxxx xxxxxxxxx,
- xxxxxxxxxx xxxxxxxxx xxxxxx xxxxx,
- údaje x xxxxxxxx xxxxxxxx xxxxx,
- xxxxx x xxxxxxxx zkoušené xxxxx,
- xxxxxxxxxx xxxxxxx xxxxxxxx,
- xxxxxxxxx xxxxxx ověření, xxx se zkoušená xxxxx xxxxxxx xx xxxxxxxx oběhu xxxx xx xxxxxx xxxxx,
- xxxxxxxx xxxxxxxx xxxx xxxxxxxxxxx xxxxxxxx xxxxx x xxxxxx xxxx xxxx (ppm) xx xxxxxxxxxxxx xxxxx (xx/xx xxxxxxx xxxxxxxxx/xxx),
- podrobné xxxxx x xxxxxxx xxxxxx x vody,
- xxxxxxxx xxxxx xxxxxxx xxxxxxxx x odběru,
- xxxxxx xxxxxxxx preparátů,
- xxxxxx stanovení toxicity,
- xxxxxxxx hodnocení xxxxxxxxxx x nezralých xxxxxxxxxxxx,
- xxxxx analyzovaných buněk xx xxxxx xxxxx,
- xxxxxxxx klasifikace xxxxxx xx xxxxxxxxx, xxxxxxxxx xxxx dvojznačnou.
Výsledky:
- xxxxxx xxxxxxxx,
- xxxxx nezralých xxxxxxxxxx x celkového xxxxxxxx xxxxxxxxxx,
- xxxxx xxxxxxxxx xxxxxxxxxx x xxxxxxxxxx xxxxxxx xxxxxxxxxx xxx xxxxx xxxxx,
- xxxxxxx xxxxxxx ± xxxxxxxxxx odchylka xxxxx xxxxxxxxx xxxxxxxxxx x xxxxxxxxxx ve skupině,
- xxxxx možnosti xxxxxxxxx xxxxxxxx xx xxxxx,
- xxxxxxxx xxxxxxxxxxx xxxxxxx x metody,
- xxxxx x souběžné x xxxxxxxxx xxxxxxxxx kontrole,
- xxxxx x xxxxxxxx xxxxxxxxx kontrole.
Rozbor xxxxxxxx.
Xxxxxx.
4. XXXXXXXXXX
1) Xxxxxx, X. X. (1973), X Xxxxx Xx vivo Xxxx xxx Xxxxxxxxxxx Xxxxxx, Xxxxxxxxxx Xxx., 18, 187-190.
2) Xxxxxx, X. (1975), Xxx Xxxxxxxxxxxx Xxxx, Mutatation Xxx., 31, 9-15.
3) Xxxxxx, J. A., Xxxxxxxx, M. X., Xxxx, X., Kirkhart, X., Xxxxxxxxx, K., XxxXxxxxx, X. X., Xxxxxx, X. W. (1983), The Induction xx Xxxxxxxxxxx a. x. a Measure xx Genotoxicity, Xxxxxxxxxx Xxx. 123, 61-118.
4) Xxxxxxxxx, X. H., Xxxxxx, X. X., Xxxxxx, X. C., Xxxxxxxx, X. X., Xxxxxx, X. X. (1990), Xxx In xxxx Xxxxxxxxxxxx Xxxxx xx Xxxxxxxxx Xxxx Xxxxxx xxx Xxxxxxxxxx Xxxxx. A xxxxxx xx xxx U. X. Xxxxxxxxxxxxx Xxxxxxxxxx Xxxxxx Gene-Tox Xxxxxxx, Xxxxxxxxxx Xxx., 239, 29-80.
5) XxxXxxxxx, X. X., Xxxxxxxx, X., Xxxx, X. N., Xxxx, X. X. (1983), Xxxxxxxxxxx xx Xxxxxxxxxxx Xxxxxxxxxxxx: X Xxxxx Xxxxxx xxx Xxxxxxxxxxx Damage Xxxxxx Xxxxxxx Toxicity Xxxxxxx xx Xxxx, in: Xxxxxxxxxxxx xx Xxxxxxx xxx Practice of Xxxxxxxxxx, xx. X. X. Xxxxx, R. X. Schnell, X. X. Miya. Xxxxxxxx, Xxxxxxxxx, 555-558.
6) MacGregor, X. X., Heddle, X. X. Xxxx, X., Margolin, G. X., Ramel, X., Xxxxxxxx, X. F., Xxxx, R. X., Xxxx, X. (1987), Xxxxxxxxxx xxx the Xxxxxxx xx Micronucleus Xxxxxx xx Xxxxxxxxx Xxxx Xxxxxx Xxxxxxxxxxxx, Xxxxxxxxxx Xxx., 189, 103-112.
7) XxxXxxxxx, X. X., Xxxx, X. X., Xxxxxx, X. X., Shelby, X. X. (1990), The xx xxxx Xxxxxxxxxxx Xxxxxxxxxxxx Test: Xxxxxxxxxxx xx Steady Xxxxx Xxxxxxxxx Xxxxx Efficiency xxx Xxxxxxx Integration xxxx Xxxxxxxx Studies, Xxxxxx. Xxxx. Xxxxxxx. 14, 513-522.
8) Xxxxxxx, X., Morita, X., Xxxxxx, X., Xxxxxx, X., Xxxxxxxx, M. Xx. (1990), Xxx Xxxxxxxxxxxx Xxxxx xxxx Xxxxx Xxxxxxxxxx Blood Xxxxxxxxxxxxx Xxxxx Xxxxxxxx Xxxxxx-Xxxxxx Xxxxxx, Xxxxxxxxxx Xxx., 245, 245-249.
9) Xxx Xxxxxxxxxxxxx Xxxxx Xxxxx for xxx Xxxxxxxxxxxx Test (1992). Xxxxxxxxxxxx Xxxx with Xxxxx Xxxxxxxxxx Blood Xxxxxxxxxxxx by Xxxxxxxx Xxxxxx Xxxxxxxxxx Xxxxxxxx: Xxx Xxxxxxx Xxxxxx xx xxx 5xx Xxxxxxxxxxxxx Xxxxx by XXXXX/XXXXX, XXX, Mutatation Xxx., 278, 83-98.
10) Xxx Collaborative Xxxxx Xxxxx xxx xxx Xxxxxxxxxxxx Test (CSGMT/JEMMS, XXX: The Xxxxxxxxx Xxxxxxxxxxx Study Group xx xxx Xxxxxxxxxxxxx Xxxxxxx Xxxxxxx of Xxxxx) (1995), Protocol xxxxxxxxxxx xxx xxx xxxxx-xxxx xxxxx peripheral xxxxx micronucleus xxxx, Xxxxxxxxxxx, 10, 53-159.
11) Xxxxxxx, X., Tice, X. R., MacGregor, X. X., Xxxxxxxx, X., Xxxxxxx, X. X., Xxxxxx-Xxxxxxx, M., Xxxxxx, Xx. F. X., Xxxxxxxxxxxx, X., Xxxxxxx, F., Xxxxxxx, X., Xxxxx, X., Xxxxxxx, X. (1994), Xx xxxx Xxxxxx Xxxxxxxxxxx Xxxxxxxxxxxx Xxxxx, Xxxxx. Xxx., 312, 293-304.
12) Higashikuni, X., Xxxxx, X. (1995), Xx optimal, xxxxxxxxxxx xxxxxxxx time xx 30 ± 6 x xxxxx xxxxxx xxxxxx xx xxx xxxxx peripheral micronucleus xxxx, Xxxxxxxxxxx, 10, 313-319.
13) Fielder, X. X., Allen, X. X., Xxxxxx, X. X., Xxxxxx, X. X., Xxx, X., Xxxxxxx, X. J., Xxxxxxxxx, X. X., Xxxxxx-Xxxxxx, X., Xxxxxx, X. X., Kirkland, X. X., Xxxxxxx, X. (1992), Report xx British Toxicology Xxxxxxx/XX Xxxxxxxxxxxxx Mutagen Xxxxxxx Working Xxxxx: Xxxx Xxxxxxx xx Xx xxxx Xxxxxxxxxxxx Xxxxxx, Xxxxxxxxxxx, 7, 313-319.
14) Xxxxxxx, M., Xxxxxx, X., Xxxxxxxx, X. Xx. (1983), Xx Application xx Xxxxxxxx Orange Xxxxxxxxxxx Xxxxxxxx xx xxx Xxxxxxxxxxxx Test, Xxxxxxxx Xxx., 120, 241-247.
15) XxxXxxxxx, J. T., Xxxx, X. X., Xxxxxxxx, X. X. (1983), A Simple Xxxxxxxxxxx Xxxxxxxx Xxxxxxxxx xxx Xxxxxxxxxxx and XXX xx Erythrocytes Xxxxx Xxxxxxx 33258 xxx Pyromin X, Xxxxxxxx Xxx., 120, 269-275.
16) Romagna, F., Xxxxxxxxxx, C. X. (1989), Xxx xxxxxxxxx xxxx marrow xxxxxxxxxxxx xxxx, Xxxxxxxxxx Res., 213, 91-104.
17) Xxxxxxxxx, X., XxXxxxxx, L. X. (1995), Sample Xxxx xxx the Xxxxxxxxxx xx Xxxxxxxxxxxxx xx Xxxxxxxxxxxxxx Xxxxxxxxxxx Xxxxx in the Xxxx Xxxxxx Xxxxxxxxxxxx Xxxx, Xxxxxxxxxx Res., 347, 97-99.
18) Xxxxxxx, X., Xxxxx, X., Xxxxxxx, X., Xxxxxxxx, X., Xxxxxxxxx, X. X., Xxxxxxxxx, X. (1990), Xx vivo Xxxxxxxxxxxx Xxxxx, xx: X. X. Kirkland (xx.), Xxxxx Xxxxxxxxxxxx xxxxx, XXXXX Xxxxxxxxxxx Xxxxxxxxxx, XXXXX Sub-Committee xx Guidelines xxx Xxxxxxxxxxxx Xxxxxxx. Xxxxxx, Xxxx 1, xxxxxxx, Xxxxxxxxx University Xxxxx, Xxxxxxxxx, Xxx Xxxx, Xxxx Xxxxxxx, Xxxxxxxxx, Xxxxxx, 115-141.
19) Xxxxxx, X. X., Xxxxxxxx, X., Xxxxxxxx, R., Xxxxxxxx, X. E., Xxxxx, X., Ferguson X., Xxxxxxx, M., Xxxxxxxx, X. G., Xxxxxx, X. R. X. (1989), Xxxxxxxxxx Xxxxxxxx xx In xxxx Xxxxxxxxxxx Xxxxxx, xx: X. J. Xxxxxxxx (ed.), Xxxxxxxxxxx Xxxxxxxxxx xx Xxxxxxxxxxxx Xxxx Xxxx. XXXXX Xxx-Xxxxxxxxx xx Guidelines xxx Xxxxxxxxxxxx Xxxxxxx. Xxxxxx, Part XXX, Xxxxxxxxx Xxxxxxxxxx Xxxxx, Xxxxxxxxx, Xxx Xxxx, Xxxx Chester, Xxxxxxxxx, Xxxxxx, 184-232."
PŘÍLOHA 4D
"B.13/14 MUTAGENITA — XXXXXXX XX XXXXXXXX XXXXXX X XXXXXXXXXX
1. METODA
Tato metoda xx xxxxxxxx xxxxxx XXXX XX 471 — Xxxxxxx xx xxxxxxxx xxxxxx s xxxxxxxxxx (1997).
1.1 XXXX
Xxx xxxxxxx na reverzní xxxxxx x bakteriemi xx xxxxxxxxx xxxxxxxxxxx xxxxx závislé xx xxxxxxxxxxxxxxx Xxxxxxxxxx xxxxxxxxxxx x Escherichia coli, x xxxxxxx xxxxxxxx xxxxxx, xxxxx xxxxxxxx xxxxxxxxxx, adici x xxxxxx xxxxxxx nebo xxxxxxxx xxxx xxxx XXX (1, 2, 3). Podstata xxxx xxxxxxx xx reverzní xxxxxx x xxxxxxxxxx xxxxxxx x xxxxxxx xxxxxx, které revertují xxxxxx xxxxxxxx v xxxxxxxxxxx xxxxxxx a xxxxxxxx xxx funkční xxxxxxxxx xxxxxxxx syntetizovat xxxxxxxxxx xxxxxxxxxxxxx. Xxxxxxxx xx xxxxxxx xxxx xxxxxxxxxx xxxx xxx xxxxxxxxxx růst x xxxxxxxxxxxxx aminokyselin, xxxxx xxxx xxxxxxxxxx mateřským xxxxxxxxxx kmenem.
Bodové xxxxxx x xxxxxxx jevy xxxx xxxxxxxx xxxxx xxxxxxxxx xxxxxxxxxxx chorob x xxxxxxx x xxxxxxxx mnoho důkazů x xxx, xx xxxxxx xxxxxx v xxxxxxxxxx x v xxxxxx somatických xxxxx xxxxxxxxx xxxxxx xxxx xxxxx xx xxxxxx xxxxxxxx x člověka x x xxxxxxxxx xxxxxx. Xxxxxxx xx xxxxxxxx xxxxxx x xxxxxxxxxx xx rychlá, xxxxxxxxxx x xxxxxxxxx xxxxxx. Mnoho xxxxxxxxxxx xxxxx xx xxxx xxxxxxxxxx, xxxx xxxx xxxx citlivější na xxxxxxx xxxxxx, xxxxxx xxxxxxxxxxxxx xxxxxxxx XXX xx xxxxxxxxxx místech, xxxxxxx xxxxxxxxxxxx xxxxx xxx xxxxx xxxxxxxx x xxxxxxxxx reparačních xxxxxxx XXX nebo xxxxxxxx xxxxxxxxxxx xxxxxxx XXX xxxxxxxxxx x xxxxxx. Xxxxxxxxxxxx xxxxxxxxxxx xxxxx xxxx poskytnout xxxxxxx užitečné xxxxxxxxx x typech mutací, xxx xxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxx. Xxx xxxxxxx xx xxxxxxxx xxxxxx s bakteriemi xx k dispozici xxxxx xxxxxxxx databáze xxxxxxxx pro xxxxxxx xxxxx xxxxxxxx x xxxx byly xxxxxxxx xxxxx xxxxxxxxxx xxxxxx xxxxxxxx chemických látek, xxxxxx xxxxxxxx xxxxxxxxx, x xxxxxxx xxxxxxxxx-xxxxxxxxxx xxxxxxxxxxx.
Xxx xxxx xxxxxx xxxx, část B.
1.2 XXXXXXXX
Xxxxxxx xx xxxxxxxx xxxxxx s bakteriemi Xxxxxxxxxx xxxxxxxxxxx xxxx Xxxxxxxxxxx xxxx xxxxxx x detekci xxxxxx x kmeni xxxxxxxxxxx xxxxxxxxxxxxx (xxxxxxxx xxxx. xxxxxxxxx), xxxxxxx vzniká xxxx xxxxxxxxx xx xxxxxxx xxxxxxx aminokyseliny.
Mutageny xxxxxxxxxx párů xxxx xxxx činitele, xxx xxxxxxxxx xxxxx x xxxxxx XXX. Xxx xxxxxxx xxxxxxxxxx mutací xx xxxxx tyto xxxxx xxxxxxxxxx xx xxxxx xxxxxxx xxxxxx xxxx jiném xxxxx xxxxxxxxxxxxx xxxxxx.
Xxxxxxxx xxxxxxxx xxxx xxxxxxxx, xxx xxxxxxxxx xxxxx xxxx xxxxxx xxxxxxx xxxx xxxx xxxx xxxx XXX x posunují xxx čtecí xxxxx XXX.
1.3 XXXXXXX XXXXX
Xxx xxxxxxxxx na xxxxxxxx xxxxxx s xxxxxxxxxx xx využívají xxxxxxxxxxxxx xxxxx, které xx xxxx xx xxxxx xxxxx xxxxxxx, jako xxxx příjem, xxxxxxxxxxxx, xxxxxxxxxxxx xxxxxxxxx a xxxxxxxxx xxxxxxx XXX. Xxxxxxx prováděné xx xxxxx xxxxxx vyžadují xxxxxxx xxxxxxxx zdroje xxxxxxxxxxx xxxxxxxx. Xxxxxxxxxxx xxxxxxxxx systémy xx xxxxx xxxxxxx xxxxx xxxxxxxxx xxxxxxxx xx xxxx x savců. Xxxxxxx xxxx neposkytuje xxxxxx informaci x xxxxxxxxxx x xxxxxxxxxxxxx xxxxxxxxxx xxxxx pro xxxxx.
Xxxxxxx xx reverzní xxxxxx x xxxxxxxxxx xx zpravidla xxxxxxxxx xxx počáteční vyšetření xxxxxxxxxxx aktivity, x xxxxxxx aktivity xxxxxxxxxxxx xxxxxx xxxxxx. X xxxxxxxx xxxxxxxx xxxxxxx, xx xxxxx chemických xxxxx, xxxxx xxxx x xxxx zkoušce xxxxxxxxx, vykazuje xxxxxxxxx xxxxxxxx i v xxxxxx xxxxxxxxx. Xxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxxxxx, xxxxx nejsou xxxxxxxxxx xxxxx zkouškou. Příčiny xxxxxx skutečností xxx xxxxxxxxx xx specifické xxxxxx xxxxxxxxxxxxxxxxxxxxx xxxx, x rozdílech x xxxxxxxxxxx xxxxxxxx xxxx x rozdílech x xxxxxxxxxx xxxxxxxxxxx. Xx xxxxx xxxxxx faktory, xxxxx zvyšují citlivost xxxxxxx na xxxxxxxx xxxxxx na xxxxxxxxxx, xxxxx xxxx x xxxxxxxxxxxx xxxxxxxxx xxxxxxxx.
Xxxxxxx xx reverzní xxxxxx x bakteriemi xxxxxx xxx xxxxxx xxx xxxxxx xxxxx xxxxxxxxxx xxxxx, xxxxxxxxx xxxxxx xxxxxxxxxxxx xxxxxxxxxx (xxxx. xxxxxx xxxxxxxxxxx) a xxx xxxxxxxx xxxxx, x xxxxx se xxxxxxxxxxx (xxxx o xxxxx xx xx), xx xxxxxxxxxx xxxxxxxx xx replikačního xxxxxxx xxxxx savců (xxxx. xxxxxxx xxxxxxxxxx xxxxxxxxxxxxx x xxxxxxx xxxxxxx xxxxxxxxxx). V takových xxxxxxxxx xxxxx xxx xxxxxxxxx zkoušky mutagenity x savců.
Přestože xxxxx xxxxxxxxx, pro něž xx tato zkouška xxxxxxxxx, xx karcinogenní xxx xxxxx, není xxxxxxxx xxxxxxxxx. Závisí xx xxxxxxxx třídě x existuje mnoho xxxxxxxxxxx, xxx xxxxxx xxxxxxxxxx xxxxx zkouškou, xxxxx působí jinými, xxxxxxxxxxxxxxx xxxxxxxxxx, xxxx xxxxxxxxxx, xxxxx x xxxxxxxxxxxxx xxxxxxx xxxxxxxxxx.
1.4 XXXXXXXX XXXXXXXX METODY
Suspenze xxxxxxxxxxxxx xxxxx jsou xxxxxxxxx xxxxxxxx xxxxx, x xx xx xxxxxxxxxxx vnějšího xxxxxxxxxxxxx xxxxxxxxxxx systému x xxx xxxx. Xx xxxxxxxxxxx xxxxxxxx xxxxx xx xxxxxxxx xxxxxxxx x vrchním xxxxxx x xxxxx se xxxxxxx na xxxxxxxxx xxxx. X xxxxxxxxxxxx xxxxxx se zkoušená xxxx inkubuje a xxxx xx xxxx xxxxxxxxx xx minimální xxxx xxxxxx s xxxxxxx xxxxxx. Xxx xxxx xxxxxxxxxx xx xx xxxx xxxx xxxxx dnech xxxxxxxx xxxxxxxxx xxxxxxx xxxxxxxxxx x xxxxxxx xx xxxxxxxx s xxxxxx xxxxxxx spontánních xxxxxxxxxx xx xxxxxxxxx misce x rozpouštědlem.
Je xxxxxxx xxxxxxx xxxxxxx provedení xxxxxxx xx xxxxxxxx xxxxxx x bakteriemi. Xxxx xxxxx používané xxxxx xxxxxxxxxx xxxxxxx xxxx (1, 2, 3, 4), xxxxxxxxxxxx xxxxxx (2, 3, 5, 6, 7, 8), fluktuační xxxx (9, 10) x xxxxxxxxx xxxxxx (11). Xxxxxx pro zkoušení xxxxx a xxx xxxx popsány (12).
Xxx xxxxxxx xxxxxxx xx xxxxxx hlavně standardního xxxxxxxxx testu x xxxxxxxxxxxxxx xxxxx. Každá x xxxx xx xxxxxxxxxx xxx xxxxxxxxx xxxxxxxxxxx jak x xxxxxxxxxxxx aktivací, xxx xxx xx. Xxxxxxx xxxxx xxx účinněji xxxxxxxxx xx použití xxxxxxxxxxxx xxxxxx. Tyto xxxxx patří do xxxxxxxxxx xxxx, xx xxxxx xxxxx xxxx xxxxx krátké alifatické xxxxxxxxxxx, dvojvazné kovy, xxxxxxxx, xxxxxxxxxx x xxxxxxxxxx xxxxxxxxxx, xxxxxxxxxxxxxxx xxxxxxxxx, allylové xxxxxxxxxx x nitrosloučeniny (3). Xxxxxx xx xxxxxxxxx, xx xxxxxx xxxxx xxxxxxxx xxxxx vždy xxxxxxxxx standardními xxxxxxx, xxxx xx xxxxxxxxxx xxxxxxx test xxxx xxxxxxxxxxxx xxxxxx. Xxxx xx být xxxxxxxxxx xx "xxxxxxxx xxxxxxx" x x jejich xxxxxxx se důrazně xxxxxxxxxx xxxxxx xxxxxxxxxxxx xxxxxxx. Xx možné xxxxxxxxxxxxx tyto "xxxxxxxx xxxxxxx" (společně s xxxxxxxx postupů jejich xxxxxxx): xxxxxxxxxx a xxxxxxxxxx xxxxxxxxxx (3, 5, 6, 13), xxxxx a xxxxxx xxxxxxxx xxxxx (12, 14, 15, 16), x xxxxxxxxx (17, 18). Xxxxxxxx xx xxxxxxxxxxxx xxxxxxx xxxx xxx vědecky xxxxxxxxxx.
1.5 XXXXX XXXXXXXX XXXXXX
1.5.1 Xxxxxxxxx
1.5.1.1 Xxxxxxxx
Xxxxxxx kultury xxxxxxxx xx xxxx xxx kultivovány do xxxxxx xxxxxxxxxxxxx xxxx xxxx xx xxxxx xxxxxxxxxxx fáze růstu (xxxxxxxxx 109 buněk xx ml). Xxxxx x xxxxxx xxxxxxxxxxx xxxx xx neměly xxx xxxxxxx. Je xxxxxxxx, aby xxxx xxxxxxx xxxxxxxx xxxxxx xxxx xxxxxxxxxxxxxxx xxxxxxxx. Xxxx může být xxxxxxxx buď xx xxxxxxx dosavadních xxxxxxxxxxx xxxxx x xxxxxxx xxxxxx, xxxx xxx xxxxxx xxxxxxx stanovením xxxxx životaschopných buněk xx xxxxxxx.
Xxxxxxxxxx inkubační xxxxxxx je 37 °X.
Xxxx xx xxx xxxxxxx alespoň xxx xxxxx xxxxxxxx. Xxxx xxxx xx měly xxx xxxxx xxxxx X. xxxxxxxxxxx (XX1535; XX1537 nebo TA97a xxxx XX97; TA98 x TA100), xxxxxxx xxxxxxx xx ukázala x různých xxxxxxxxxxxx xxxx spolehlivá a xxxxxxxxxxxxxxxx. Xxxx xxxxx xxxxx S. xxxxxxxxxxx xxxx pár bází XX na primárním xxxxxxxxx xxxxx a xx známo, xx xxxxxx xxxxxxxxxxxxxxx xxxxx xxxxxxxxx xxxxxx xxxxxxxx xxxxxxxx, xxxxxxxx xxxxxxxxxxx xxxxxxxxxx xxxxxx XXX x hydraziny. Tyto xxxxx xxxxx být xxxxxxxxxx xxxxx X. xxxx XX2 xxxx X. xxxxxxxxxxx XX102 (19), xxxxx xxxx xx xxxxxxxxx xxxxxxxxx xxxxx xxx xxxx XX. Doporučená xxxxxxxxx xxxxx je tedy xxxx:
- S. xxxxxxxxxxx XX1535 a
- S. xxxxxxxxxxx XX1537 xxxx XX97x x
- S. xxxxxxxxxxx TA98 x
- X. typhimurium XX100 x
- X. coli XX2 xxxX, xxxx X. xxxx XX2 xxxX (pKM101), xxxx X. xxxxxxxxxxx TA102.
Pro xxxxxxx xxxxxxxx způsobujících xxxxxxxxxx xxxxxx XXX xxxx xxx vhodnější xxxxxxx TA102 xxxx xxxxxx xxxx X. xxxx s xxxxxxx xxxxxxxxxx xxxxxxxx DNA, (xxxx. X. xxxx XX2 (xXX101)).
Xxxx by xxx xxxxxxx xxxxxxxx xxxxxxx xxxxxxxx xxxxxxx xxxxxxx, xxxxxxxxxx xxxxxxx x xxxxxxxxxx. Xxxxxxx xxxxxxxxxxxxx xxx xxxx xx měla xxx xxxxxxxxx pro xxxxxx xxxxxxxxx xxxxxxxx xxxxxxx (xxxxxxxx xxx kmeny X. xxxxxxxxxxx a xxxxxxxxx xxx X. xxxx). Podobně xx xxxx být xxxxxxxxxxxx xxxx fenotypové charakteristiky, xxxxxxxxx xxxxx xxxxxxx xxxxxxxxxx nebo xxxxxxxxxxxx X-xxxxxxx xxxxxxxx (tj. xxxxxxxxxxxx rezistence x xxxxx XX98, TA100 x XX97x nebo XX97, WP2 xxxX x WP2 xxxX (xXX101) x ampicilinová x tetracyklinová rezistence x kmene XX102), xxxxxxxxxx charakteristických xxxxxx (xx. rfa xxxxxx x S. xxxxxxxxxxx xxxxxxxxxx xx xxxxxxxxxxx xxxxxx x xxxX xxxxxx x X. xxxx xxxx uvrB xxxxxx u X. xxxxxxxxxxx citlivostí na xxxxxxxxxxxx xxxxxx) (2, 3). Xxxxx xx xxxx xxxxxx xxxxx xxxxx kolonií xxxxxxxxxxx xxxxxxxxxx xx xxxxx x xxxxxxx xxxxxxxx xxxxxxxxxxx xx xxxxxxx xxxxxxxxxxx xxxxx xxxxxxxxxxxxx xxxxxxx x xxxxxxx x xxxxxxx uvedeném x xxxxxxxxxx.
1.5.1.2 Xxxxxx
Xxxxxxx xx xxxxxx minimální xxxx (např. xxxxxxxxxx xxxxxxxxx xxxx X (Xxxxx-Xxxxxx) a xxxxxxx) x xxxxxx xxxx xxxxxxxxxx xxxxxxxx x xxxxxx nebo xxxxxxxxx xxxxxxxxxx xxxxxxx xxxxxxxxx xxxxxx (1, 2, 9).
1.5.1.3 Metabolická xxxxxxxx
Xxxxxxxx xx xxxx xxx xxxxxxxxx xxxxxxxx látce, x xx x xxxxxxx xxxxxxxx xxxxxxxxxxx xxxxxxxx x xxx xxxx. Nejčastěji xxxxxxxxxx xxxxxxxx je xxxxxxxxxx xxxxxxxx postmitochondriální frakce (X9) připravená z xxxxx hlodavců xxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxx enzymy, xxxx xx Xxxxxxx 1254 (1, 2) xxxx xxxxxxxxxxxxx a β-xxxxxxxxxxxx (18, 20, 21). Postmitochondriální xxxxxx xx xxxxxxx používána x koncentracích v xxxxxxx 5 až 30 % xxx. xx směsi S9. Xxxxx x podmínky xxxxxxxxxxxxx xxxxxxxxxxx systému xxxx xxxxxxx xx xxxxx xxxxxxxx xxxxxxxx xxxxx. X xxxxxxxxx xxxxxxxxx xxxx být xxxxxx xxxxxx více xxx xxxxx xxxxxxxxxxx xxxxxxxxxxxxxxxxxxx xxxxxx. X xxxxxxxxx x diazoniových xxxxxxxxx může xxx xxxxxxxxx xxxxxxx redukčního xxxxxxxxxxxxx aktivačního xxxxxxx (6, 13).
1.5.1.4 Xxxxxxxx xxxxx xxxx přípravek
Pevné xxxxxxxx látky xx xxxx xxx před xxxxxxxx na xxxxxxxx xxxxxxxxxx nebo xxxxxxxxxxxx xx xxxxxxxx rozpouštědlech xxxx xxxxxxxxxx a xxxxxxxxx zředěny. Xxxxxxx xxxxxxxx xxxxx xxxxx xxx přidány xxxxx x xxxxxxxxxx xxxxxxxx x/xxxx xxxxx xxx xxxx aplikací zředěny. Xxxx xx xxx xxxxxxx čerstvě xxxxxxxxxx xxxxxxxx chemické látky, xxxxx xxxxx x xxxxxxxx xxxxxxxxxxx možnost xxxxxxxxxx.
Xxxxxxxxxxxx/xxxxxxxxx by xxxx xxx mimo xxxxxxxxx, xx reaguje xx xxxxxxxxx xxxxxx, a xxxx by xxx xxxxxxxxxx x xxxxxxxx xxxxxxxx x x xxxxxxxxx X9 (22). Xxxx-xx použita xxxx xxx známá xxxxxxxxxxxx/xxxxxxxx, xxxx xx xxx xxxxxx xxxxxxxx podloženo xxxxx x jejich xxxxxxxxxxxxx. Xxxxxxxxxx xx xxxxx xxxxx nejdříve xxxxxx xxxxxxx xxxxxxx xxxxxxxxxxxx/xxxxxxx. Xxx xxxxxxxx xxxxx xxxxxxxxx ve xxxx by měla xxx xxxxxxx organická xxxxxxxxxxxx xxxxxxxxxxxx xxxx.
1.5.2 Xxxxxxxx podmínky
1.5.2.1 Xxxxxxxx xxxxx (xxx 1.5.1.1)
1.5.2.2 Xxxxxxxxx xxxxxxxxxxx
Xxxx xxxxxxxx, xxxxx xxxx xxx xxxxxxxxxx xxx xxxxxxxxx xxxxxxxxxx množství xxxxxxxx xxxxx xxxxx xxxxxxxxxxxx x rozpustnost x xxxxxxx xxxxx pro xxxxxxxx.
Xxxx xxx xxxxxxxx xxxxxxxx xxxxxxxx a xxxxxxxxxxxxx x xxxxxxxxxxx xxxxxxxxxxxxx. Xxxxxxxxxxxx může xxx xxxxxxxxxx xxxxxxxx xxxxx xxxxxxx revertantů, xxxxxxxxx xxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxx xxxx xxxxxxxx stupně přežití xxxxxxxxxxxx xxxxxx. Xxxxxxxxxxxx xxxxx xx xxxx xxxxxx v xxxxxxxxxxx xxxxxxxxxxxxx aktivačních systémů. Xxxxxxxxxxxxx by xxxx xxx xxxxxxxxx xx xxxxxxx xxxxxxxxxxx xxxxxxx x xxxxxxx směsi xx xxxxxxxxxx zkušebních xxxxxxxx.
Xxxxxxxxxx xxxxxxxxx zkušební xxxxxxxxxxx pro xxxxxxxxx xxxxxxxxxxxxx xxxxx xx 5 xx/xxxxx xxxx 5 μl/misku. U xxxxxxxxxxxxxxx látek nerozpustných xxx koncentracích 5 xx/xxxxx xxxx 5 μx/xxxxx xx měla xxx xxxxx nebo xxxx xxxxxxxxxx xxxxxxxxxxx xxxxxxxx, xxx xxxxx xxxx x xxxxxxx xxxxx xxx aplikaci xxxxxxxxxxx. Xxxxxxxx xxxxx, xxxxx xxxx xxxxxxxxxxx xxx xxx koncentracích xxxxxxx než 5 xx/xxxxx nebo 5 μx/xxxxx, xx xxxx xxx xxxxxxxx xx xx cytotoxické koncentrace. Xxxxxxxxx xx xxxxxx xxxxx při xxxxxxxxxxx.
Xxxx xx xxx použito xxxxxxx xxx xxxxxxx xxxxxxxxxxxxxxxx xxxxxxxxxxx xxxxxxxx xxxxx, xxxxxxx xxx xxxxxx xxxxxxxxxxx xx xxxx xxx intervaly xxxx zkušebními xxxx xxxxx přibližně xxxxxxxx xxxxx xxxxxxxxxxxx xxxxxxxx (xx. Ö10). Xxxxx xxxxxxxxx xxxx xxxxxx x xxxxxxx, kdy xx xxxxxxxxx xxxxxx xxxxxxxxxx xxxxxxxx na xxxxxxxxxxx. Xxxxxxxx xxxxxxxxxxx xxxxxxx než 5 xx/xxxxx xxxx 5 μx/xxxxx může xxx xxxxxxx při xxxxxxxxx xxxxx xxxxxxxxxxxx významné xxxxxxxx potenciálně xxxxxxxxxxx xxxxxxxx.
1.5.2.3 Xxxxxxxxx x xxxxxxxxx kontroly
Součástí xxxxxxx xxxxxxxxx by xxxx xxx kmenově specifické xxxxxxxxx x negativní (xxxxxxxxxxxx xxxx xxxxxxxxx) xxxxxxxx x xxxxxxxxxxxx xxxxxxxx x xxx xx. Xxx pozitivní xxxxxxxx xx měly xxx xxxxxxx xxxxxxxxxxx xxxxxxxxxxx xxxxxxxx každé xxxxxxx.
X případě zkoušek x xxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxx xxxxxxx xx xxxx xxx xxxxx (xxxxx) xxx xxxxxxxxx xxxxxxxx xxxxxxx (xxxxxxx) xx základě xxxx xxxxxxxxx xxxxx xxxxxxxx.
Xxxxxxxxx xxxxxx xxxxxxxxx xxxxxxxx x xxxxxxx x xxxxxxxxxxxx xxxxxxxx xxxx xxxx xxxxx:
|
Xxxxx |
Xxxxx XXX |
Xxxxx xxxxx EINECS |
|
9,10-dimethylanthracen |
781–43–1 |
212–308–4 |
|
7,12-dimethylbenzo[a]anthracen |
57–97–6 |
200–359–5 |
|
benzo[a]pyren |
50–32–8 |
200–028–5 |
|
2-aminoanthracen |
613–13–8 |
210–330–9 |
|
Cyklofosfamid |
50–18–0 |
200–015–4 |
|
cyklofosfamid monohydrát |
6055–19–2 |
Tato xxxxx xx vhodnou xxxxxxxxx kontrolou xxx xxxxxx redukční xxxxxxxxxxx xxxxxxxx:
|
Xxxxx |
Xxxxx XXX |
Xxxxx xxxxx XXXXXX |
|
XX Xxxxxx Xxx 28 |
573–58–0 |
209–358–4 |
2-xxxxxxxxxxxxxx by neměl xxx použit xxxx xxxxxx indikátor xxxxxxxxx xxxxx X9. Při xxxxxxx 2-xxxxxxxxxxxxxxx xx xxxx xxx každá xxxxx X9 xxxxxxxxxxxxxxxx xxxxxxxxx, xxxxx xxxxxxxx xxxxxxxxxxxx xxxxxxxx xxxxxxxxxxxxxx xxxxxx, xxxxxxxxx xxxxx[x]xxxxx xxxx 7,12-xxxxxxxxxxxxx[x]xxxxxxxxx.
Xxxxxxxxx xxxxxxxxxxxxxxxxx xxxxxxxxx xxxxxxxx x xxxxxxx xxx vnější xxxxxxxxxxx xxxxxxxx xxxx xxxx látky:
|
Látka |
Číslo XXX |
Xxxxx xxxxx XXXXXX |
Xxxx |
|
xxxx sodný |
26628–22–8 |
247–852–1 |
TA1535 x XX100 |
|
2-xxxxxxxxxxxx |
607–57–8 |
210–138–5 |
XX98 |
|
9-xxxxxxxxxxxx |
90–45–9 |
201–995–6 |
XX1537, XX97 x TA97a |
|
ICR 191 |
17070–45–0 |
241–129–4 |
XX1537, XX97 x TA97a |
|
Kumenhydroperoxid |
80–15–9 |
201–254–7 |
TA102 |
|
mitomycin X |
50–07–7 |
200–008–6 |
XX2xxxX x TA102 |
|
1-methyl-3-nitro-1-nitrosoguanidin |
70–25–7 |
200–730–1 |
WP2, XX2 uvrA x XX2 xxxX (pKM101) |
|
4-nitrochinolin-1-oxid |
56–57–5 |
200–281–1 |
WP2, XX2 xxxX a XX2 xxxX (xXX101) |
|
α-[(5-xxxxx-2-xxxxx)xxxxxxxxxx]xxxxx-2-xxxxxxxx (XX2) |
3688–53–7 |
xxxxx xxxxxxxxxx xxxxxxxx |
Xxx xxxxxxxxx xxxxxxxx xxxxx xxx xxxxxxx xxxx xxxxxx xxxxxxxxxx xxxxx. Xxx xxxxxxxxx xxxxxxxx xx xxxx xxx xxxxx x xxxxx xxxxxxx xxxxxxxxxx xxxxx xx stejné xxxxxxxx xxxxx, xxxx li x xxxxxxxxx.
Xxxx by xxx xxxxxxx xxxxxxxxx xxxxxxxx xxxxxxxxxx se xx xxxxxxxxx xxxxxxxxxxxx xxxx xxxxxxxx, xxx xxxxxxxx látky, zpracované xxxxx stejným xxxxxxxx xxxx exponované xxxxxxx. Xxxxx xxxx xx xxxx být xxxxxxxxxxxx xxxxxxxx xxxxxxx xxxx xxxxx, neexistují-li xxxxx xxxxxxxxx xxxxx xxxxxxxxxxx, xx xxxxxxx xxxxxxxxxxxx xxxxxxxxxx xxxxx xxxxxxx xxxx xxxxxxxxx xxxxxx.
1.5.3 Xxxxxx
X xxxxxxxxxx xxxxxxx xxxxxx (1, 2, 3, 4) xxx xxxxxxxxxxx xxxxxxxx se xxxxxxx smíchá 0,05 xx nebo 0,1 xx xxxxxxxxxx xxxxxxx, 0,1 xx xxxxxxx xxxxxxxxxxx kultury (xxxxxxxxxx xxxxxxxxx 108 xxxxxxxxxxxxxxx xxxxx) x 0,5 xx sterilního pufru x 2,0 xx xxxxxxxx xxxxx. X xxxxxxx xxxxxxx x xxxxxxxxxxxx aktivací xx xxxxxxx xxxxxx 0,5 xx metabolické xxxxxxxxx xxxxx obsahující přiměřené xxxxxxxx xxxxxxxxxxxxxxxxxxx xxxxxx (x xxxxxxx 5 xx 30 % xxx. v xxxxxxxxxxx xxxxxxxxx xxxxx) x xxxxxxx xxxxxx (2,0 xx) x xxxxxxx x xxxxxxxxxx x xxxxxxxxx xxxxxx xxxx xxxxxxxxx xxxxxxxx. Xxxxx xxxxx xxxxxxxx xx xxxxxxxx a přelije xxxx xxxxxx xxxxxxxxxxx xxxxx xx xxxxx. Xxxx xxxxxxxx xx xxxxx xxxxxx xxxx xxxxxxxx.
X xxxxxxxxxxxx xxxxxx (2, 3, 5, 6) xx zkoušená xxxxx xxxx xxxxxxxx xxxxxx před xxxxxxxxx x xxxxxxx xxxxxx x přelitím xxxx xxxxxx minimálního xxxxx xx xxxxx obvykle 20 minut xxxx xxxx preinkubuje s xxxxxxxxxx xxxxxx (xxxxxxxxxxx xxxxxxxxx 108 xxxxxxxxxxxxxxx xxxxx) x sterilním xxxxxx nebo metabolickým xxxxxxxxxx xxxxxxxx (0,5 xx) xxx 30 — 37 °X. Xxxxxxx xx xxxxxx 0,05 xxxx 0,1 xx xxxxxxxx xxxxx xxxx zkušebního xxxxxxx, 0,1 ml xxxxxxxx x 0,5 xx xxxxx X9 xxxx xxxxxxxxxx xxxxx s 2,0 xx xxxxxxxx xxxxx. Xxxxxxxx by xxxx xxx xxxxx xxxxxxxx xxxxxxxxxxxxxx xx xxxxxxxx.
X xxxxxxxxxxxx xxxxxx xxxxxxxx by měly xxx xxx xxxxx xxxxxx xxxxx xxxxxxx 3 xxxxx. Použití xxxx xxxxx je xxxxxxxxxx xx xxxxxxxx xxxxxxxxxx. Xxxxxxxx xxxxxx xxxxx nemusí znamenat xxxxxxxxxxxx xxxxxxx.
Xxxxxx xxxx xxxxxx látky xx xxxx xxx xxxxxxxx xxxxxxxx metodami, xxxx. x xxxxx uzavřených xxxxxxxxxxxx xxxxxxxx (12, 14, 15, 16).
1.5.4 Xxxxxxxx
Xxxxxxx xxxxx v xxxx zkoušce xx xxxx být inkubovány xxx 37 °X xx 48 –72 xxxxxxxx. Xx xxxxxxxx xxxxxxxxx xxxx xx xxxxxx xxxxx xxxxxxx xxxxxxxxxx xx xxxxx.
2. XXXXX
2.1 XXXXXXXXXX XXXXXXXX
Xxxxxxxxxxxx xxxxx by měly xxx xxxxx xxxxxxx xxxxxxxxxx xxxxxxxxxxx xx xxxxx. Měl xx xxx xxxxxx xxxxxx xxxxx kolonií xxxxxxxxxx xxx na miskách x xxxxxxxxx xxxxxxxxx (xxxxxxxx xxxxxxxxxxxx x xxxxxxxx xxxxxxxxxxxx xxxxxxxx), xxx xx miskách x xxxxxxxxx xxxxxxxxx. Xxxxx na xxxxxxxxxxxx xxxxxxx, střední xxxxxxx xxxxx kolonií xxxxxxxxxx xx misku x xxxxxxxxxx xxxxxxxx xx xxxx xxx xxxxxxxxxx xxx xxxxxxxxx xxxxx x xxxxxxxxx x xxxxxxxxx xxxxxxxx (xxxxxxxxxxxxx xxxxxxxx a/nebo xxxxxxxx xxxxxxxxxxxx).
Xxxxxxx xxxxx xxxxxxxxx xxxxxxxx xx xxxxxxxxxx. Xxxxxxxxxx výsledky xx xxxx xxx xxxxxxxxx xxxxxx xxxxxxxxx, xxxxxxx x úpravou experimentálních xxxxxxxx. Negativní výsledky xxxx xxx xxxxxxxxx xxxxxx xx xxxxxxx. Xxxxxxxx se xxxxxxxxx xxxxxxxxxxx xxxxxxxx xxxxxxxxxx xx xxxxxxxx, mělo xx xxx podáno xxxxxxxxxx. Xxxxx parametrů xxxxxx x xxxxx xxxxxxxx xxxxxx posuzovaných xxxxxxxx xx měla xxx xxxxxxx x xxxxxxxxxx xxxxxxxxxxxxx. X xxxxxxxxxx studie, xxxxx xx mohly být xxxxxxx, xxxxx rozmezí xxxxxxxxxxx, xxxxxx xxxxxxxxxx (xxxxxxxxxx xxxxxxx xxxxxx xxxx xxxxxxxxxxx x xxxxxxxx médiu) x xxxxxxxx metabolické xxxxxxxx.
2.2 XXXXXXXXX X INTERPRETACE XXXXXXXX
Xxx xxxxxxxxx xxxxxxxxxxx xxxxxxxx existuje několik xxxxxxxx, xxxx. nárůst xxxxx kolonií xxxxxxxxxx xx xxxxx nad xxxxxxxxx xxxxxx x xxxxxxx xxxxxxx kmene x metabolickým aktivačním xxxxxxxx xxxx bez xxxx, x to x xxxxxxxxxx xx xxxxxxxxxxx, xxxx xxxxxxxxxxxxxxxx xxxxxx tohoto xxxxx xxx xxxxx nebo xxxx xxxxxxxxxxx (23). Xxxxxxxx by měla xxx uvážena xxxxxxxxxx xxxxxxxxx xxxxxxxx. Při xxxxxxxxx xxxxxxxx xxxxxxx xxxxx xxx použity xxxx xxxxxxx prostředek xxxxxxxxxxx xxxxxx (24). Xxxxxxxxxxx xxxxxxxxxx xx xxxxxx být xxxxxxx xxxxxxxxx xxxxxxxx xxx xxxxxxxxx xxxxxxx.
Xxxxxxxx xxxxx, xxxxx výsledky xxxxxxxxx xxxx xxxxxxx kritéria, xx považuje v xxxxx xxxxxxx xx xxxxxxxxxxx.
Xxxxxx xxxxxxx xxxxxxxxxxx xxxxxxxx xxxxx pozitivní xxxx negativní výsledky, x xxxxxxxxxxx případech xxxxxxxx xxxxxx xxxxx xxxxxxxx xxxxxxx xxxxx x aktivitě xxxxxxxx xxxxx. Xxxxxxxx xxxxx xxxxxx xxxxxxxxxx xxxx xxxxxx xxx xxxxxx xx to, kolikrát xx xxxxxxxxxx xxxxxxxx.
Xxxxxxxxx xxxxxxxx xxxxxxx na xxxxxxxx xxxxxx x xxxxxxxxxx xxxxxxxxx, xx xxxxxxxx xxxxx indukuje x genomu kmenů Xxxxxxxxxx xxxxxxxxxxx x/xxxx Xxxxxxxxxxx coli xxxxxx xxxxxx xxxxxxxxxx bází xxxx xxxxxxx čtecího xxxxx. Xxxxxxxxx xxxxxxxx xxxxxxxxx, xx xxxxxxxx xxxxx xxxx xx xxxxxxxx xxxxxxx pro xxxxxxxxx xxxxx xxxxxxxxx.
3. XXXXXX
XXXXXXXX X XXXXXXX
Xxxxxxxx x zkoušce xxxx xxxxxxxxx xxxx xxxxxxxxx:
Xxxxxxxxxxxx/xxxxxxxxx:
- xxxxxxxxxx xxxxx xxxxxxxxxxxx/xxxxxxxx,
- xxxxxxxxxxx x xxxxxxx xxxxxxxx xxxxx v xxxxxxxxxxxx/xxxxxxxx, je-li xxxxx.
Xxxxx:
- xxxxxxx xxxxx,
- počet xxxxx x xxxxxxx,
- xxxxxxxxxxxxxxx xxxxx.
Xxxxxxxx xxxxxxxx:
- xxxxxxxx xxxxxxxx xxxxx xx misku (xx/xxxxx xxxx μx/xxxxx) x xxxxxxxxxxx xxxxxx xxxxx x xxxxx xxxxx xx xxxxxxxxxxx,
- xxxxxxx xxxxx,
- xxx x xxxxxxx metabolického aktivačního xxxxxxx, xxxxxx xxxxxxxx xxxxxxxxxxxxx,
- xxxxxx xxxxxxxx.
Xxxxxxxx:
- xxxxxx xxxxxxxx,
- známky xxxxxxx,
- počty xx xxxxxxxxxxxx miskách,
- xxxxxxx xxxxxxx xxxxx kolonií xxxxxxxxxx na xxxxx x xxxxxxxxxx xxxxxxxx,
- xxxxx možnosti xxxxxxxxx xxxxxxxx xx xxxxx,
- xxxxxxxx statistické xxxxxxx,
- xxxxx o xxxxxxxx xxxxxxxxx (rozpouštědlo/vehikulum) x xxxxxxxxx xxxxxxxx x xxxxxxxxx, xxxxxxxxx hodnotami x xxxxxxxxxxxx xxxxxxxxxx,
- xxxxxxxxx xxxxx o xxxxxxxxx (xxxxxxxxxxxx/xxxxxxxxx) x xxxxxxxxx xxxxxxxx x xxxxxxxxx, středními hodnotami x směrodatnými odchylkami.
Rozbor xxxxxxxx.
Xxxxxx.
4. XXXXXXXXXX
1) Xxxx, X. X., XxXxxx, X., Yamasaki X. (1975), Xxxxxxx of Xxxxxxxxx Carcinogens and Xxxxxxxx xxxx xxx Xxxxxxxxxx/Xxxxxxxxx-Xxxxxxxxx Xxxxxxxxxxxx Test, Xxxxxxxxxx Res., 31, 347-364.
2) Xxxxx, D. X., Xxxx, B. X. (1983), Revised Xxxxxxx xxx xxx Xxxxxxxxxx Xxxxxxxxxxxx Xxxx, Xxxxxxxxxx Xxx., 113, 173-215.
3) Gatehouse, X., Xxxxxxx, X., Xxxxxx, X., Xxxxx, X., Xxxx, X., Xxxxxxxxxx, X., Xxxxxxx, X., Xxxxx, X., Xxxxxx, X., Zeiger, X. (1994), Recommendations xxx xxx Xxxxxxxxxxx xx Xxxxxxxxx Xxxxxxxx Xxxxxx, Xxxxxxxxxx Xxx., 312, 217-233.
4) Xxxx, L. X., Brusick D. X., Xxxxxxx, X. X., Xxx Xxxxx, X. X., Xxxxx, X. M., Xxxxxx, X. X., Xxxxxx, X., XxXxxx, X., Xxxxxxxxxx, K., Prival, X., Xxx, X. X., Xxx V. (1986), Xxx Xxxxxxxxxx xxxxxxxxxxx/Xxxxxxxxx Microsomal Xxxxx: X Xxxxxx of xxx X. S. Xxxxxxxxxxxxx Protection Agency Xxxx-Xxx Xxxxxxx, Xxxxxxxxxx Xxx., 168, 69-240.
5) Xxxxxx, X., Xxxxxx, X., Xxxxx, X. X., Xxxxxxxxxx, X., Xxxxx, X., Sugimura, X., Xxxxxxxxx, Y. (1975), Mutagenicity of Xxxxxxxxxx Xxx Xxxx xxx xxxxx Xxxxxxxxxxx, Xxxxxx Lett. 1, 91-96.
6) Matsushima, X., Xxxxxxxx, X., Xxxxx, X., Xxxxxx, X., Xxxxxx, A., Xxxxxxxx, X. (1980), Xxxxxxx Xxxxxxxxxx Mutagenicity Xxxxxxxxx Xxxxx, xx: Xxxxx-xxxx Xxxx Systems xxx Xxxxxxxxx Carcinogens, ed. Xxxxxxx K. X., Xxxxxx, R. X., Xxxxxxxx, Xxxxxx-Xxxxxxxxxx-Xxx Xxxx, 273-285.
7) Xxxxxxxxx, X. X., Xxxxxxx, X. X., Xxxxxx, P., Xxxxxxxxx, R. X., Xxxxxx, R. (1980), Xxxxxxxxx Xxxxxxxx Xxxxxx, xx: Xxxxx Xxxxxxxxxxxx Xxxxx: XXXXX Xxxx 1 Revised, ed. X. X. Xxxxxxxx, Xxxxxxxxx Xxxxxxxxxx Xxxxx, 13-61.
8) Aeschacher, X. X., Xxxxxx, U., Xxxxxxx, X. (1987), Xxxxxx Xxxxxxxxxxxxx Xxxxxxxxxxxx Xxxx for Foods, X. Xxxx Xxxxxx., 8, 167-177.
9) Green, X. X. X., Xxxxxx, X. J., Xxxxxxx, X. X. (1976), Xxx xx x xxxxxxxxxx xxxxxxxxxxx xxxx xx detect xxx xxxxxx xx xxxxxxxx, Mutatation Xxx., 38, 33-42.
10) Hubbard, X. X., Green, X. X. L., Xxxxxxxxx, X., Xxxxxxx, X. X. (1984), Xxx Xxxxxxxxxxx Xxxx xx Xxxxxxxx, xx: Xxxxxxxx of Xxxxxxxxxxxx Xxxx Xxxxxxxxxx, 2. xxx., Kilbey, B. X., Legator, M., Xxxxxxx, X., Xxxxx, X. (xxx.), Xxxxxxxx, Xxxxxxxxx-Xxx York-Oxford, 141-161.
11) Xxxxxxxx, X. D., Xxxxxxx, X. X. (1981), Xx Examination xx the Xxxxxxxxxxxx Xxxxxxxxxx Xxxxx xxx Xxxxxxxxxxx with Strains xx Salmonella xxxxxxxxxxx, Xxxxxxxxxxxxx Xxxxxxxxxxx, 3, 453-465.
12) Araki, X., Xxxxxxx, T., Xxxx, X., Xxxxxxxxxx, T. (1994), Improved Method xxx Xxxxxxxxxxxx Xxxxxxx xx Xxxxxxx Compounds xx Xxxxx x Xxx Xxxxxxxx Bag, Xxxxxxxxxx Res., 307, 335-344.
13) Xxxxxx, X. X., Bell, S. X., Xxxxxxxx, V. X., Xxxxxxx, X. X., Xxxxxxx, X. X. (1984), Mutagenicity xx Xxxxxxxxx and Xxxxxxxxx-Xxxxxxxx Xxxx xxx Xxxxxxxx Xxxxxxx Xxxx xx x Xxxxxxxx Xxxxxxxxxx Xxxxx, Mutatation Xxx., 136, 33-47.
14) Xxxxxx, X., Xxxxxxxx, X. X., Xxxxxxx, X., Lawlor, T., Xxxxxxxxxx, X. (1992), Xxxxxxxxxx Mutagenicity Tests. X. Xxxxxxx from xxx Xxxxxxx xx 311 Xxxxxxxxx, Xxxxxxx. Xxx. Mutagen., 19, 2-141.
15) Xxxxxx, X., Xxxxxxxx, X., Xxxxxxx, X. G. (1977), Xxxxxxxxx Xxxxxxxx of Xxxxxxxxx Xxxxxxxxxx xx Xxxxxxxx Xxxxx, xx Xxxxxxxx xx Genetic Xxxxxxxxxx, D. Scott, X. Xxxxxxx, X. Xxxxxx (xxx.) Xxxxxxxx, Xxxxxxxxx, 249-258.
16) Hughes, X. X., Xxxxxxx, X. X., Xxxxxxxx, X. G., Xxxxxxx, X. X. (1987), Xxxxxxxxxxxx Technique xx Xxxxxxx Xxxxxxxxx Xxxxxxxx xx Xxxxxxxx Xxxxxxx Xxxxxxxxx in xxx Xxxx/Xxxxxxxxxx Assay, Environmental Xxxxxxxxxxx, 9, 421-441.
17) Xxxxxxxxxx, X., Xxxxxxxxx, X., Shirai, X., Xxxxxxxx, M., Xxxxxxxx, X. (1979), Xxxxxxxxxxxx xx xxx Xxxxxxxxx Xxxxxxxxx Carcinogen Xxxxxxx xxx Xxxxxxxxx Methylazoxy Xxxxxxx Xxxxxxxxxx in Xxxxxxxxxx xxxxxxxxxxx, Cancer Xxx., 39, 3780-3782.
18) Xxxxxx, X., Gold, X., Ferro-Luzzi, A., Xxxx, B. X. (1980), Xxxxxxxx: X Xxxxx xxx Activation xx Xxxxxxx Glycosides xx Xxxxxxxx by Xxxxxxxxxx Xxxxx, Proc. Xxxx. Xxxx. Xxx. X. X. X, 77, 4961-4965.
19) Xxxxxx, X., Xxxxxx, A., Xxxx, X. X., Xxxxxxxxx, D. G. (1990), Comparison xx Xxxxxxxxxx typhimurium XX 102 xxxx Xxxxxxxxxxx xxxx XX2 Xxxxxx xxxxxxx, Xxxxxxxxxxx, 5, 285-291.
20) Xxxxxxxxxx, T., Xxxxxxxx, M., Xxxx, X., Xxxxxxxx, X. (1976), A Safe Xxxxxxxxxx for Xxxxxxxxxxxxxxx Xxxxxxxxx x. x. xx Xxxxxxx xx Xxxxxxxxx Xxxxxxxxxx Systems, xx: In vitro Xxxxxxxxx Xxxxxxxxxx xx Xxxxxxxxxxx Testing, xxx. X. X. xx Xxxxxx xx xx. Xxxxxxxx, Xxxxx Xxxxxxx, 85-88.
21) Xxxxxx, X. X., Xxxxxx, X. X., Xxxxxxx, C. X., Xxxxxxxxx, X. X., Xxxxxx, X. X., Mackay, J. X., Xxxx, X. X. (1992), Xxxxxxxxxxxx xx Xxxxxxx 1254-induced X9 xx xx xxxxx Xxxxxxxxxxxx Xxxxxx, Xxxxxxxxxxx, 7, 175-177.
22) Xxxxx, X., Xxxxxxxxxxxxxxxx, X., Xxxx, X. X. (1981), Xxxxxxxxxxxxx xx Organic Xxxxxxxx xxxx xxx Xxxxxxxxxx/Xxxxxxxxx Xxxx, Xxxxxxxxxx Xxx., 88, 343-350.
23) Xxxxxxx, X. X., Xxxxx, X., Auletta, X., Xxxxxxxxxx, X., Nestmann, X., Xxxxxx, X. (1987), Xxxxx xxx xxx Xxxxxxxxxx typhimurium/Mammalian Xxxxxxxxx Tests xxx Xxxxxxxxx Mutagenicity, Xxxxxxxxxx Xxx., 189, 83-91.
24) Xxxxx, X. X. X., Green, X. X. L., Middleton, X., Mitchel, I., Xxxxxxxx, W. X., Xxxxxx, X. X. (1989), Analysis of Xxxx from Xxxxxxxxx Xxxxxx Assays, xx: XXXXX Sub-Committee xx Xxxxxxxxxx xxx Xxxxxxxxxxxx Xxxxxxx, Xxxx XX. Xxxxxxxxxxx Xxxxxxxxxx xx Xxxxxxxxxxxx Xxxx Xxxx, xx. Xxxxxxxx, X. X., Cambridge Xxxxxxxxxx Xxxxx, 28-65."
XXXXXXX 4X
"X.17 MUTAGENITA — ZKOUŠKA XX XXXXXX XXXXXX V XXXXXXX XXXXX XX XXXXX
1. XXXXXX
Xxxx xxxxxx xx xxxxxxxx xxxxxx XXXX TG 476 — Zkouška xx xxxxxx mutace x xxxxxxx xxxxx xx xxxxx (1997).
1.1 XXXX
Xxxxxxx xx xxxxxx xxxxxx x xxxxxxx xxxxx xx xxxxx lze xxxxxx pro detekci xxxxxxxx xxxxxx xxxxxxxxxxxx xxxxxxxxxx látkami. Xxxx xxxxxx xxxxxxx linie xxxxx xxxxx xxxxxxx X5178X myší, xxxxxxx xxxxx XXX, CHO-AS52 x V79 xxxxxx xxxxxxxx a xxxxxxxxxxxxxxx xxxxx XX6 člověka (1). U těchto xxxxxxxxx xxxxx xxxx xxxxxxxxxxxxxxx xxxxx xxxxxxxxxxx xxxxxx mutace genů xxx xxxxxxxxxxxxxx (XX) x xxxxxxxxxxx-xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (XXXX) x xxxxxxxx xxxxxxx-xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (XXXX). Xxxxxxx xx xxxxxx TK, XXXX x XXXX detekují xxxxx xxxxxxxx xxxxxxxxxxx xxxxxxxx. Autosomální lokace XX x XPRT xxxx umožnit xxxxxxx xxxxxxxxxxx xxxxxxxx (xxxx. xxxxxxxx delece), xxxxx xxxxx detekovat v XXXX lokusu xx X chromozomech (2, 3, 4, 5, 6).
Xx xxxxxxx na xxxxxx mutace x xxxxxxx savců in xxxxx xxx xxxxxx xxxxxxx xxxxxxxxxx xxxxx xxxxx nebo xxxxxxx xxxxx. Xxxxx xx xxxxxxxx podle xxxxxxxxxx xxxxx v xxxxxxx x stálosti četnosti xxxxxxxxxxx mutací.
Zkoušky xxxxxxxxx xx xxxxx obecně xxxxxxxx xxxxxxx vnějšího xxxxxx xxxxxxxxxxx aktivace. Xxxxx xxxxxxxxxxx xxxxxxxxx xxxxxx nemůže xxxxx xxxxxxxxx xxxxxxxx in xxxx u savců. Xx třeba se xxxxx xxxxxxxxx podmínek, xxxxx xx xxxxx x pozitivním výsledkům, xxx neodrážejí xxxxxxx xxxxxxxxxx. X pozitivním xxxxxxxxx, xxx xxxxxxxxxx xxxxxxx xxxxxxxxxx, xxxx xxxxx xxxxxx xX, xxxxxxxxxx xxxx xxxxxxxx xxxxxx xxxxxxxxxxxx (7).
Xxxx xxxxxxx xx xxxxxxx xx xxxxxxxx možných xxxxxxxx a karcinogenů xxxxx. Mnoho xxxxxxxxx, xxx xxx xx xxxx xxxxxxx xxxxxxxxx, xxxx karcinogeny xxxxx; xxxx touto xxxxxxxx x xxxxxxxxxxxxxx xxxx xxxx xxxxxxxxx korelace. Xxxxxxxx xxxxxx na xxxxxxxx xxxxx x xxxxxxxxx důkazy x xxx, xx existují xxxxxxxxxxx, xxxxx xxxxxx xxxxxxxx xxxxx xxxxxxxx, xxxxx zřejmě xxxxxx xxxxxx, negenotoxickými xxxxxxxxxx, xxxx xxxxxxxxxx, které x bakteriálních buňkách xxxxxxxxxx (6).
Xxx xxxx xxxxxx úvod, část X.
1.2 XXXXXXXX
Xxxxx mutace : xxxxxx xxxxxx xxxxxxxxx typu mutované xxxxx, která xxxxxxxxx xxxxx nebo xxxxxx xxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxx.
Xxxxxxxx xxxxxxxxxx xxxx xxxx : xxxxx, xxxxx způsobují xxxxxxxxxx xxxxxxx nebo xxxx xxxx xxxx x XXX.
Xxxxxxxx xxxxxxxx : xxxxx, xxxxx xxxxxxxxx xxxxx nebo deleci xxxxxxx nebo více xxxx xxxx x xxxxxxxx XXX.
Xxxx exprese xxxxxxxx : doba, xxxxx xxx xxxxxx x xxxx xxxxxxxxxx xxxxx nezměněné xxxxxx xxxxxxxx.
Xxxxxxx xxxxxxx : xxxxx xxxxxxxxxxxx mutantních xxxxx dělený xxxxxx xxxxxxxxxxxxxxx xxxxx.
Xxxxxxxxx xxxxxxx xxxx : xxxxxx xxxxx xxxxx v xxxx xx srovnání x kontrolní xxxxxxxx xxxxx; xxxxxxx se xxxx xxxxxx xxxxxx xxxxxxxxx růstu x xxxxxxxx x x xxxxxxxxx kontrole a xxxxxxxxx účinnosti xxxxxxxxx xxxxxxxx k xxxxxxxxx xxxxxxxx.
Xxxxxxxxx xxxx v xxxxxxxx : nárůst xxxxx xxxxx v xxxxxxx xxxxxxx vzhledem x negativní xxxxxxxx.
Xxxxxxxxxxxxxxx : xxxxxxxx klonování xxxxx x xxxxxxxx xxxxxxxx xx xxxxx xx xxxxxxxxxxxx xxxxxxxx xx xxxxxxx.
Xxxxxxx : xxxxxxxx klonování xxxxx xxx nasazení na xxxxx na xxxxx xxxxxx xxxxxxxx; xxxxxxx xx obvykle xxxxxxxxx x xxxxxx x xxxxxxx xxxxxxxxx xxxxxxxx xxxxx.
1.3 XXXXXXXX XXXXXXXX XXXXXX
Xxxxx, xxxxx x xxxxxxxx xxxxxx TK+/-® XX— /- xxxxxxxxxx xxxxxxxxxxxxxx (TK) xxxx xxxxxxxxxxx x xxxxxxxxxxxx xxxxxxx analogu xxxxxxxxxx xxxxxxxxxxxxxxxxx (XXX). Xxxxx xxxxxxxxxxx xxxxxxxxxxxxxx xxxx xxxxxxx na XXX, xxx xxxxxxxxx xxxxxxxx xxxxxxxxx xxxxxxxxxxx x xxxxxxxxx xxxxx xxxxxxx xxxxxx. Mutantní xxxxx xxxx xxxx xxxxxxx xxxxxxxxxxx za xxxxxxxxxxx XXX, xxxxxxx xxxxxxxx xxxxx, xxxxx xxxxxxxx xxxxxxxxxxxxxx xxxx schopnost xxxxxx. Xxxxxxx lze x xxxxx s xxxxxxxxxxxx XXXX xxxx XXXX xxxxxxx xxxxxxx xxxxxxxxxxxxxxx rezistence x 6-xxxxxxxxxxx (XX) xxxx 8-xxxxxxxxxx (XX). Xxxxxxxxxx xxxxxxxx xxxxx xx xxxx xxx xxxxxxx xxxxxxx, xxxxxxxx xx xx xxxxxxx xx xxxxxx xxxxxx x xxxxxxx savců zkoušen xxxxxx xxxx xxxx xxxxxxxxxx podobná selekčnímu xxxxxxx. Mělo xx xxx xxxxxxxxx xxxxxxxxx xxxxxxxx podezření na xxxxxxxxxx xxxxxxxx xxxxxxxx xxxxx xxx xxxxxxxx xxxx xxxxxxxxxx buňky. Xxx xxxxxxxx xxxxxxxxxx xxxxx, které mají xxxxxxxx xxxxxxxxx xxxx xxxxxxxx xxxxxxx, xxxx xxxx xxx xxxxxxxxx xxxxxxxx xxxxxxx xxxx xxxxxxx xxx xxxxxxx (8).
Xxxxx x xxxxxxxxx xxxx xxxxxxxxxxxxx xxxxxxx xxxx xxxxxxx xxxx xxxxxxxxx xxxxxxxx xxxxx xxx s xxxxxxxxxxxx xxxxxxxx, xxx xxx xx, a xxxxxxxxxxxxxx xx xxxxxx stanovení xxxxxxxxxxxx a xx xxxxxx exprese xxxxxxxx xxxx selekcí xxxxxxx (9, 10, 11, 12, 13). Xxxxxxxxxxxx xx obvykle zjistí xxxxxxxxxx xxxxxxxxx xxxxxxxxx xxxxxxxxx (xxxxxxx) nebo xxxxxxxxxx xxxxxxxxxxx xxxxxxxxx xxxxx kultur po xxxxxxxx xxxx xxxxxxxx. Xxxxxxxxxx kultury xx xxxxxxx x růstovém xxxxx xx vhodnou xxxx charakteristickou xxx xxxxx xxxxxxx lokus x xxx buněk, xxx xxxxxxx xxxxxxxxx xxxxxxxxx fenotypová exprese xxxxxxxxxxxx mutací. Xxxxxxx xxxxxxx xx stanoví xxx, xx se xxxxxx xxxxx xxxxx xxxxx do média xxxxxxxxxxxx selekční činidlo xxx xxxxxxx mutantních xxxxx a do xxxxx bez xxxxxxxxxx xxxxxxx, aby xxxx xxxxxxxxx xxxxxxxx klonování (xxxxxxxxxxxxxxx). Xx xxxxxx xxxxxxxxx xxxx se xxxxxxxxx xxxxxxx. Xxxxxxx xxxxxxx xx xxxxxxx x xxxxx xxxxxxxxxx xxxxxxx v xxxxxxxxx xxxxx x xxxxx xxxxxxx x xxxxx xxx xxxxxxxxxx činidla.
1.4 XXXXX XXXXXXXX XXXXXX
1.4.1 Xxxxxxxxx
1.4.1.1 Buňky
Pro použití x xxxx xxxxxxx xxxx x dispozici xxxxx typy xxxxx, xxxxxx xxxxxxxx xxxxx X5171X, CHO, XXX-XX52, X79 xxxx XX6. Xxxx buněk v xxxx xxxxxxx by xxxx vykazovat xxxxxxxxx x xxxxxxxxx xxxxxxxxx, xxxxxxx xxxxxxxxx schopnost x xxxxxxxx frekvenci xxxxxxxxxxx xxxxxx. Buňky xx měly xxx xxxxxxxxxxxx, xxx xxxxxx xxxxxxxxxxxxx mykoplasmaty, x x případě xxxxxxxxxxx xx neměly xxx xxxxxxx.
Xxxxxxx by xxxx xxx navrženy tak, xxx měly xxxxxx xxxxxxxxxx citlivost x xxxx. Počet xxxxxxxxx xxxxx, xxxxxx a xxxxxxxxxxx zkoušené xxxxx xx měl xxxx xxxxxxxxxx xxxxxxxxx odrážet (14). Xxxxxxxxx počet xxxxx, které xxxxxxx xxxxxxxx x xxxxx xxxxx xxxxxxx x xxxxxx stadiu xxxxxxx, xx xxx být xxxxxxx xx xxxxxxxx xxxxxxxxxxx xxxxxx. Xxxxxxx xxxxxxxxx xx, xxx xxx xxxxxx xxxxx xxxxx, který xx xxxxxxxxxxxxxx xxxxxxxxxx hodnoty xxxxxxxx xxxxxxxxxxx xxxxxx. Xx však xxxxxxxxxx, xxx xxxx xxxxxxx xxxxxxx 106 xxxxx. Xxxx xx xxx x xxxxxxxxx dostatečné xxxxxxxxx xxxxx o xxxxxxxx buněčném xxxxxxx, xxx xxxx xxxxxxxx xxxxxxxxxxxx xxxxxxxxx xxxxxxx xxxxxxx.
1.4.1.2 Média a xxxxxxxxxx podmínky
Pro xxxxxxxxx xxxxxx xx xxxx xxx použita vhodná xxxxxxxxxx xxxxx x xxxxxxxxx podmínky (xxxxxxxxxx xxxxxx, koncentrace XX2, xxxxxxx x xxxxxxx). Xxxxx by xxxx xxx xxxxxxx xxxxx xxxxxxxxxx xxxxxxx x xxxx xxxxx xxxxxxxxx xxx zkoušce. Xx xxxxxxx xxxxxxxx, xxx xxxxxxxxxx xxxxxxxx xxxx xxxxxxx xxx, xxx xxxx xxxxxxxxx xxxxxxxxx xxxx xxxxx xxxxx xxxxxx xxxxxxx x xxxxxxxxx xxx xxxxxxxxxx, xxx nemutovaných xxxxx xxxxxx xxxxxxx.
1.4.1.3 Příprava xxxxxx
Xxxxx xx xxxx xxx xxxxxxxxx x xxxxxxxxx xxxxxx, xxxxxxxx xx xxxxxxxxxxxx média x xxxxxxxxxx při 37 °X. Xxxx xxxxxxxx x této xxxxxxx může být xxxxxxxx odstranit z xxxxxxx již xxxxxxxx xxxxxxxx xxxxx.
1.4.1.4 Xxxxxxxxxxx xxxxxxxx
Xxxxx xx měly xxx vystaveny xxxxxxxx xxxxx, x xx x vhodným xxxxxxxx xxxxxxxxxxx xxxxxxxx a xxx něho. Xxxxxxxxxx xxxxxxxxxx xxxxxxxx je xxxxxxxxxx xxxxxxxx xxxxxxxxxxxxxxxxxxx xxxxxx (X9) xxxxxxxxxx x xxxxx hlodavců xxxxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxxx, jako xx Xxxxxxx 1254 (15, 16, 17 x 18), xxxx xxxx xxxxxxxxxxxxx x β-xxxxxxxxxxxx (19, 20).
Xxxxxxxxxxxxxxxxxxx frakce xx x xxxxxxxx xxxxxxxxxx xxxxx obvykle xxxxxxxxx x xxxxxxxxxxxxx 1 — 10 % obj. Volba x xxxx metabolického xxxxxxxxxxx xxxxxxx xxxx xxxxxxx xx xxxxx xxxxxxxx xxxxx, která xx xxxxxxxx. X xxxxxxxxx xxxxxxxxx může xxx xxxxxx xxxxxx xxxx xxx xxxxx xxxxxxxxxxx postmitochondriální xxxxxx.
Xxxx xxxxxxxx xxxxxx, xxxxxx xxxxxxxx xxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxx xxxxx xxxxxxxxxxxxx xxxxxxxxxx xxxxxxxxx xxxxxx, xxxxxxxxx možnosti pro xxxxxxxxx aktivaci. Volba xxxxxxxxx xxxxxxxxx linií xx xxxx xxx xxxxxxx xxxxxxxxxx (xxxx. xxxxxxxxxxx xxxxxxxxx cytochromu X450 xxx xxxxxxxxxxxx xxxxxxxx xxxxx).
1.4.1.5 Xxxxxxxx xxxxxxxx xxxxx
Xxxxx zkoušené xxxxx by xxxx xxx xxxx xxxxxxxx xx buňky xxxxxxxxxx xxxx xxxxxxxxxxxx xx xxxxxxxx xxxxxxxxxxxxxx nebo xxxxxxxxxx x xxxxxxxxx xxxxxxx. Kapalné xxxxxxxx xxxxx mohou být xxxxxxx xxxxx k xxxxxxxxxx xxxxxxxx x/xxxx xxxxx být xxxx xxxxxxxx xxxxxxx. Měly xx být xxxxxxx xxxxxxx xxxxxxxxxx zkoušené xxxxxxxx látky, pokud xxxxx x xxxxxxxx xxxxxxxxxxx xxxxxxx skladování.
1.4.2 Xxxxxxxx xxxxxxxx
1.4.2.1 Xxxxxxxxxxxx/xxxxxxxxx
Xxxxxxxxxxxx/xxxxxxxxx xx xxxx být xxxx xxxxxxxxx, xx xxxxxxx xx xxxxxxxxx xxxxxx, x xxxx xx být xxxxxxxxxx x přežitím xxxxx x x xxxxxxxxx X9. Xxxx-xx použita xxxx než xxxxx xxxxxxxxxxxx/xxxxxxxx, mělo by xxx xxxxxx xxxxxxxx xxxxxxxxx xxxxx x xxxxxx xxxxxxxxxxxxx. Xxxxxxxxxx xx xxxxx možno xxxxxxxx zvážit použití xxxxxxx xxxxxxxxxxxx/xxxxxxx. Xxx xxxxxxxx látek xxxxxxxxx xx xxxx by xxxx být xxxxxxx xxxxxxxxx rozpouštědla xxxxxxxxxxxx xxxx. Vodu lze xxxxxxxxx xxxxxxxx xxxxxxxxxxxx xxxx.
1.4.2.2 Xxxxxxxxx xxxxxxxxxxx
Xxxx xxxxxxxx, xxxxx mají xxx xxxxxxxxxx při xxxxxxxxx nejvyšší xxxxxxxxxxx, xxxxx xxxxxxxxxxxx, xxxxxxxxxxx x xxxxxxxxxx xxxxxxx x xxxxx xX xxxx xxxxxxxxxx.
Xxxxxxxxxxxx xx xxxx xxx stanovena x xxxxxxxxxxxx xxxxxxxx x xxx xx x xxxxxxx xxxxxxxxxxx xx xxxxxxx xxxxxxxx xxxxxxxxxx buněčné xxxxxxxxx x růstu, xxxx xxxx xxxxxxxxx účinnost xxxxxxxxx (xxxxxxx) xxxx xxxxxxxxx xxxxxxx xxxx. Xxxx být výhodné xxxxxxxx xxxxxxxxxxxx a xxxxxxxxxxx x xxxxxxxxxx xxxxxxxxxxx.
Xxxx xx xxx xxxxxxx alespoň xxxxx xxxxxxxxxxxxxx koncentrace. X xxxxxxx xxxxxxxx xx xxxx xxxx xxxxxxxxxxx xxxxxxxx xxxxxxx xxxx xxxxxxxxx x xxxxxxxxx xxxxxxxxx, případně xxxxxx xxxxxxxxx, xxx xxxx xxxxxxx xxxxxxxx, xx xx xx xxxxxxxxxxx xxxx xxxxx faktorem 2 až Ö10. Xx-xx xxxxxxxxx xxxxxxxxxxx xxxxxxxx xx xxxxxxxxxxxx, xxxx xx xxx xxxxxxxxx přibližně 10 — 20 % (xxx xxxxxxx 10 %) xxxxxxx (xxxxxxxxx xxxxxxxx xxxxxxxxx) xxxx xxxxxxxxx celkový xxxx. X případě xxxxxxxxx xxxxxxxxxxxxxxx xxxxx xx xxxx xxx maximální xxxxxxxx xxxxxxxxxxx 5 μx/xx, 5 mg/ml xxxx 0,01 X, xxxxx toho, která x xxxx xx xxxxxxxx.
Xxxxxxxxx nerozpustné xxxxx xx měly xxx xxxxxxxx xx k xxxx xxxxxxxxxxxx za xxxxxxxxxxxx xxxxxxxx, xxxx xx za xxxx xxx. Xxxx by xxx xxxxxxxxx případná xxxxxxxxxxxxx x konečném xxxxx, xx xxxxxxx xxxx xxxxx xxxxxxxxxx. Xxxx být výhodné xxxxxxxx xxxxxxxxxxx xx xxxxxxx x xx xxxxx xxxxxxxx, neboť xxxxxxxxxxx se může x průběhu expozice x testovacím xxxxxxx xxxxx x xxxxxxxx xxxxxxxxxxx xxxxx, S9 xxxx, xxx. Xxxxxxxxxxxxx xxx zjistit xxxxxxxx. Xxxxxxxxx xx xxxxxx xxxxx xxx xxxxxxxxxxx.
1.4.2.3 Xxxxxxxx
Xxxxxxxx xxxxxxx experimentu xx xxxx xxx xxxxxxxxx a xxxxxxxxx (xxxxxxxxxxxx xxxx xxxxxxxxx) xxxxxxxx jak x xxxxxxxxxxxx xxxxxxxx, tak xxx xx. Xxx xxxxxxx metabolické aktivace xx xxxx být xxxxxxxxx xxxxxxxxx xxxxxxxx xxxxx, xxxxx x xxxxxxxxx odpovědi xxxxxxxx xxxxxxxx.
Xxxxxxxxx xxxxxxxxx xxxxxxxx xxxxx xxx xxxx xxxxx:
|
Xxxx xxxxxxxxxxx xxxxxxxx |
Xxxxx |
Xxxxx |
Xxxxx XXX |
Xxxxx xxxxx Xxxxxx |
|
Xxx xxxxxx xxxxxxxxxxx aktivace |
HPRT |
ethyl-methansulfonát |
62–50–0 |
200–536–7 |
|
1-ethyl-1-nitrosomočovina |
759–73–9 |
212–072–2 |
||
|
TK (xxxx a xxxxx xxxxxxx) |
xxxxxx-xxxxxxxxxxxxxx |
66–27–3 |
200–625–0 |
|
|
XXXX |
xxxxx-xxxxxxxxxxxxxx |
62–50–0 |
200–536–7 |
|
|
1-xxxxx-1-xxxxxxxxxxxxxxx |
759–73–9 |
212–072–2 |
||
|
X vnější xxxxxxxxxxxx xxxxxxxx |
XXXX |
3-xxxxxxxxxxxxxxxxx |
56–49–5 |
200–276–4 |
|
X-xxxxxxxxxxxxxxxxxxx |
62–75–9 |
200–549–8 |
||
|
7,12-xxxxxxxxxxxxxxxxxxxxxx |
57–97–6 |
200–359–5 |
||
|
XX (xxxx x xxxxx kolonie) |
cyklofosfamid |
50–18–0 |
200–015–4 |
|
|
cyklofosfamid xxxxxxxxxx |
6055–19–2 |
|||
|
xxxxx[x]xxxxx |
50–32–8 |
200–028–5 |
||
|
3-xxxxxxxxxxxxxxxxx |
56–49–5 |
200–276–5 |
||
|
XXXX |
X-xxxxxxxxxxxxxxxxxxx (xxx xxxxxx úrovně X9) |
62–75–9 |
200–549–8 |
|
|
xxxxx[x]xxxxx |
50–32–8 |
200–028–5 |
Xxxxx být xxxxxxx xxxx xxxx referenční xxxxx pro pozitivní xxxxxxxx, např. xx-xx xxxxxxxxx databázi dosavadních xxxxx o 5-xxxx-2′-xxxxxxxxxxxx (XXX 59–14–3, XXXXXX 200–415–9), může být xxxx xxxxxxxxxx látka xxxxxx xxxxxxx. Xxx xxxxxxxxx xxxxxxxx xx xxxx xxx xxxxx x úvahu použití xxxxxxxxxx xxxxx pokud xxxxx xx xxxxxx xxxxxxxx třídy.
Měly xx xxx xxxxxxx negativní xxxxxxxx tvořené xxxxxx xxxxxxxxxxx xxxxxxx xxxxxxxxxxxx xxxx vehikulum x xxxxxxxxxx xxxxx stejným xxxxxxxx xxxx xxxxxxxxxx xxxxxxx. Xxxxx toho xx měly být xxxxxxxxxxxx xxxxxxxx xxxxxxx xxxx xxxxx, xxxxxxxxxx-xx xxxxx xxxxxxxxx údaje xxxxxxxxxxx, xx zvolené xxxxxxxxxxxx nevyvolává žádné xxxxxxx xxxx mutagenní xxxxxx.
1.4.3 Xxxxxx
1.4.3.1 Xxxxxxxx xxxxxxxx xxxxx
Xxxxxxxxxxxxx xxxxx xx xxxx být xxxxxxxxx xxxxxxxx látce xxx za xxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxx xxxxxxx, xxx xxx něho. Xxxxxxxx by xxxx xxxxx vhodnou xxxx (xxxxxxx xx účinná xxxx 3 xx 6 hodin). Xxxxxxxxx xxxx může xxx xxxxxxxxxxx na xxxxx xxxx xxxx xxxxxxxxx xxxxx.
Xxx xxxxxx xxxxxxxx xxxxxxxxxxx mohou být xxxxxxx xxxxxxxxxx kultury xxxx jedna exponovaná xxxxxxx. Je-li xxxxxxx xxxxx xxxxxxx, xxx xx xxx xxxxx xxxxxxxxxxx xxxxxx xxx, xxx xxx zajištěn xxxxxxxxxxxx počet xxxxxx xxx xxxxxxx (např. xxxxxxx xxx analyzovatelných xxxxxxxxxxx). Xxxx xx xxx xxxxxxx xxxxxxxxxx xxxxxxxxx xxxxxxxxx kultury (xxxxxxxx xxxxxxxxxxxx).
Xxxxxx xxxx xxxxxx xxxxx xx xxxx být zkoušeny xxxxxxxx xxxxxxxx, xxxx. x těsně xxxxxxxxxx xxxxxxxxxxxx xxxxxxxx (21, 22).
1.4.3.2 Xxxxxxxxx xxxxxxx, xxxxxxxxxxxxxxxx x četnosti xxxxxx
Xx xxxxx xxxxxxxxx xxxx se xxxxx xxxxxxx x kultivují xx xxxxxx xxxxxxxxx xxxxxxx x za xxxxxx xxxxxxxx xxxxxxx xxxxxxxx xxxxxxx. Xx xxxxxxxxxx xxxxxxxxxxxx prostřednictvím xxxxxxxxx relativní xxxxxxxxx xxxxxxxxx (přežití) nebo xxxxxxxxxxx xxxxxxxxx růstu xxxxxx xx započne xxxxxxx xx xxxxxxxxx xxxx.
Xxxxx xxxxx xx xxxxxxxxxx xxxxxxxxx xxxxxx xxxxxx, aby umožnil xxxxxxxxx xxxxxxxxx xxxxxxxxxxx xxxxxxx nově indukovaných xxxxxxx (XXXX x XXXX vyžadují xxxxxxx 6 xx 8 xxx, XX alespoň xxx xxx). Xxxxx xxxx xxxxxxxxxxx x xxxxx se xxxxxxxxx xxxxxxxx (xxxxxxxxxx činidly) x xxx xxxx (xxx nich) xx xxxxxx xxxxxxxxx xxxxx xxxxxxx a xxxxxxxxx xxxxxxxxx. Xx xxxxxxxxxx xxxxxxxxxxxxxxxx (použité xxx xxxxxxx xxxxxxxx mutantů) xx xxxxxxx xx xxxxx doby xxxxxxx xxxxxxxxx na misku xxx selekčního xxxxxxx.
Xx-xx xxxxxxxx látka xxxxxxxxx xx zkoušce X5178X XX+/-, xxxx by xxx xxxxxxxxx xxxxxxx xx xxxxx xx xxxxxxxxxx kultur (x xxxxxxxx xxxxxxxxx xxxxxxxxxxx) x xx negativních x xxxxxxxxxxx kontrolách xxxxxxxxx xxxxxxx podle xxxxxxxxx xxxxxxx. Je-li xxxxxxxx látka xx xxxxxxx X5178X TK+/- xxxxxxxxx, mělo by xxx rozdělení xxxxxxx xxxxx xxxxxxxxx xxxxxxx xxxxxxxxx xx xxxxxxxxxxx x xxxxxxxxxxx kontrolách. Xxx xxxxxxxx xx xxxxxxx TK6 XX+/- xxxx xxx také xxxxxxxxx xxxxxxxxx kultury xxxxx velikosti kolonií.
2. XXXXX
2.1 ZPRACOVÁNÍ VÝSLEDKŮ
Údaje xx xxxx xxxxxxxxx xxxxxxxxx xxxxxxxxxxxx x xxxxxxxxxxxxxxxx, počtu xxxxxxx x xxxxxxxx xxxxxxx xxx xxxxxxxxxx x xxxxxxxxx xxxxxxx. X xxxxxxx xxxxxxxxx odpovědi xx zkoušku X5178X XX+/- xx xxxxxxx xxxxxxxxx xxxxxxx u xxxxx xxxxxxxxxxx zkoušené xxxxx (xxxxxxxx xxxxxxxxx xxxxxxxxxxx) x x xxxxxxxxx a xxxxxxxxx xxxxxxxx xx použití xxxxxxxx xxxx xxxxxxx — xxxxx xxxxxxx. Xxxxxxxxxxx a xxxxxxxxxxxxx xxxxxx xxx mutantů xxxxxxxxx xxxxx xxxxxxx, xxx mutantů tvořících xxxx xxxxxxx xxxx xxxxxxxx xxxxxxxx (23, 24). Xx xxxxxxx XX+/- xxxx xxxxxxx xxxxxxxxxxx xx použití xxxxxxxx xxxxxxx x xxxxxxxxx xxxxxx (xxxxx) x kolonie x xxxxxxx xxxxxx (xxxx) (25). X xxxxxxxxxx xxxxx, xxxxx xxxxxxx xxxxxxxxxxxxxx xxxxxxxxx xxxxxxxxx, xx xxxxxxxxxxx xxxx xxxxxxxx, x tvoří xxxx malé xxxxxxx. Xxxxxxxxx xx xxxxxxx xxxxxx xx ztrát xxxxxx xxxx xx xx xxxxxxxxxxxx viditelné xxxxxxxxxxxx aberace. Indukce xxxxxxx tvořících xxxx xxxxxxx xx spojuje x xxxxxxxxxx xxxxxxx, xxxxx xxxxxxxx xxxxx xxxxxxxxxxxx xxxxxxx (26). Xxxx xxxxxxx xxxxxxxxx xxxxx xxxxxxx xxxxxx xxxxxxxx xxxxxx jako xxxxxxxx buňky x xxxxx xxxxx xxxxxxx.
Xxxx xx být udáno xxxxxxx (relativní účinnost xxxxxxxxx) nebo xxxxxxxxx xxxxxxx xxxx. Xxxxxxx xxxxxxx by xxxx xxx xxxxxxxxx xxxx xxxxx xxxxxxx k xxxxx xxxxxxxxxx buněk.
Měly xx xxx uvedeny xxxxx xxx xxxxxxxxxx xxxxxxx. Xxxx xx xxxx být xxxxxxx xxxxx xxxxxxx ve xxxxx xxxxxxx.
Xxxxxxx xxxxx xxxxxxxxx odpovědi se xxxxxxxxxx. Xxxxxxxxxx xxxxxxxx xx xxxx xxx xxxxxxxxx xxxxxx zkoušením, xxxxxxx s xxxxxxx xxxxxxxxxxxxxxxx xxxxxxxx. Xxxxxxxxx xxxxxxxx musí xxx xxxxxxxxx xxxxxx od xxxxxxx. Xxx, xxx xxxx xxxxxxxxx xxxxxxxxxxx xxxxxxxx považováno xx xxxxx, xx třeba xxxxx xxxxxxxxxx. Xxxxx xxxxxxxxx xxxxxx s xxxxx xxxxxxxx xxxxxx xxxxxxxxxxxx xxxxxxxx by xxxx xxx xxxxxxx x následných experimentech xxx xxx xxxxxxxxxx xxxxxxxx, xxx pro xxxxxxxxx xxxxxxxx. K xxxxxxxxxx studie, xxxxx xx xxxxx xxx xxxxxxx, patří rozmezí xxxxxxxxxxx x podmínky xxxxxxxxxxx xxxxxxxx.
2.2 XXXXXXXXX X XXXXXXXXXXXX XXXXXXXX
Xxx xxxxxxxxx pozitivního xxxxxxxx xxxxxxxx xxxxxxx xxxxxxxx, xxxx. xxxxxx xxxxxxxx xxxxxxx v xxxxxxxxxx xx koncentraci, xxxx xxxxxxxxxxxxxxxx xxxxxx této xxxxxxxx. Xxxxxxxx xx xxxx být xxxxxxx xxxxxxxxxx relevance xxxxxxxx. Xxx xxxxxxxxx výsledků xxxxxxx mohou xxx xxxxxxx xxxx xxxxxxx xxxxxxxxxx xxxxxxxxxxx metody. Xxxxxxxxxxx významnost xx xxxxxx xxx xxxxxxx xxxxxxxxx xxxxxxxx xxx xxxxxxxxx xxxxxxx.
Xxxxxxxx xxxxx, xxxxx výsledky xxxxxxxxx xxxx xxxxxxx xxxxxxxx, xx x tomto xxxxxxx xxxxxxxx za xxxxxxxxxxx.
Xxxxxx xxxxxxx experimentů xxxxxxxx xxxxx xxxxxxxxx xxxx xxxxxxxxx výsledky, x xxxxxxxxxxx xxxxxxxxx xxxxxxxx xxxxxx údajů xxxxxxxx xxxxxxx xxxxx x xxxxxxxx zkoušené xxxxx. Xxxxxxxx xxxxx xxxxxx dvojznačné xxxx xxxxxx bez ohledu xx xx, xxxxxxxx xx xxxxxxxxxx xxxxxxxx.
Xxxxxxxxx xxxxxxxx xxxxxxx xx xxxxxx mutace v xxxxxxx savců xx xxxxx xxxxxxxxx, xx xxxxxxxx látka indukuje x použitých xxxxxxxxxxxxx xxxxxxx savců genové xxxxxx. Reprodukovatelná pozitivní xxxxxxxxx xxxxxxxx xx xxxxxxxxxxx je xxxxx xxxxxxxx. Xxxxxxxxx xxxxxxxx xxxxxxxxx, že zkoušená xxxxx za podmínek xxxxxxx neindukuje v xxxxxxxxx xxxxxxxxxxxxx xxxxxxx xxxxx xxxxxx xxxxxx.
3. XXXXXX
XXXXXXXX O XXXXXXX
Xxxxxxxx x xxxxxxx musí xxxxxxxxx tyto xxxxxxxxx:
Xxxxxxxxxxxx/xxxxxxxxx:
- xxxxxxxxxx xxxxx rozpouštědla/vehikula,
- xxxxxxxxxxx x xxxxxxx xxxxxxxx xxxxx x xxxxxxxxxxxx/xxxxxxxx, xx-xx známa.
Buňky:
- xxx x xxxxx xxxxx,
- xxxxx xxxxxxxxx xxxxxx,
- případně počet xxxxxx,
- xxxxxxxx xxxxxx xxxxxxxxx buněčné kultury,
- xxxxxxxxxxxx xxxxxxxxxxx.
Xxxxxxxx podmínky:
- xxxxxxxxxx xxxxxx koncentrací x xxxxx xxxxxx, xxxxxx např. xxxxx x cytotoxicitě x xxxxxx xxxxxxxxxxxx, jsou-li x xxxxxxxxx,
- xxxxxxx xxxxx, xxxxxxxx koncentrace XX2,
- koncentrace zkoušené xxxxx,
- objem vehikula x přidané zkoušené xxxxx,
- xxxxxxxxx xxxxxxx,
- xxxxxxxxx xxxx,
- délka xxxxxxxx,
- xxxxxxxx xxxxxxx xxxxx během xxxxxxxx,
- xxx x složení xxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxx xxxxxxx, včetně xxxxxxxx xxxxxxxxxxxxx,
- xxxxxxxxx x xxxxxxxxx xxxxxxxx,
- xxxxx xxxx exprese (xxxxxxxx xxxxxx xxxxx xxxxxxxxxx xxxxx, subkultur a xxxxxx xxxxx),
- selekční xxxxxxx,
- kritéria klasifikace xxxxxxx xx pozitivní, xxxxxxxxx nebo xxxxxxxxxxx,
- xxxxxx xxxxxxx x xxxxxxxx xxxxxxxxxxxxxxx x xxxxxxxxxx xxxxx,
- xxxxxxxx xxxxxxx xxxxx xxxxxxxxx x typu (případně xxxxxx kriterií pro "xxxx" x "xxxxx" xxxxxxx).
Xxxxxxxx:
- xxxxxx xxxxxxxx,
- xxxxxx srážení,
- údaje x xX x xxxxxxxxxx xxxxx xxxxxxxx xxxxxxxx látce, xxxxx xxxx stanoveny,
- velikost xxxxxxx, byla-li vyšetřována, xxxxxxx xxx xxxxxxxxx x pozitivní xxxxxxxx,
- xxxxxxxxx xxxxxxxxxxx laboratoře xxxxxxxxx xxxxxxx tvořící xxxx xxxxxxx xxxxxxxx X5178X TK+/-,
- podle xxxxxxxx xxxxxxxxx xxxxxxxx xx xxxxx,
- xxxxxxxx xxxxxxxxxxx xxxxxxx,
- xxxxx x souběžné xxxxxxxxx (xxxxxxxxxxxx/xxxxxxxxx) a xxxxxxxxx xxxxxxxx,
- xxxxxxxxx xxxxx x negativní (xxxxxxxxxxxx/xxxxxxxxx) x pozitivní xxxxxxxx x rozmezími, xxxxxxxxx xxxxxxxxx x směrodatnými xxxxxxxxxx,
- četnost xxxxxxx.
Xxxxxx xxxxxxxx.
Xxxxxx.
4. XXXXXXXXXX
1) Xxxxx, X. M., XxXxxxxx, X. M., XxXxxxxx, X. J., Tindal, X. X. (xxx.) (1987), Xxxxxxx Xxxxxx 28; Xxxxxxxxx Cell Xxxxxxxxxxx, Xxxx Spring Xxxxxx Laboratory, Xxx Xxxx.
2) Chu, X. X. X., Malling X. X. (1968), Xxxxxxxxx Xxxx Xxxxxxxx. XX. Xxxxxxxx Xxxxxxxxx xx Xxxxxxxx Locus Xxxxxxxxx xx Xxxxxxx Xxxxxxx Xxxxx Xx xxxxx, Xxxx. Natl. Xxxx. Xxx. U. X. X, 61, 1306-1312.
3) Xxxxx, X. X., Xxxxxx, X. X. (1982), Xxxxxxxx Xxxxx xx the Xxxxxxxxx Kinase Xxxxx xx Xxxxxxx Human Xxxxxxxxxxxx, Xxxxxxxx Xxx. 94, 467-485.
4) Xxxxx, X. X., Harington-Brock, X., Xxxxx, X. X., Dearfield, X. X. (1989), Differential Xxxxxx Xxxxxxxxxxxx xx xxx Xxxxx Xxxxxxxx XX xxx XXX XXXXX Loci, Xxxxxxxxxxx, 4, 394-403.
5) Xxxxx, X. X., Xxxxxxxxxx, Xx. X. F., (1989), Comparison xx xxx AS52/XPRT xxx xxx XXX/XXXX Assays: Xxxxxxxxxx of Six Xxxx Candidates, Mutatation Xxx. 223, 121-128.
6) Xxxxx, X. X., Xxxxxxxxxx, G., Xxxxx, X. X., Xxxxx, X., Nishi, X., Xxxxxxxxxx, Jr. X. X., Theiss, X., Xxxxxxxx, X. (1994), Xxxxxxxxx Xxxx Xxxx Xxxxxxxx Xxxxxx Xxxxxxx Xxxxx Report. Xxxxxx xx the International Xxxxxxxx xx Standardisation xx Xxxxxxxxxxxx Xxxx Xxxxxxxxxx. Xxxxxxxx Xxx. 312, 235-239.
7) Scott, X., Xxxxxxxx, X. X., Xxxxxxxx, R. X., Ishidate, X., Xxxxxxx, X., Xxxxx, X., Xxxx, X. X. (1991), Xxxxxxxxxxxx Xxxxx Extreme Culture Xxxxxxxxxx. A xxxxxx xxxx XXXXXX Xxxx Xxxxx 9, Mutation Xxx. 257, 147-204.
8) Xxxxx, X., XxXxxx, X., Xxxxxxx, J. X. S., Xxxxx, X., Xxxxxxxxx, X. X. (1983), Specific Xxxx Mutations xx X5178X Xxxxx xx Xxxxxxx. A Xxxxxx xx the X. X. Environmental Protection Xxxxxx Xxxx-Xxx Xxxxxxx, Xxxxxxxxxx Xxx., 115, 225-251.
9) Xx, X. X., Xxxxx, R. X., Xxxxxxx, R. X., Xxxxxx, X. X. (1988), X Xxxxxx and Analysis xx xxx Chinese Xxxxxxx Xxxxx/Xxxxxxxxxxxx Guanine Xxxxxxxxxxxxxx Transferase System xx Xxxxxxxxx xxx Xxxxxxxxxxxx of Xxxxxxxx Xxxxxx: X Xxxxxx xx Xxxxx XXX xx the X. X. Xxxxxxxxxxxxx Xxxxxxxxxxx Xxxxxx Xxxx-Xxx Program, Xxxxxxxxxx Res., 196, 17-36.
10) Xx, X. X., Xxxxxx, X. X., Xxxx, W. X., Hsie, X. X., Gupta, R. X., Loveday, K. X., X'Νxxxx, J. X., Xxxxxx, J. X., Stankowski, X. X. Xx., Xxxx, X. X. (1987), X Guide xxx xxx Xxxxxxxxxxx xx xxx Chinese Xxxxxxx Xxxxx Xxxx/Xxxxxxxxxxxx-Xxxxxxx Xxxxxxxxxxxxxx Xxxxxxxxxxx Gene Mutation Xxxxx, Mutatation Xxx., 189, 135-141.
11) Liber, X. X., Xxxxxxx, X. X., Little, X. B. (1989), X Xxxxxxxxxx of Xxxxxxxx Induction xx xxx XX xxx XXXX Xxxx xx Xxxxx Xxxxxxxxxxxxxx Xxxxx: Xxxxxxxxxxxx Xxxxxxxxxxx xxx Xxx xx an Xxxxxxxxxx Class of Xxxxxxxxx xx xxx Xxxxxxxxx XX Xxxxx, Xxxxxxxxxx Res., 216, 9-17.
12) Xxxxxxxxxx, X. X. Xx., Xxxxxx, X. X., Xxxx, X. X. (1986), Xxxxxxxxxxxx xxx Molecular Xxxxxxxx of Xxxxx Xxxxxxxxxxxxxxxxx xxx XXX 191-Xxxxxxx Xxxxxxxxx Xxxxxxxx xx Xxxxx Methanesulphonate xxx XXX 191 Xxxxxxx Mutation in XX52 Xxxxx, Xxxxxxxxxx Xxx., 160, 133-147.
13) Xxxxxx, N. X., Xxxxxx, X. G., Xxxxx, D. (1984), Xxxxxxxxx xxx xxx X5178X/XX+/--XX+/- Xxxxx Xxxxxxxx Xxxx Mutagenicity Assay, xx: Xxxxxx, X. X. et xx (xxx.) Handbook xx Xxxxxxxxxxxx Xxxx Procedures, Xxxxxxxx Xxxxxxx Publishers, Xxx Xxxx, 239-268.
14) Xxxxxx, X. X., Xxxxx, X. X., Xxxxxx, X. M., Xxxxx, M. H. X., Xxxx, J., XxXxxxxx, D. B., Xxxxxxx X. X. (1989), Xxxxxxxxx Cell Xxxx Xxxxxxxx Xxxxxx Xxxxx xxxx Xxxxxx Xxxxxxxxx, xx: Statistical Xxxxxxxxxx xx Mutagenicity Xxxx Xxxx, Xxxxxxxx, X. X., xx., Xxxxxxxxx Xxxxxxxxxx Xxxxx, 66-101.
15) Xxxxxxxxxxxx, X., Xxxxxxx, X., Corti, X., Xxxxxx, X., Xxxxxxxx, X., Xxxxxxxxxx, X. (1977), Induction xx 6-Xxxxxxxxxxx-Xxxxxxxxx Mutants xx V79 Xxxxxxx Xxxxxxx Cells xx Xxxxx-Xxxxx Microsome-Activated Dimethylnitrosamine, Xxxxxxxxxx Xxx. 46, 365-373.
16) Ames, B. X., XxXxxx, X., Xxxxxxxx, X. (1975), Xxxxxxx for Xxxxxxxxx Xxxxxxxxxxx xxx Xxxxxxxx xxxx the Xxxxxxxxxx/Xxxxxxxxx-Xxxxxxxxx Xxxxxxxxxxxx Test, Xxxxxxxxxx Xxx. 31, 347-364.
17) Xxxxx, X., Xxxxxxx, X. X., Spector, X. X. X., Xxxxxx X. G., Xxxxx X. M. X. (1979), Xxxxxxxxxx xxx Xxxxxxxxxxxxxxxx xx xxx L5178Y/TK+/--Mouse Lymphoma Xxxxxxx Assay System, Xxxxx. Res. 59, 61-108.
18) Maron, D. X., Xxxx, X. X. (1983), Revised Xxxxxxx for xxx Xxxxxxxxxx Xxxxxxxxxxxx Test, Xxxxxxxxxx Xxx. 113, 173-215.
19) Xxxxxxx, B. X., Xxxxxx, R. X., Xxxxxxx, X. X., Xxxxxxxxx, X. X., Xxxxxx, X. X., Xxxxxx, J. X., Xxxx, X. X. (1992), Alternatives xx Xxxxxxx 1254-Xxxxxxx X9 in: Xx xxxxx Genotoxicity Xxxxxx, Xxxxxxxxxxx 7, 175-177.
20) Xxxxxxxxxx, T., Xxxxxxxx, X., Hara, X., Xxxxxxxx, X. (1976), X Safe Xxxxxxxxxx xxx Polycholrinated Xxxxxxxxx x. s. xx Xxxxxxx of Metabolic Xxxxxxxxxx Xxxxxxx, X: Xx xxxxx Xxxxxxxxx Xxxxxxxxxx in Mutagenesis Xxxxxxx, xx Serres, X. J., Xxxxx, X. X., Xxxx, X. X., Philpot, X. M. (eds), Xxxxxxxx, North-Holland, 85-88.
21) Xxxxx, X. X., Xxxxxx, X. C., XxXxxxx, X. X. (1982), XXX/XXXXX Xxxxxxxx Xxxxx: Xxxxxxxxxx xx Xxxxx and Xxxxxxxx Xxxxxxx, in: Xxxx, X. X., Costa, X. X., Xxxxxxx, X. X. (xxx), Xxxxxxxxx Xxxxxxx xx Xxxxxxxx Agents, New Xxxx, Xxxxxx, 91-103.
22) Xxxxxx, P. X., Xxxxxx, X. X., Xx, X. X., Xxxxxx, X. X. (1983), Xxxxxxxxxx xx xx Xxxxxxxx Xxxxxx Xxxxx Xxxxx Grown xx Xxxxxxxx Xxxx xxx Xxxxxxxxx Xxxxxx Xxxxxxxx Mutagens xx xxx CHO/HGPRT Xxxxxxxx Xxxxx, Xxxxxxx. Xxxxxxxxxxx, 5, 795-801.
23) Applegate, X. X., Xxxxx, X. X., Broder, X. X., Xxxxxxx, X., Xxxxxx, X. X. (1990), Molecular Xxxxxxxxxx xx Xxxxxxxxx xx the Xxxxxxxxxxxx Xxxxxxxxx Xxxxxx Xxxxx xx Xxxxx Xxxxxxxx Xxxxx, Xxxx. Natl. Xxxx. Xxx. X. X. A, 87, 51-55.
24) Moore, M. X., Xxxxx, X., Xxxxxx, J. C., Xxxxxx, B. E., Xxxxxx, X. X., Xxxxxx, N. T., Xxxxxx, J. (1985), Xxxxxxxx xx Xxxxxxxxxxxxxxxxxx, Xxxxxxxxx (XXX+) Xxxxxxx xx L5178Y/TK+/--Mouse Xxxxxxxx Xxxxx, Mutatation Xxx. 151, 161-174.
25) Xxxxxxx, X. X., Xxxxx, X. X., Little, X. B. (1990), Xxxxxxxxx Genetic Analysis xx Xxxxxxxxx Mutations xx x Heterozygous Xxxxxxxxx Xxxxx xx Xxxxx Cells, Xxxxxxxxxx Xxx. 229, 89-102.
26) Xxxxx, X. M., Xxxxx, C. X. (1990), Comparison of Xxxxxxxxxx Xxxxxxxxxx Xxxxxxxxx xxx Small Xxxxxx XX-Xxxxxxxxx Xxxxxx Xxxxxxxxx xx X5178X/XX+/- 3.7.2X Xxxxx Xxxxxxxx Xxxxx, Xxxxxxxxxxx, 5, 609-614."
PŘÍLOHA 4X
"X.23 XXXXXXX XX XXXXXXXXXXXX ABERACE XX SPERMATOGONIÍCH SAVCŮ
1. XXXXXX
Xxxx xxxxxx xx xxxxxxxx xxxxxx XXXX XX 483 — Xxxxxxx xx chromozomové xxxxxxx xx xxxxxxxxxxxxxxx xxxxx (1997).
1.1 XXXX
Xxxxxx xxxxxxx xx chromozomové xxxxxxx ve xxxxxxxxxxxxxxx xxxxx xx xxxx xx xxxxxxxxxxxxx xxxxxx xxxxx, xxxxx způsobují xxxxxxxxxx xxxxxxxxxxxx aberace xx xxxxxxxxxxxxxxx xxxxx (1, 2, 3, 4, 5). Rozlišují xx dva xxxx xxxxxxxxxxxx aberací: chromozomové x chromatidové. X xxxxxxx xxxxxxxxxx xxxxxxxx xxxx indukované xxxxxxx xxxxxxxxxxxxxx xxxx, xxxxx xxxxxxxxxxxx aberace se xxxxxx xxxxxxxxx. Tato xxxxxx xxxx xxxxxx xx stanovení xxxxxxxxxxx xxxxxxx a xxxx x xxxxxx účelu xxxxxxx xxxxxxxxx. Chromozomové xxxxxx x xxxxxxx xxxx xxxx xxxxxxxx xxxxx xxxxxxxxx xxxxxxxxxxx xxxxxx x xxxxxxx.
Xxxxx xxxxxxxx se xxxxxxxxx xxxxxxxxxxxx xxxxx ve xxxxxxxxxxxxxxx x předpokládá xx xxxx, xx xxxx zkouška xxxxxxxx xxxxxxxxx xxxxxxx dědičných xxxxxx v xxxxxxxxxxxx xxxxxxx.
X této xxxxxxx xxxx xxxxxxx xxxxxxxxx xxxxxxxx. Xxxxx xxxxxxxxxxxxxx xxxxxxxx in xxxx xx detekují xxxxxxxxxxxx xxxxxxx při mitose xxxxxxxxxxxxx. Xxxx xxxxxx xxxxx xxxxxx předmětem xxxx zkoušky.
Pro detekci xxxxxxx xxxxxxxxxxxxxx typu xx spermatogoniích by xxxx být — xxxxx xxx xxxxx xx ztrátě xxxx — vyšetřeno xxxxx xxxxxxxxx buněčné dělení, xxxxx xxxxxxxxx xx xxxxxxxx. Další xxxxxxxxx x exponovaných xxxxxxxxxxxxxxxxxx xxxxxxxxx buněk xxx xxxxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxx xxxxxxx chromozomového xxxx v diakinese-metafázi X, xxx xx xxxxxxxxxx xxxxx xxxxxxx xxxxxxxxxxxx.
Xxxx xxxxxxx xx xxxx xx xxxxxxxx xxx xxxxxxxxx, xxx xxxx xxxxxxxx xxxxxxxxxxx xxxxx xxxxxxx také x xxxxxxxxxxxx xxxxxxx. Xxxxx xx tato xxxxxxx xx xxxxxxxxxxxxxxx xxxxxxxx xxx xxxxxxxxx xxxxxxxxx mutagenese, xxxxx xxxxxxxx xxxxxxxxx faktory xxxxxxxxxxx in xxxx, xxxxxxxxxxxxxxx x procesy xxxxxxxx XXX.
Xx xxxxxxxxx xx xxxxxxxx řada xxxxxxxx spermatogonií x xxxxxx citlivostí xx xxxxxxxx xxxxxxxx látce. Xxxxxxxxxx aberace xxxx xxxxxxxxxxx souhrnnou odpověď xxxxxxxxxx xxxxxxxx xxxxxxxxxxxxx x převládajícími xxxxxxxxxxxxxxx xxxxxxxxxxxxxxx. X xxxxxxxxxx xx xxx xxxxxx xx varlatech, xxxxx xxxx xxxxxx xxx xxxxx xxxxxxxx xxxxxxxxxxxxx xxxxxxxxxx celkovému xxxxxxxx xxxxx v xxxxxxxx xxxxxxxxx x xxxxxxxxxxxx xxxxxxx Sertoliho buněk x xxxxxxx xxxx xxxxxxx xxxxxx x xxxxxxx.
Xxxxxxxx xxxxxxxx xxxxx x xxx, že xx zkoušená látka xxxx reaktivní xxxxxxxxxx xxxxxxxxxx xx xxxxxx xxxxx, není vhodné xxxx zkoušku xxxxxx.
Xxx xxxx xxxxxx xxxx, xxxx X.
1.2 XXXXXXXX
Xxxxxxxxxxxx xxxxxxx : xxxxxxxxxx xxxxxxxxx xxxxxxxxxx x xxxxxx zlomu xxxxxxxxxxxx xxxxxxxxx nebo zlomu x opětného spojení xxxxxxxxx.
Xxxxxxxxxxxx xxxxxxx : xxxxxxxxxx xxxxxxxxx chromozomu x xxxxxx zlomu xxxx zlomu x xxxxxxx xxxx xxxxxxxxx x xxxxxx místě.
Gap : achromatická xxxx xxxxx xxx šířka xxxxx chromatidy x x xxxxxxxxx xxxxxxxxx xxxxxxxxx.
Xxxxxxxxx xxxxxxx : xxxxxxxx počtu xxxxxxxxxx xx normální xxxxxxx x xxxxxxxxx xxxxx.
Xxxxxxxxxxx : násobek xxxxxxxxxxx xxxxx chromozomových sad (x), xxxx xxx xxxxxxxxx (xx. 3 x, 4 n xxx.).
Xxxxxxxxxx xxxxxxx : xxxxxxxxxxxxx xxxxxxxxxxxxx změny xxxxxxxxx chromozomů při xxxxxxxx xxxxxx ve xxxxxx xxxxxxxx xxx xxxxxxxxxxx, jeví se xxxx delece a xxxxxxxxx, xxxxxxxxxxxxxxxxxx xxxx xxxxxxxxxxxxxxxxxx xxxxx.
1.3 XXXXXXXX XXXXXXXX XXXXXX
Xxxxxxx xxxx xxxxxxx způsobem exponována xxxxxxxx xxxxx x xx vhodné xxxx xx xxxxxxxx xxxxxxxx. Xxxx xxxxxxxxx se xxxxxxxx xxxx látka xxxxxxxxxxx metafázi (např. xxxxxxxxx xxxx Xxxxxxxx®). X xxxxxxxxxxxx xxxxx xx xxxx připraví xxxxxxxxx xxxxxxxxxx, xxxxxx xx a analyzují xx xxxxxxxxxxxx xxxxxxx xxxxxxxxxxxxxx xxxxx.
1.4 XXXXX XXXXXXXX XXXXXX
1.4.1 Přípravky
1.4.1.1 Xxxxx xxxxx zvířete
Běžně xxxx používáni samci xxxxxx xxxxxxxx x xxxx; xxx xxxx xxxxxx xxxxx jakéhokoli xxxxxx xxxxxxxx xxxxx xxxxx. Měly by xxx xxxxxxx xxxxx xxxxxxx laboratorní kmeny xxxxxxx zdravých xxxxxxxx xxxxxxxxx zvířat. X xxxxxxxx xxxxxxxx xxxxxx xx xxxx být xxxxxxxx v hmotnosti xxxxxx xxxxxxxxx a xxxxxx xx xxxxxxxxx ± 20 % xxxxxxx xxxxxxx hmotnosti.
1.4.1.2 Xxxxxxxx chovu a xxxxxx
Xxxxx xxxxxx podmínky xxxxx obecného xxxxx x xxxxx X, xxxxxxx by xxxx xxx dosaženo xxxxxxxx xxxxxxx 50 – 60 %.
1.4.1.3 Příprava xxxxxx
Xxxxxx xxxxx pohlavně xxxxxxx xxxxx xx xxxxxxxx xxxxxxx xxxxxxx xx xxxxxxxxx skupinu x xxxxxxx, xxxxx xx exponuje. Xxxxx xx xxxx xxx xxxxxxxxxx xxx, xxx xxx xxxx xxxxxx xxxxxx xxxxxxxxxxxxx. Xxxxxxx xx jednoznačně identifikují. Xxxx započetím studie xx nechají x xxxxxxxxxxxxx podmínkách alespoň xxx xxx xxxxxxxxxxxxx.
1.4.1.4 Xxxxxxxx dávek
Pevné xxxxxxxx xxxxx xx xxxx xxx xxxx xxxxxxxx xxxxxxxx xxxxxxxxxx nebo xxxxxxxxxxxx ve xxxxxxxx xxxxxxxxxxxxxx xxxx xxxxxxxxxx x xxxxxxxxx xxxxxxx. Xxxxxxx xxxxxxxx xxxxx xxxxx xxx podávány xxxxx nebo xxxxx xxx xxxx xxxxxxx xxxxxxx. Xxxx xx xxx xxxxxxx čerstvě xxxxxxxxxx zkoušené xxxxxxxx xxxxx, pokud údaje x stálosti neprokazují xxxxxxx skladování.
1.4.2 Zkušební xxxxxxxx
1.4.2.1 Xxxxxxxxxxxx/xxxxxxxxx
Xxxxxxxxxxxx/xxxxxxxxx xx xxxxxx mít xxx xxxxxxxxx hladinách xxxxx xxxxxxx xxxxxx x xxxx xx xxx xxxxxxxxx xxxxxxxxx, xx xxxxxxx xx xxxxxxxxx xxxxxx. Jsou-li použita xxxx xxx známá xxxxxxxxxxxx/xxxxxxxx, xxxx xx xxx xxxxxx zařazení xxxxxxxxx xxxxx x xxxxxx xxxxxxxxxxxxx. Xxxxxxxxxx xx xxxxx xxxxx xxxxxxxx xxxxxx použití xxxxxxx rozpouštědel/vehikul.
1.4.2.2 Xxxxxxxx
Xxxxxxxx xxxxxxx experimentu xx xxxx xxx xxxxxxxx xxxxxxxxx x xxxxxxxxx (xxxxxxxxxxxx/xxxxxxxxx) kontroly. S xxxxxxxx aplikace xxxxxxxx xxxxx xx xxxx xxxxxxx kontrolní xxxxxxx xxxxxxxxxx xxxxxxxxx xxxxxx xxxx xxxxxxx ve xxxxxxxxx, x nichž xxxxx x xxxxxxxx.
Xxxxxxxxx xxxxxxxx by xxxx xxxxxxxxxx xxxxxxxxxx aberace xx xxxxxxxxxxxxxxx xx xxxx xxx xxxxxxxxxxx xxxxxxxx, u nichž xx xxxxxxxxxxx, xx xxxxxxxxx xxxxxxxxxxxxx nárůst xxx pozadí.
Dávky pozitivní xxxxxxxx xx xxxx xxx xxxxxxx xxx, xxx byl xxxxxx xxxxxxxx, xxx xxx xxx odečtu xxxxxxx xxxxx najevo xxxxxxxx xxxxxxxxxxxx preparátu. Xx xxxxxxxxxx, xxx xxxx xxxxxxxxx kontrola podávána xxxxx xxxxxxxx než xxxxxxxx xxxxx a xxx xxx xxxxx x jejím xxxxxxx xxxxxxxx xxx jednou. Xxx xxxxxxxxx xxxxxxxx xxxx být xxxxx xxxxx v xxxxx xxxxxxx xxxxxxxxxx xxxxx xx stejné xxxxxxxx xxxxx, jsou-li x xxxxxxxxx. Příklady xxxxx xxx xxxxxxxxx kontrolu:
|
Látka |
Číslo XXX |
Xxxxx xxxxx Einecs |
|
cyklofosfamid |
50–18–0 |
200–015–4 |
|
cyklofosfamid xxxxxxxxxx |
6055–19–2 |
|
|
xxxxxxxxxxxxxx |
108–91–8 |
203–629–0 |
|
xxxxxxxxx X |
50–07–7 |
200–008–6 |
|
xxxxxxxxx (monomer) |
79–06–1 |
201–173–7 |
|
2,4,6-tris(aziridin-1-yl)-1,3,5-triazin |
51–18–3 |
200–083–5 |
V xxxxxxxx každého xxxxxx xx xxx být xxxxxxxx odběr x xxxxxxx xxxxxxxxx xxxxxxxx, xxxxx je aplikováno xxxxx xxxxxxxxxxxx nebo xxxxxxxxx x která xxxxx xxxxxxxxxx stejný xxxxxx xxxx xxxxxxxxxx xxxxxxx, xxxxx nejsou x xxxxxxxxxxx xxxxxxxxxxx xxxxx x dispozici xxxxxxxxxx údaje x xxxxxxxxxxx xxxxxx x xxxxxxxx buněk x xxxxxxxxxxxxxx xxxxxxxxx. Xxxxx xxxx xx xxxx xxx xxxxxxxxxxxx kontroly xxxxxxx xxxx xxxxx, xxxxxxxxxx-xx xxxxx kontrolní xxxxx prokazující, xx xxxxxxx xxxxxxxxxxxx/xxxxxxxxx nevyvolává xxxxx xxxxxxx nebo xxxxxxxxx xxxxxx.
1.5 XXXXXX
1.5.1 Xxxxx zvířat
Každá exponovaná x kontrolní xxxxxxx xxxx zahrnovat xxxxxxx xxx xxxxxxxxxxxxxxxx samců.
1.5.2 Xxxx xxxxxxxx
Xxxxxxxx xxxxx xx měly xxx xxxxx xxxxx podávány xxxxxxxxxxx xxxx xxxxxxxxx (xx. xxx jedné xxxxxxxx xxxx xxxx xxxxxxxxxx). Zkoušené xxxxx xxxxx xxx xxxxxxxx xxxx xx xxxx xxxxxxx, xxx. dvě xxxxx v xxx xxx x rozmezí xx více xxx xxxxxxxx xxxxx, aby xxxx xxxxxxxxx xxxxxxxx xxxxxxx objemů xxxxxxxxx. Xxxx xxxxxx xxxxxxxx xx xxxx být xxxxxxx zdůvodněny.
Ve skupině x xxxxxxxx xxxxxx xx xxxx xxx xx xxxxxxxx provedeny xxx odběry. Xxxxxxxx xxxxxxxx xxxxxxxxx cyklu xxxx xxx xxxxxxxxx xxxxxx xxxxxxxxx, provede xx xxxxx xxxxx xxxxx x xxxxx xxxxxxxx xxxxx xxxxxxxxx 24 a 48 xxxxx xx xxxxxxxx. X xxxxxxx xxxx xxx nejvyšší xxxxx xx měl xxx xxxxx xxxxxxxx po 24 xxxxx nebo xx takové xxxx xxxxxxxx, xxxxx xxxxxxxx 1,5xxxxxxx délky xxxxxxxxx xxxxx, xxxxx xxxx xxxxx xxxx xxxxxxxxx xxxx xxx xxxxxxx xxxxxx (6).
Navíc mohou xxx xxxxxx xxxxxxxxx xxxx x xxxx xxxx. Například x xxxxxxx chemických xxxxx, xxxxx xxxxx indukovat xxxxxxxx replikace (xxxxxxx) xxxxxxxxxx nebo mohou xxxxxxxxxx X-xxxxxxxxx účinky, xxxx xxx vhodnější xxxxxxxx xxxxx (1).
Vhodnost xxxxx xxxxxxxxx xxxxxxxx xxxx být xxxxxx xxxxxx xx xxxxxxx. X xxxxxxx xxxxx x xxxxxxxxxx xxxxxxxx xx xxxx xxx xxxxxxx xxxxxxxx 24 xxxxx (1,5násobek xxxxx xxxxx) po poslední xxxxxxxx. Podle xxxxxxx xxxxx být xxxxxxxxx xxxxx xxxxxx x xxxx xxxx.
Xxxx xxxxxxxxx xx xxxxxxxx intraperitoneálně xxxx xxxxxx xxxxx xxxxx zastavující xxxxxxxx (xxxx. Colcemid® nebo xxxxxxxxx). Xxxx se xx xxxxxx xxxx xxxxxxx u xxxxxx xxxxx. X xxxx xx tato xxxx xxxxxxxxx 3 — 5 xxxxx; u xxxxxx čínského xx xxxx doba přibližně 4 — 5 xxxxx.
1.5.3 Xxxxxxxxx
Xxxxxxx-xx xx xxxxx xxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxx xxxxxx xxx xxxxxxxx xxxxxxx, xxxx by xxx xxxxxxxxx ve xxxxxx xxxxxxxxxx, xx stejným xxxxxx x xxxxxx x xx xxxxxxxx xxxxxx xxxxxxxx, xxxxx xx použije x xxxxxx xxxxxx (7). X případě toxicity xx xxx xxxxx xxxxx použijí xxx xxxxxx dávky. Xxxx xxxxxx dávky by xxxx pokrývat rozmezí xxxx maximální x xxxxxxxxx toxicitou, xxxxxxxx xxxxxx xxxxxxxxx. Xxx xxxxxxxxx odběru xxxxx, xxxx bude xxxxxxx xxxxx xxxxxxxx xxxxx. Xxxxxxxx xxxxx xx xxxxxxxxxx xxxx xxxxx xxxxxxxxxxxx takové známky xxxxxxxx, že by xxxxx xxxxx vedly xxx xxxxxxx režimu xxxxxxxxx xxxxx očekávání x xxxxxxxx.
Xxxxx se xxxxxxxxxxx biologickou aktivitou xxx xxxxxxx netoxických xxxxxxx (xxxx. xxxxxxx x xxxxxxxx) nemusí xxxxxxxxx xxxxxxxxx dávky xxxxxxxxx x xxxx xx xxx hodnoceny xxxxxx xx případu. Xxxxxxxx xxxxx xxxx xxx xxxx definována xxxx xxxxx xxxxxxxxxxxx xx spermatogoniích některé xxxxxx xxxxxxxx (xxxx. xxxxxxx xxxxx spermatogonií x xxxxxx xxxxxxxx x první x xxxxx xxxxxxxxx metafázi; xxxx xxxxxxx xx xxxxxx xxxxxxxxx 50 %).
1.5.4 Limitní xxxxxxx
Xxxxxxxx xxxxxxx x xxxxxx xxxxxx xxxxxxx 2000 xx/xx xxxxxxx xxxxxxxxx xxxxxxx jednorázově nebo xx xxxx dávkách x xxxxxx xxx xxxxxxxxxx xxxxx xxxxxxxxxxxxx xxxxxxx xxxxxx a xxxx-xx na základě xxxxx x látkách, xxxxx mají xxxxxxxx xxxxxxxxx, očekávána xxxxxxxxxxxx, xxxxxxxxxx xx úplná xxxxxx se třemi xxxxxxxx xxxxx za xxxxxxxxx. Očekávaná xxxxxxxx xxxxxxx xxxx xxxxxxxx xxxxxxx xxxxxx x xxxxxxx xxxxxxx vyšší xxxxxx xxxxx.
1.5.5 Xxxxxxxx xxxxx
Xxxxxxxx xxxxx xx xxxxxxx xxxxxx xxxxxxxxxxxxxx, xxxxxxxxx sondou nebo xxxxxxx xxxxxxxxx kanylou, xxxx xxxxxxxxxxxxxxxxx xxxxxxx. Xxxx xxxxxxx xxxxxxxx xxxx přijatelné, xxxx-xx xxxxxxxxxxxxx. Maximální objem xxxxxxxx, který může xxx xxxxxxxx xxxxx xxxxxxxxx sondou nebo xxxxxxxx, závisí xx xxxxxxxxx xxxxxxxxxxx xxxxxxx. Xxxxx by neměl xxxxxxxxx 2 xx/100 x xxxxxxx hmotnosti. Xxxxxxx xxxxxxx objemů, xxx xx uvedený xxxxx, xxxx xxx xxxxxxxxxx. Xx xx xxxxxxxx x xxxxxx xxxxx, které obvykle xxx xxxxxxx xxxxxxxxxxxxx xxxxxxxx xxxxxxxx xxxxxx, xx xxxx xxx xxxxxxxxxxx xxxxxxxxxx xxxxxx xxxxxxxxxxxxxx nastavením koncentrace xxxxxxxxxxx xxxxxxxxxx xxxxx xxx xxxxx xxxxxxxx xxxxx.
1.5.6 Xxxxxxxx xxxxxxxxx xx analýzu xxxxxxxxxx
Xxxxx xx xxxxxxxx xx x xxxxxxx nebo xxxx xxxxxx xxxxx xxxxxxx xxxxxxxx, xxxxxxxxxxxx xx x xxxxxx. Xxxx se nanese xx xxxxxxxx xxxxxxx x xxxxxx xx.
1.5.7 Xxxxxxx
X každého zvířete xx mělo být xxxxxxxxxxx xxxxxxx 100 xxxxx x xxxxx xxxxxxxxxxxx metafázi (xx. xxxxxxxxx 500 xxxxxxxx xx skupinu). Tento xxxxx xxx snížit, xx-xx xxxxxxxxx velký xxxxx xxxxxxx. Xxxxxxx xxxxxxxxx xxxxxx xxxxxxxxx xxxxxxxxxxx x negativních xxxxxxx, xx xxxx xxx xxxx mikroskopickou xxxxxxxx nezávisle xxxxxxxx. Xxxxxxxx xxx xxxxxx xxxxx xxxxxxx ke xxxxxxxxxxxxxx zlomům xxxx xxxxxx xxxxxxxxxx x xxxxx xxxxxxxx, xxxx xx xxxxxxxxxxx buňky xxxxxxxxx xxxxxxxxxx v xxxxx odpovídajícímu xxxxx 2 x ± 2.
2. XXXXX
2.1 ZPRACOVÁNÍ XXXXXXXX
Xxxxx pro xxxxxxxxxx xxxxxxx xx xxxx xxx xxxxxxxxxx ve xxxxx xxxxxxx. Experimentální xxxxxxxxx xx xxxxx. Xxx xxxxx zvíře xx měl xxx xxxxxxxxxx počet buněk xx strukturními xxxxxxxxxxxxxx xxxxxxxxx a xxxxx xxxxxxxxxxxxxx xxxxxxx xx xxxxx. Pro xxxxxxxxxx x xxxxxxxxx skupiny xx měly xxx xxxxxxx xxxxx xxxx xxxxxxxxxxxx chromozomových xxxxxxx x jejich xxxxxx x xxxxxxxx. Xxxx xx xxxxxxxxxxxxx odděleně x xxxxxxx xx, xxx xxxxxx se xxxxxxxxxx xx xxxxxxx xxxxxxxx aberací.
Je-li pozorována xxxxxx x také xxxxxx, měl xx xxx pro xxxxxxxxx xxxxxxx cytotoxických účinků xxxx míra xxxxxxxxxxxx xxxxxxxx u xxxxx xxxxxxxxxxxx xxxxxx a xxxxxx sloužících jako xxxxxxxxx xxxxxxxx xxxxx xxxxxxxxxxxxx x xxxxxx xxxxxxxx k první x xxxxx meiotické xxxxxxxx, a xx x celkovém xxxxxx 100 dělících se xxxxx xx jedno xxxxx. Xxxxx je xxxxxxxxx pouze mitosa, xxxxxxx x 1000 xxxxxxx xx xxxxx xx xxx xxx xxxxxxxx xxxxxxxxx xxxxx.
2.2 XXXXXXXXX X XXXXXXXXXXXX XXXXXXXX
Xxx stanovení xxxxxxxxxxx xxxxxxxx xxxxxxxx xxxxxxx xxxxxxxx, např. xxxxxx xxxxx xxxxx x xxxxxxxxxxxxxx xxxxxxxxx x xxxxxxxxxx na dávce xxxx xxxxx xxxxxx xxxxx xxxxx x xxxxxxxxx pro xxxxxxx x určitou dávkou x x xxxxxxxx xxxxxxxx odběru. Xxxxxxxx xx xxxx xxx xxxxxxx xxxxxxxxxx xxxxxxxxx xxxxxxxx. Xxx hodnocení xxxxxxxx zkoušky mohou xxx použity jako xxxxxxx xxxxxxxxxx xxxxxxxxxxx xxxxxx (8). Xxxxxxxxxxx xxxxxxxxxx by xxxxxx xxx jediným xxxxxxxxx xxxxxxxx xxx xxxxxxxxx xxxxxxx. Dvojznačné výsledky xx xxxx být xxxxxxxxx xxxxxx xxxxxxxxx, xxxxxxx x úpravami xxxxxxxxxxxxxxxx xxxxxxxx.
Xxxxxxxx látka, xxxxx xxxxxxxx xxxxxxxxx xxxx uvedená kritéria, xx v tomto xxxxxxx považuje xx xxxxxxxxxxx.
Xxxxxx xxxxxxx xxxxxxxxxxx xxxxxxxx xxxxx pozitivní xxxx xxxxxxxxx výsledky, x xxxxxxxxxxx případech xxxxxxxx xxxxxx xxxxx xxxxxxxx xxxxxxx xxxxx x aktivitě zkoušené xxxxx. Xxxxxxxx mohou xxxxxx dvojznačné nebo xxxxxx xxx xxxxxx xx xx, xxxxxxxx xx xxxxxxxxxx xxxxxxxx.
Xxxxxxxxx xxxxxxxx zkoušky xx xxxxxxxxxxxx aberace ve xxxxxxxxxxxxxxx xxxxx xx xxxx xxxxxxxxx, xx xxxxxxxx látka xxxxxxxx x xxxxxxxxxxxx xxxxxxx xxxxxxxxxxx druhu xxxxxxxxxx xxxxxxxxxxxx aberace. Negativní xxxxxxxx xxxxxxxxx, xx xxxxxxxx xxxxx xx xxxxxxxx xxxxxxx xxxxxxxxxx x xxxxxxxxxxxx xxxxxxx xxxxxxxxxxx xxxxx xxxxxxxxxxxx xxxxxxx.
Xxxx by být xxxxxxxxxxx pravděpodobnost, x xxxxx xx zkoušená xxxxx xxxx její xxxxxxxxxx xxxxxxxx do xxxxxx tkáně.
3. XXXXXX
XXXXXXXX X ZKOUŠCE
Protokol x xxxxxxx xxxx obsahovat xxxx xxxxxxxxx:
Xxxxxxxxxxxx/xxxxxxxxx:
- xxxxxxxxxx xxxxx xxxxxxxx,
- rozpustnost x xxxxxxx zkoušené xxxxx x xxxxxxxxxxxx/xxxxxxxx, xx-xx xxxxx.
Xxxxxxxxx xxxxxxx:
- xxxxxxx xxxx/xxxx,
- xxxxx x xxxxx xxxxxx,
- xxxxx, xxxxxxxx chovu, xxxxxx xxx.,
- xxxxxxxxxxxx xxxxxxxx zvířat na xxxxxxx xxxxxxx, xxxxxx xxxxxxx xxxxxxx xxxxxxxxx, xxxxxxx hodnoty x xxxxxxxxxx xxxxxxxx xxx xxxxxx xxxxxxx.
Xxxxxxxx podmínky:
- xxxxx xx studie xxx xxxxxxxx xxxxxxx, xxxxx xxxx xxxxxxxxx,
- xxxxxxxxxx xxxxxxxxx xxxxxx xxxxx,
- xxxxxxxxxx xxxxxxx xxxxxxxx,
- xxxxx o xxxxxxxx xxxxxxxx xxxxx,
- xxxxx x podávání xxxxxxxx xxxxx,
- xxxxxxxxxx xxx xxxxxxxx,
- případně xxxxxxxx mezi xxxxxxxxxxx xxxxxxxx xxxxx x xxxxxx xxxx xxxx (xxx) xx odpovídající xxxxx (xx/xx xxxxxxx xxxxxxxxx/xxx),
- xxxxxxxx xxxxx x kvalitě krmiva x vody,
- xxxxxxxx xxxxx xxxxxxx xxxxxxxx x xxxxxx,
- xxxxxx xxxxxxxxx toxicity,
- xxxxxxxxxxxx xxxxx xxxxxxxxxxx xxxxxxxx, xxxx xxxxxxxxxxx a xxxxx xxxxxxxx,
- xxxxxx xxxxxxxx xxxxxxxxx,
- xxxxxxxx xxxxxxxxx aberací,
- xxxxx xxxxxxxxxxxxx buněk xx xxxxx xxxxx,
- xxxxxxxx xxxxxxxxxxx xxxxxx xx xxxxxxxxx, xxxxxxxxx nebo xxxxxxxxxxx.
Xxxxxxxx:
- xxxxxx toxicity,
- xxxxxxxxx xxxxx,
- poměr xxxxxxxxxxxxx x xxxxxx xxxxxxxx x xxxxx x xxxxx xxxxxxxx xxxxxx,
- xxx x xxxxx xxxxxxx xxxxxxx xxxxxxxxxx xxx xxxxx xxxxx,
- xxxxxxx počet xxxxxxx ve xxxxxxx,
- xxxxx xxxxx x xxxxxxxxx xx skupině,
- xxxxx xxxxxxxx xxxxxxxxx xxxxxxxx na xxxxx,
- xxxxxxxx statistické xxxxxxx,
- xxxxx o xxxxxxxx xxxxxxxxx xxxxxxxx,
- dosavadní xxxxx x negativní xxxxxxxx x xxxxxxxxx, xxxxxxxxx hodnotami a xxxxxxxxxxxx xxxxxxxxxx,
- xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxx,
- změny xxxxxxx, xxxxx byly xxxxxxxxxx.
Xxxxxx xxxxxxxx.
Xxxxxx.
4. LITERATURA
1) Xxxxx, X. D., (1986), Xxxxxxxxxxx Potential xx Xxxxx Spermatogonia xx Xxxxxxxx Xxxxxxxx Xxxxxxx xx xxxxx Xxxx-Xxxxx Xxxxxxxxxxxxxx, xx: Genetic Xxxxxxxxxx xx Environmental Xxxxxxxxx, Xxxx X: Xxxxxxx Effects xxx Xxxxxxx Xxxxxxxxxxx, Xxxxx, X., Xxxxxxx, B., Xxxxxxxxx, X. (xxx) Xxxx, New Xxxx, 477-484.
2) Adler, I. X., (1984), Xxxxxxxxxxx xxxxx xx Xxxxxxx, xx: Mutagenicity Xxxxxxx: x Xxxxxxxxx Approach, (xx.) S. Venitt, X. M. Parry, XXX Press, Xxxxxx, Xxxxxxxxxx DC, 275-306.
3) Xxxxx, X. X., Xxxxxxx, X., Xxxx, X. X. (1964), Xx Xxx-xxxxxx Method xxx Meiotic Xxxxxxxxxxxx xxxx Xxxxxxxxx Xxxxxx, Xxxxxxxxxxxx Xxxx Xxxxxxxx, 3, 289-294.
4) Richold, X., Ashby, X., Xxxxxxxx, X., Xxxxxxxxx, X. X., Xxxxxxxxx, X. (1990), Xx xxxx Xxxxxxxxxxx Assays, xx: X. X. Xxxxxxxx (ed.), Xxxxx Xxxxxxxxxxxx Xxxxx, XXXXX Xxxxxxxxxxx Xxxxxxxxxx. XXXXX Xxxxxxxxxxxx xx Guidelines xxx Xxxxxxxxxxxx Testing. Xxxxxx. Xxxx X xxxxxxx, Xxxxxxxxx Xxxxxxxxxx Xxxxx, Cambridge, Xxx Xxxx, Xxxx Chester, Xxxxxxxxx, Sydney, 115-141.
5) Xxxxxxxx, K., Kikuchi, X. (1978), X Xxx Xxxxxx for Xxxxxxxxxxx xx Xxxxxxxxx Xxxxxxxxxxxxxx Xxxxxxxxxxx, Mutatation Xxx., 52, 207-209.
6) Xxxxx, I. X., Xxxxxx X. X., Xxxxxxx, X., Xxxxx, X., Xxxxxxxx, X., Xxxxxxxxxxxx, F., Xxxxxxx, X., Xxxxxx X. (1994), Xxxxxxxxxxxxx Xxxxxxxx xx Xxxxxxxxxxxxxxx xx Xxxxxxxxxxxx Xxxx Procedures. Xxxxxxx Report xx xxx Working Xxxxx xx Mammalian Xxxx Xxxx Tests, Mutatation Xxx., 312, 313-318.
7) Xxxxxxx, X. X., Xxxxx, X. X., Xxxxxx, A. X., Xxxxxx, P. X., Xxx, J., Esdaile, X. X., Xxxxxxxxx, X. X., Xxxxxx-Xxxxxx, X., Xxxxxx, X. X., Kirkland, X. X., Xxxxxxx, X. (1992), Report xx Xxxxxxx Xxxxxxxxxx Society/UK Xxxxxxxxxxxxx Xxxxxxx Xxxxxxx Xxxxxxx Group: Xxxx Xxxxxxx xx Xx xxxx Xxxxxxxxxxxx Assays, Xxxxxxxxxxx, 7, 313-319.
8) Xxxxxx, D. X., Xxxxxxxx, X., Xxxxxxxx, X., Xxxxxxxx, X. X., Xxxxx, X., Xxxxxxxx, X., Xxxxxxx, X., Papworth, X. X., Savage X. X. X. (1989), Xxxxxxxxxxx Xxxxxxxx xx Xx xxxx Cytogenetic Xxxxxx, xx: X. X. Xxxxxxxx (xx.), Xxxxxxxxxxx Xxxxxxxxxx xx Xxxxxxxxxxxx Xxxx Xxxx. XXXXX Subcommittee xx Xxxxxxxxxx xxx Xxxxxxxxxxxx Xxxxxxx, Xxxxxx, Xxxx XXX. Xxxxxxxxx Xxxxxxxxxx Xxxxx, Cambridge, Xxx Xxxx, Xxxx Xxxxxxx, Xxxxxxxxx, Xxxxxx, 184-232."
XXXXXXX 4X
"X.39 XXXXXXX XX XXXXXXXXXXXX SYNTÉZU XXX (UDS) V XXXXXXXXX BUŇKÁCH SAVCŮ XX VIVO
1. XXXXXX
Xxxx xxxxxx xx xxxxxxxx xxxxxx XXXX XX 486 — Xxxxxxx xx xxxxxxxxxxxx xxxxxxx XXX (XXX) x xxxxxxxxx xxxxxxx savců xx xxxx (1997).
1.1 XXXX
Xxxxxx zkoušky na xxxxxxxxxxxx xxxxxxx DNA (XXX) x jaterních xxxxxxx xxxxx xx xxxx je xxxxxxxxxxxxx xxxxxxxx xxxxx, xxxxx xxxxxxxx reparace DNA x xxxxxxxxx buňkách xxxxxxxxxxxx xxxxxx (1, 2, 3, 4).
Tato xxxxxxx xx xxxx xxxxxxxxx xxxxxx xxxxxxxxx xxxxxxxxxxxxx účinků chemických xxxxx v játrech. Xxxxxxxxxxx xxx je xxxxxxxxxx xxxxxxxxx XXX x xxxxxxxx reparace x jaterních xxxxxxx. Xxxxx xxxx xxxxxxx xxxxxxx xxxxxx, xxx xxxx xxxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxxx. Xxxx tedy xxxxxxx místem xxx xxxxxxxxx xxxx xxxxxxxxx XXX xx xxxx.
Xxxxxxxx xxxxxxxx xxxxx x xxx, že xx xxxxxxxx xxxxx xxxxxxxxx xx xxxxxx tkáně, xxxx vhodné xxxx xxxxxxx xxxxxx.
Xxxxxx neplánované xxxxxxx DNA (XXX) xx xxxxxxxx stanovením xxxxxxxxxxx xxxxxxxxx xxxxxxxxxx xx xxxxx, xxxxx xxxxxxxx plánovanou syntézou XXX (X-xxxx). Nejrozšířenější xxxxxxxxx xx autoradiografické xxxxxxxxx inkorporace xxxxxxxxx xxxxxxxxx tritiem (3X-XxX). Xxx zkoušky xx XXX xx xxxx xx xxxxxxxxxx používají xxxxx xxxxxxx. Jiné xxxxx než xxxxx xxxxx xxx xxxxxx xxxxxxx, xxxxxx xxxx xxxxxxxxx xxxx metody.
Detekce xxxxxxxx XXX závisí xx xxxxx bází XXX vyštěpených a xxxxxxxxxxx x xxxxx xxxxxxxxx. Zkouška xx XXX xx tedy xxxxxx xxxxxxx xxx xxxxxxx dlouhých reparací ("xxxx-xxxxx repair") (20 xx 30 xxxx) xxxxxxxxxxxx xxxxxx. Xxxxxx xxxxxx ("short-patch xxxxxx") (xxxxx xx xxx xxxx) jsou xxxxxxx xxxx xxxxxxxxxx x xxxxxx xxxxx citlivostí. Xxxxx xxxx xxxxxxxxx xxxxxxxxxxxxx reparace, chybné xxxxxxxx xxxx chybné xxxxxxxxx xxxx XXX xxxxx x xxxxxxxxxx xxxxxxxxx. Xxxxxx xxxxxxxx XXX neposkytuje žádnou xxxxxxxxx x xxxxxxxx xxxxxxxxxxx procesů. Navíc xx možné, xx xxxxxxx reaguje x XXX, xxx xxxxxxxxx XXX není opraveno xxxxxxxxxxx xxxxxxxx. Xxxxxxxxxx xxxxxxxxxxxx informací, které xxxx xxxxxxx xxxxxxxxx x xxxxxxxxx xxxxxxxx, xx xxxxxxx xxxxxxxxxxx xxxxxxxxxx tohoto xxxx, xxxxx je xxxxxxxxxx x celém xxxxxx.
Xxx xxxx xxxxxx xxxx, xxxx X.
1.2 XXXXXXXX
Xxxxxxxxxx xxxxx : xxxxx xxxxx xxx xxxxxxxxxxxxxx xxxxxxxx xxxxxx (NNG), xxxxx než předvolená xxxxxxx stanovená xxxxxxxxxx xxxxxxxxxxx xxxxxxx.
Xxxxx počet xxx odpovídajících buněčným xxxxxx (NNG) : xxxxxxxxxxxxx míra UDS xxxxxxxx xxxxx x xxxxxxxxxxxxxxxxx xxxxxxx na XXX, vypočtená xxxxxxxxx xxxxxxxxxx xxxxx zrn x xxxxxxxxxxxxxxxxx xxxxxxxxx (XX) odpovídajících xxxxxx xx počtu xxx xxxxxxxxxxxxxx buněčným jádrům (XX): XXX = XX — XX. Xxxxxxx XXX xx xxxxxxx xxx jednotlivé xxxxx, poté společně xxx xxxxx v xxxxxxx, x xxxxxxxxxxx xxxxxxxxx xxx.
Xxxxxxxxxxx xxxxxxx XXX (UDS) : Xxxxxxx reparací XXX xx vyštěpení x xxxxxxxxxx xxxxx XXX xxxxxxxxxxxx xxxxxx s xxxxxxxxxx xxxxxxxxxxx xxxxxxxxxx xxxxxxx xxxx fyzikálními xxxxxxxx.
1.3 XXXXXXXX XXXXXXXX XXXXXX
Xxxxxxx xx XXX x jaterních buňkách xxxxx xx xxxx xxxxxxxx xxxxxxx xxxxxxxx XXX xx xxxxxxxxx x xxxxxxxxxx úseku XXX obsahujícího xxxxxx x poškozením xxxxxxxxxxx xxxxxxxxxx látkami xxxx xxxxxxxxxxx xxxxxxxx. Xxxxxxx xx obvykle založena xx xxxxxxxxxxx 3X-XxX xx XXX xxxxxxxxx xxxxx, xxx xx xxxx xxxxxxx xxxxx x S-fázi buněčného xxxxx. Xxxxxxxxxxx 3H-TdR xx xxxxxxx stanoveno xxxxxxxxxxxxxxx, jelikož xxxx xxxxxxxx není tak xxxxxxx na xxxx X-xxxx xxxxx jako xxxx. xxxxxxx xxxxxxxxxxx xxxxxxxxxxxxx.
1.4 POPIS XXXXXX
1.4.1 Xxxxxxxxx
1.4.1.1 Xxxxx druhu xxxxxxx
Xxxxx xx xxxxxxxx xxxxxx, xxxxxx lze xxxxxx xxxxxxxx xxxxxx xxxx xxxxx. Měly xx xxx použity xxxxx xxxxxxxxx xxxxxxxxxxx xxxxx xxxxxxx zdravých xxxxxxxx xxxxxxxxx xxxxxx. X okamžiku xxxxxxxx xxxxxx xx xxxx xxx odchylka v xxxxxxxxx xxxxxx xxxxxxxxx x xxxxxx xx xxxxxxxxx ± 20 % xxxxxxx hodnoty xxxxxxxxx pro obě xxxxxxx.
1.4.1.2 Xxxxxxxx xxxxx x xxxxxx
Xxxxx xxxxxx xxxxxxxx xxxxx obecného xxxxx k části X, xxxxxxx by xxxx xxx xxxxxxxx xxxxxxxx vzduchu 50 - 60 %.
1.4.1.3 Xxxxxxxx xxxxxx
Xxxxxx xxxxxxxx xxxxxxx xxxxxxx se xxxxxxxx xxxxxxx xxxxxxx xx xxxxxxxxx skupinu x skupinu, xxxxx xx xxxxxxxx. Xxxxx xx xxxx být xxxxxxxxxx xxx, xxx xxx xxxx xxxxxx xxxxxx xxxxxxxxxxxxx. Zvířata xx jednoznačně xxxxxxxxxxxx x před xxxxxxxxx xxxxxx xx xxxxxxx x xxxxxxxxxxxxx podmínkách xxxxxxx xxx xxx xxxxxxxxxxxxx.
1.4.1.4 Xxxxxxxx xxxxxxxx xxxxx
Xxxxx zkoušené xxxxx xx xxxx xxx xxxx xxxxxxxx xxxxxxxx xxxxxxxxxx xxxx xxxxxxxxxxxx xx xxxxxxxx rozpouštědlech xxxx xxxxxxxxxx a xxxxxxxxx zředěny. Kapalné xxxxxxxx xxxxx xxxxx xxx xxxxxxxx xxxxx xxxx xxxxx být xxxx xxxxxxx zředěny. Xxxx by být xxxxxxx xxxxxxx xxxxxxxxxx xxxxxxxx xxxxxxxx xxxxx, xxxxx údaje o xxxxxxxx xxxxxxxxxxx možnost xxxxxxxxxx.
1.4.2 Xxxxxxxx podmínky
1.4.2.1 Xxxxxxxxxxxx/xxxxxxxxx
Xxxxxxxxxxxx/xxxxxxxxx by xxxxxx xxx xxx xxxxxxxxx xxxxxxxx xxxxx xxxxxxx xxxxxx x xxxx xx xxx xxxxxxxxx xxxxxxxxx, xx reaguje xx xxxxxxxxx xxxxxx. Xxxx-xx použita jiná xxx xxxxx xxxxxxxxxxxx/xxxxxxxx, xxxx by být xxxxxx zařazení podloženo xxxxx x jejich xxxxxxxxxxxxx. Xxxxxxxxxx xx xxxxxxxx zvážit xxxxxxx xxxxx xxxxx xxxxxxx xxxxxxxxxxxx/xxxxxxx.
1.4.2.2 Xxxxxxxx
Xxxxxxxx xxxxx xxxxxxxxx prováděné xxxxx xxxxxxxxxxx by xxxx xxx xxxxxxxx xxxxxxxxx x xxxxxxxxx (xxxxxxxxxxxx/xxxxxxxxx) xxxxxxxx. X xxxxxxxx xxxxxxxx xxxxxxxx xxxxx xx měla zvířata xxxxxxxxx xxxxxxx podstoupit xxxxxx xxxxxx xxxx xxxxxxx xx xxxxxxxxx, x xxxxx xxxxx x expozici.
Pozitivními xxxxxxxxxx xx xxxx být xxxxx, x nichž xx známo, xx xxxxxx xxxxxxxx x xxxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxxxx xxxx x xxxxxxx XXX detekovatelnému nad xxxxxxx. Pozitivní xxxxxxxx xxxxxxxxxx metabolickou xxxxxxxx xx xxxx být xxxxxxx v dávkách xxxxxxxxxxxx mírnou xxxxxxx (4). Xxxxx xxxxx xxx zvoleny xxx, xxx byl xxxxxx xxxxxxxx, ale aby xxx xxxxxx xxxxxxx xxxxx xxxxxx xxxxxxxx xxxxxxxxxxxx xxxxxxxxx. Xxxxxxxx xxxxx xxx pozitivní xxxxxxxx:
|
Xxxx odběru |
Látka |
Číslo XXX |
Xxxxx xxxxx Einecs |
|
Časné xxxx xxxxxx (2 až 4 x) |
X-xxxxxxxxxxxxxxxxxxx |
62–75–9 |
200–249–8 |
|
Xxxxxx xxxx xxxxxx (12 xx 16 h) |
N-(fluoren-2-yl)acetamid (2-XXX) |
53–96–3 |
200–188–6 |
Xxxxx xxx xxxxxxx také xxxx xxxxx xxx xxxxxxxxx kontrolu. Je xxxxxxxxx, xxx xxxx xxxxxxxxx xxxxxxxxx látka xxxxxxxx jiným xxxxxxxx, xxx zkoušená látka.
1.5 XXXXXX
1.5.1 Počet x xxxxxxx xxxxxx
Xxx by xxx xxxxxx xxxxxxxxxx xxxxx xxxxxx, xxx xxxx zohledněno přirozené xxxxxxxxxx kolísání xxxxxxxx xx zkoušku. Xxxxx xxxxxxx by xx xxxx xxxxxxx xxxxxxx xx xxx analyzovatelných xxxxxx. Xxxxxxxx jsou xxxxxxxxxxx dostatečné xxxxxxxxx xxxxx, xx pro xxxxxxxxx x xxxxxxxxx xxxxxxxxx xxxxxxx xxxxxxxx xxxxx jedno až xxx zvířata.
Jestliže jsou x xxxx xxxxxx x dispozici údaje xx xxxxxx se xxxxxxx xxxxxx x xx xxxxxxx stejného xxxxxxx xxxxxxxx, xxx xxxxxxxxx, xx xxxxxxxxxx xxxx xxxxxxxxx xxxxxx x toxicitě, xxxx xxxxxxxxxxx zkoušení xxxxxxx xxxxxxx, nejlépe xxxxx. Xx-xx xxxxxxxx xxxxxxx xxxxxxxxxx xxx určité xxxxxxx, xxxx xx xxxx xxxxxxxxx x xxxxxxxxx xxxxxxxxxxxxxxx látek, xxxx xx být xxxxxxx provedena xx xxxxxxxx xxxxxxxxxxxxxx xxxxxxx.
1.5.2 Xxxx xxxxxxxx
Xxxxxxxx látky xxxx xxxxxxxxx podávány xxxxxxxxxxx.
1.5.3 Xxxxxxxxx
Xx xxxxxxxxxx xxxxxxxx xx xxxxxxxxx xxxxxxx xxx úrovně xxxxx. Nejvyšší dávka xx xxxxxxxxxx xxxx xxxxx xxxxxxxxxxxx takové xxxxxx xxxxxxxx, xx xxxxx dávky by xxxxx podle xxxxxxxxx xxx xxxxxxx režimu xxxxxxxxx x letalitě. Xxxxx dávka xx xxxx být xxxxxxxxx 50 % xx 25 % xxxxx xxxxx.
Xxxxx xx xxxxxxxxxxx xxxxxxxxxxx aktivitou xxx xxxxxxx xxxxxxxxxxx xxxxxxx (xxxx. xxxxxxx a xxxxxxxx) xxxxxx kritériím xxxxxxxxx xxxxx xxxxxxxxx x xxxx by xxx xxxxxxxxx případ xx případu. Xxxxxxx-xx xx xxxxx neexistenci xxxxxxxx xxxxxxxxxx xxxxx xxxxxx xxx xxxxxxxx xxxxxxx, xxxx xx xxx xxxxxxxxx xx xxxxxx xxxxxxxxxx, xx xxxxxxx druhem, kmenem, xxxxxxxx x xx xxxxxxxx xxxxxx expozice, xxx se xxxxxxx x hlavní studii.
Nejvyšší xxxxx xxxx xxx xxxxxxxxxx xxxx xxxx xxxxx xxxxxxxxxxxx xxxxxx xxxxxxxx x xxxxxxx (xxxx. xxxxxxxxxx jádra).
1.5.4 Xxxxxxx zkouška
Jestliže zkouška x jednou xxxxxx x xxxxxxx 2000 xx/xx xxxxxxx xxxxxxxxx xxxxxxx xxxxxxxxxxx xxxx xx xxxx xxxxxxx x xxxxxx dni xxxxxxxxxx xxxxx xxxxxxxxxxxxx xxxxxxx xxxxxx x xxxx-xx xx xxxxxxx xxxxx x xxxxxxx, xxxxx xxxx podobnou xxxxxxxxx, xxxxxxxxx xxxxxxxxxxxx, xxxxxx xxx úplná xxxxxx xxxxxxxx. Xxxxxxxxx xxxxxxxx člověka xxxx xxxxxxxx xxxxxxx xxxxxx x xxxxxxx xxxxxxx xxxxx xxxxxx dávky.
1.5.5 Xxxxxxxx xxxxx
Xxxxxxxx xxxxx xx xxxxxxx xxxxxx xxxxxxxxxxxxxx, žaludeční xxxxxx xxxx xxxxxxx xxxxxxxxx xxxxxxx. Xxxx xxxxxxx xxxxxxxx xxxx xxxxx, xxx-xx je xxxxxxxxx. Xxxxxxxx intraperitoneálně xx xxxx nedoporučuje, neboť xx játra xxxxx xxx xxxxxxxxxx zkoušené xxxxx xxxxx x xxxxxx xxxxxxxxxxxxxxx oběhového xxxxxxx. Maximální xxxxx xxxxxxxx, xxxxx xxxx xxx xxxxxxxx podán xxxxxxxxx sondou xxxx xxxxxxxx, xxxxxx xx xxxxxxxxx xxxxxxxxxxx xxxxxxx. Xxxxx xx xxxxx xxxxxxxxx 2 xx/100 x xxxxxxx hmotnosti. Xxxxxxx xxxxxxx xxxxxx, xxx xx xxxxxxx xxxxx, xxxx xxx xxxxxxxxxx. Až xx xxxxxxxx a xxxxxx xxxxx, xxxxx xxxxxxx xxx vyšších koncentracích xxxxxxxx xxxxxxxx xxxxxx, xx měla xxx xxxxxxxxxxx xxxxxxxxxx xxxxxx xxxxxxxxxxxxxx nastavením koncentrace xxxxxxxxxxx xxxxxxxxxx xxxxx xxx xxxxx úrovních xxxxx.
1.5.6 Xxxxxxxx jaterních xxxxx
Xxxxxxx xxxxx xx xxxxxxxxxx z exponovaných xxxxxx zpravidla 12 xx 16 xxxxx xx xxxxxx dávky. Xxxxxxxxxx xxxxxxxx odebrání xxxxxx (xxxxxx dvě xx čtyři xxxxxx xx expozici) xx xxxxxxxx, xxxx-xx po 12 xx 16 xxxxxxxx jasná xxxxxxxxx xxxxxxx. Xxxxx xxxx xxx xxxxxxx xxxx xxxx odběru, jsou-li xxxxxxxxxx na xxxxxxx xxxxxxxxxxxxxxxxx xxxxx.
Xxxxxxxxxx xxxxxxx xxxxxxxxx buněk xxxxx xx zpravidla xxxxxxxxx xxxxxxx xxxxx xxxxxxxxxxx xx xxxx a xxxxxx xx, xxx xx xxxxxxx xxxxxxxxxxx xxxxxxx buňky zachytily xx vhodném povrchu. Xxxxxxx xxxxx x xxxxxxxxx kontroly xx xxxx xxxxxxxxx xxxxxxxxxxxxxxx (5) xxxxxxx 50 %.
1.5.7 Xxxxxxxxx XXX
Xxxxxxx xxxxxxxxx jaterní buňky xxxxx xx xxxxxxx xxxxxxx dobu, xxxx. xxx xx xxx xxxxx, xxxxxxxx s xxxxxx obsahujícím 3X-XxX. Xx konci inkubační xxxx by mělo xxx médium x xxxxx odstraněno x xxxxx poté xxxxx xxx xxxxxxxxxx x xxxxxx xxxxxxxxxxx xxxxxxxx xxxxxxxxxxx thymidinu, aby xxxx xxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxxxx ("xxxx xxxxx"). Xxxxx xx xxxx xxxxxxx, fixují a xxxxxx. Xxx xxxxx xxxxxxxxx xxxx xxxxxx xxx snížení xxxxxxxxxxxxx xxxxxxxx. Xxxxxxxxx xx xxxxxx xx autoradiografické xxxxxx, xxxxxxxx se x xxxxx (xxxx. x xxxxxx 7 xx 14 xxx), xxxxxxxx se, xxxxxx x xxxxxxxxx se xxxxxxxxxx xxxx xxxxxxx. X každého xxxxxxx xx xxxxxxxx xxx xx xxx preparáty.
1.5.8 Xxxxxxx
Xxxxxxxxx by xxxx xxxxxxxxx xxxxxxxxxx xxxxx xxxxxxxxxxxx xxxxxxxxxx xxxxx, xxx xxxx hodnocení XXX xxxxxxxxx xxxxxxx. Xxxxxxxxx se xxx xxxxxxxxxxx prohlédnou na xxxxxx xxxxxx xxxxxxxxxxxx (xxxx. na pyknosu, xxxxxxxx úroveň xxxxxxx xxxxxxxxxxxxx izotopem).
Před xxxxxxxxx xxx xx xxxx xxx preparáty xxxxxxxx. Xxxxxxxxx xx vyšetřuje 100 xxxxx xx xxxxx xxxxx alespoň xx dvou xxxxxxxxx; xxxxxxxxx xxxx než 100 xxxxx/xxxxx xx xxxx být xxxxxxxxxx. Xxx xxxxxxxx xxx xx xxxxx x X-xxxx xxxxxxxxxxx, xxx xxxxx xxxxx x X-xxxx může být xxxxxxxxxx.
Xxxxxxxx 3X-XxX xxxxxxxxxxxxxxx xx xxxxx x xxxxxxxxxx xxxxxxxxxxxx normálních xxxxx xxxxxxxx navrstvením xxx stříbra by xxxx xxx xxxxxxxxx xxxxxxx metodou.
Počet xxxxx xx xxxxxxx x xxxxx zrn xxxxxxxxxxxxxx xxxxxxxx xxxxŭx (xx) x x prŭměrného xxxxx xxx x xxxxxxxxxxxxxxxxx xxxxxxxxx (cg) xxxxxxxxxxxxxx jádrŭm. xxxx xxxxxxx xx xx xxxxxxx xxx xxxxx xxxxx xxx xxxxxxxxxx xxxxxxxxx xxxxxx xxxxxxxxxx, xxxx prŭměrná hodnota xxxx xx xxx xxxxxxx xxxxxxxxx oblastí x xxxxxxxxx dotyčných xxxxxxxxx xxxxx. po xxxxxxxxxxxxx xxXxxxxxxx mohou xxx použity i xxxx xxxxxxx xxxxxxxxx xxxxx buněk (xxxx. xxxxxxxx celých xxxxx) (6).
2. ÚDAJE
2.1 XXXXXXXXXX XXXXXXXX
Xxxx by být xxxxxxx údaje xxx xxxxxxxxxx preparáty x xxxxxxx. Údaje by xxxx být xxxx xxxxxxx ve formě xxxxxxx. Xxxxxxxxx xxxxxxx XX xx xxxxxxx XX xx měl xxx vypočten pro xxxxxx xxxxx, xxx xxxxx zvíře x xxx xxxxxx dávku x xxx čistý xxxxx xxx xxxxxxxxxxxxxx xxxxxxxx xxxxxx (XXX). Xxxxxxxx jsou počítány "xxxxxxxxxx" buňky, měla xx být xxxxxxxx xxx xxxxxxxxxx "xxxxxxxxxxxx" xxxxx xxxxxxxxxx a xxxxxxxx xx xxxxxxxxxxx xxxx xxxxxxxxxx údajích x xxxxxxxxxxx xxxxxxxxxx. Xxxxxxxxx xxxxxxxx mohou xxx zhodnoceny xxxxxxxxxxxxx xxxxxxxx. Xxxx-xx xxx xxxxxxx, xxxx by xxx xxxxxxxxxxx testy xxxxxxx x xxxxxxxxxx xxxx xxxxxxxxxx xxxxxx.
2.2 XXXXXXXXX X XXXXXXXXXXXX XXXXXXXX
Xxxx příklady xxxxxxxx xxx pozitivní xxxx xxxxxxxxx xxxxxxx patří:
|
pozitivní |
i) |
hodnota XXX xxxx xxx xxxxxxxx xxxxxx, která xx zdůvodněna xx xxxxxxx xxxxxxxxxxx xxxxx xxxxxxxxxx; |
|
xxxx |
xx) |
xxxxxxx NNG je xxxxxxxx xxxxx xxx xxxxxxx pro xxxxxxxxx xxxxxxxx; |
|
xxxxxxxxx |
x) |
xxxxxxx XXX xxxx xx xxxxxxxxx prahové xxxxxxx nebo xxx xx; |
|
xxxx |
xx) |
xxxxxxx NNG xxxx xxxxxxxx xxxxx xxx xxxxxxx pro xxxxxxxxx xxxxxxxx. |
Xxxx xx xxx xxxxxxxxx xxxxxxxxxx xxxxxxxxx xxxxx, tj. xxxx xx být xxxxx x úvahu xxxxxxxxx, xxxx xxxx variabilita xxxxxx, xxxxx xxxxx x xxxxxxxx x xxxxxxxxxxxx. Xxx hodnocení xxxxxxxx xxxxxxx xxxxx xxx xxxxxxx xxxx xxxxxxx xxxxxxxxxx statistické xxxxxx. Xxxxxxxxxxx významnost xx xxxx xxxxxx xxx xxxxxxx xxxxxxxxx xxxxxxxx pro xxxxxxxxx xxxxxxx.
Xxxxxx xxxxxxx experimentů xxxxxxxx jasně xxxxxxxxx xxxx negativní xxxxxxxx, x xxxxxxxxxxx xxxxxxxxx xxxxxxxx xxxxxx údajů xxxxxxxx konečný xxxxx x aktivitě zkoušené xxxxx. Výsledky xxxxx xxxxxx xxxxxxxxxx xxxx xxxxxx xxx xxxxxx xx to, kolikrát xx experiment opakován.
Pozitivní xxxxxxxx xxxxxxx na XXX x xxxxxxxxx xxxxxxx xxxxx xx xxxx xxxxxxxxx, xx xxxxxxxx látka indukuje x xxxxxxxxx buňkách xxxxx in vivo xxxxxxxxx XXX, xxxxx xxx xxxxxxx xxxxxxxxxxxx xxxxxxxx XXX in xxxxx. Xxxxxxxxx xxxxxxxx xxxxxxxxx, že xxxxxxxx xxxxx za podmínek xxxxxxx xxxxxxxxxx xxxxxxxxx XXX, xxxxx xxx xxxxxxxxx xxxxx xxxxxxxx.
Xxxx xx xxx xxxxxxxxxxx xxxxxxxxxxxxxxx, s xxxxx xx zkoušená látka xxxxxxx xx krevního xxxxx xxxx. xx xxxxxx xxxxx (xxxx. xxxxxxxxx toxicita).
3. ZPRÁVY
PROTOKOL X XXXXXXX
Xxxxxxxx x xxxxxxx xxxx obsahovat xxxx xxxxxxxxx:
Xxxxxxxxxxxx/xxxxxxxxx:
- zdůvodnění xxxxx vehikula,
- xxxxxxxxxxx x stálost xxxxxxxx xxxxx v xxxxxxxxxxxx/xxxxxxxx, xx-xx známa.
Testovací xxxxxxx:
- xxxxxxx druh/kmen,
- počet, xxxxx a xxxxxxx xxxxxx,
- xxxxx, podmínky xxxxx, xxxxxx xxx.,
- xxxxxxxxxxxx xxxxxxxx xxxxxx xx počátku zkoušky, xxxxxx xxxxxxx tělesné xxxxxxxxx, xxxxxxx xxxxxxx x směrodatné xxxxxxxx xxx xxxxxx xxxxxxx.
Xxxxxxxx xxxxxxxx:
- pozitivní x xxxxxxxxx (xxxxxxxxx/xxxxxxxxxxxx) xxxxxxxx,
- xxxxx xx xxxxxx xxx xxxxxxxx xxxxxxx, xxxxx xxxx xxxxxxxxx,
- xxxxxxxxxx xxxxxxxxx xxxxxx xxxxx,
- údaje x xxxxxxxx xxxxxxxx látky,
- xxxxx x podávání xxxxxxxx xxxxx,
- xxxxxxxxxx xxxxxxx podávání,
- popřípadě xxxxxx xxxxxxx, xxx xx zkoušená xxxxx xxxxxxx do xxxxxxxx xxxxx xxxx xx xxxxxx xxxxx,
- xxxxxxxx xxxxxxxx xxxx xxxxxxxxxxx xxxxxxxx xxxxx v xxxxxx xxxx xxxx (xxx) xx odpovídající xxxxx (mg/kg xxxxxxx xxxxxxxxx/xxx),
- xxxxxxxx údaje x kvalitě xxxxxx x vody,
- xxxxxxxx xxxxx rozvrhu xxxxxxxx x xxxxxx,
- metody xxxxxxxxx toxicity,
- xxxxxx xxxxxxxx a xxxxxxxxx xxxxxxxxx buněk,
- použitá xxxxxxxxxxxxxxxxx xxxxxxxx,
- xxxxx xxxxxxxxx a počet xxxxxxxxxxx xxxxx,
- xxxxxxxx xxxxxxxxx,
- xxxxxxxx xxxxxxxxxxx xxxxxx xx xxxxxxxxx, xxxxxxxxx xxxx xxxxxxxxxxx.
Xxxxxxxx:
- xxxxxxx xxxxxxx xxxxx xxx xxxxxxxxxxxxxx xxxxxxxx xxxxxx a xxxxx xxx xxxxxxxxxxxxxx cytoplasmě, x xxxxx xxxxx xxx, jednotlivě xxx xxxxxxxxx, zvířata x xxxxxxx,
- podle xxxxxxxx xxxxxxxxx xxxxxxxx xx xxxxx,
- xxxxxxxx xxxxxxxxxxx xxxxxxxxx,
- známky toxicity,
- xxxxx o souběžné xxxxxxxxx (xxxxxxxxxxxx/xxxxxxxxx) a xxxxxxxxx xxxxxxxx,
- xxxxxxxxx xxxxx o xxxxxxxxx (xxxxxxxxxxxx/xxxxxxxxx) x xxxxxxxxx xxxxxxxx s rozmezími, xxxxxxxxx hodnotami a xxxxxxxxxxxx xxxxxxxxxx,
- xxxxx xxxxx "xxxxxxxxxxxx" xxxxx, xx-xx xxxxxxxx,
- xxxxx xxxxx x X-xxxx, xx-xx xxxxxxxx,
- xxxxxxxxxxxxxxx xxxxx.
Xxxxxx výsledků.
Závěry.
4. LITERATURA
1) Xxxxx, J. Xxxxxxx, X. X., Burlinson, X., Xxxxxx, M. X. (1985), Xx Xxxxxxxxxx xx xxx Xx xxxx Rat. Xxxxxxxxxx XXX Xxxxxx Xxxxx, Xxxxxxxxxx Xxx., 156, 1-18.
2) Butterworth, X. X., Ashby, X., Xxxxxxxx, X., Xxxxxxxx, D., Xxxxxxxx, X., Xxxxxx, X., Xxxxxxxx, X. (1987), X Xxxxxxxx and Xxxxx for the Xx vivo Rat Xxxxxxxxxx XXX Xxxxxx Xxxxx, Xxxxxxxxxx Res., 189, 123-133.
3) Xxxxxxxx, X. X., Xxxxxx, X., Xxxxx, X., Xxxxxxx, X. X., Xxxxxxxxx, X., Xxxxxxx, X. X., Dean, X. X., Mitchell, X. de X. (1993), Xx vivo Xxx Liver UDS Xxxxx, xx: Xxxxxxxx X. J., Fox X., (xxx), Supplementary Xxxxxxxxxxxx Xxxxx: XXXX Xxxxxxxxxxx Procedures. XXXXX Xxxxxxxxxxxx xx Xxxxxxxxxx xxx Mutagenicity Xxxxxxx. Xxxxxx. Xxxx II xxxxxxx, Xxxxxxxxx Xxxxxxxxxx Xxxxx, Xxxxxxxxx, Xxx Xxxx, Xxxx Xxxxxxx, Xxxxxxxxx, Xxxxxx, 52-77.
4) Xxxxx, X., Xxxx, X. X., Xxxxxx, X., Xxxxxxxxx. X., Xxxxxxxxx, X., Xxxxxxxxx, X. J., Xxxxxxxx, X., Hertner, X., XxXxxxx, X. X., Xxxx, X. (1993), Xxxxxxxxxxxxxxx for xxx Xxxxxxxxxxx xx XXX Xxxxx Xx vitro xxx In xxxx, Xxxxx. Res., 312, 263-285.
5) Xxxxx, R., Xxxxxxx, X., Efstathiou, X., Xxxxxxxxxxxx-Xxxxxx, X. (1993), Xxxxxxxxxx of xxx Relation Xxxxxxx xxx Xxxxxxx Xxxxxxxxx xxx xxx Xxxxxxxxxx xx Xxxxxxx Xxxxxxxx Xxx Hepatocytes Xxxx xxx xxx Xx xxxx/Xx vitro DNA Xxxxxx Xxxxx (XXX), Xxxxxxxxxx Xxx., 291, 21-27.
6) Xxxxxxxx, X. X., Xxxxx, C. X., Xxxxxxxxxxx, B. X. (1982), Xxxxxxxxx xx Xxxxxxxxx Xxxxxxxxxxx xx xxx Xx xxxx/Xx xxxxx Hepalocyte XXX Xxxxxx Xxxxx, Xxxxxxx.Xxxxxxx. 4, 553-562."
XXXXXXX 5
XXXXXX XXXXXXXXX XX XXXXXXXXXXX X XXXXXXXXXX XXXXXXXXXXXX LÁTEK X XXXXXXXXX
Xxx xxxxxxxx Xxxxxx 2001/59/ES, Úř. xxxx. L 332, 28. 12. 2000, x. 81.
PŘÍLOHA 6
"
XXXXXXX IX
ČÁST X
xxxxxxxx xxxxxxxx se xxxxxxx xxxxxxxx proti xxxxxxxx dětmi
Kromě xxxxxxxxxx xx. 22 xxxx. 1 xxxx. x) xxxx směrnice, xxxx xxx xxxxx x xxxxxxxxx objemu xxxxxxxxxx xxxxx, x xxxxx xx xxxxxxx xxxxxx xxx xxxxxxxxxx (Xx; X 65) a xxxxx xxxx xxxxxxxxxxxxx x xxxxxxxx podle xxxx 3.2.3 xxxxxxx XX xxxx směrnice, x xxxxxxxx xxxxx xxxxxxxxx xx xxx xx formě xxxxxxxx xxxx v xxxxxxxx xxxxxxxxxx aerosolovým rozprašovačem, xxxxxxxx xxxxxxx xxxxxxxx xxxxx xxxxxxxx xxxxx.
1. Xxxxxxxxx xxxxxxxxxxxx obaly
Uzávěry xxxxxx xxxxx xxxxxxxx xxxxx xxxxxxx na xxxxxxxxx xxxxxxxxxxxxxx obalech xxxx xxxxxxxx xxxxxxxxx xxxxx XXX 8317 (xxxxxx xx xxx 1. xxxxxxxx 1989) "Xxxxx odolné xxxxx — Xxxxxxxxx na xxxxxxxxx xxxxxxxxxxxx xxxxx x xxxxxx jejich xxxxxxxx" xxxxxxxx Xxxxxxxxxxx xxxxxxxxxx pro xxxxxxxxxxx (XXX).
2. Xxxxxxxxx neuzavíratelné xxxxx
Xxxxxxx xxxxxx proti xxxxxxxx dětmi xxxxxxx xx opakovaně xxxxxxxxxxxxxxxx xxxxxxx xxxx xxxxxxxx xxxxxxxxx xxxxx XXX XX 862 (vydání x xxxxxx 1997) "Xxxxx — Xxxxx xxxxxx dětem — Xxxxxxxxx x zkušební xxxxxxx pro xxxxxxxxx xxxxxxxxxxxxxx xxxxx xxxxxx xxx farmaceutických xxxxxxx" xxxxxxxx Xxxxxxxxx výborem xxx xxxxxxxxxxx (XXX).
3. Xxxxxxxx
1. Xxxxxxxxx xxxxx x xxxx uvedenými xxxxxxx xxxxx xxxxxxxxxx xxxxx laboratoře, xxxxx xxxxxxx xxxxxxxx xxxxx xxxx XX 45000.
2. Xxxxxxxxxx případy
Je-li xxxxxx, xx xxxx xx xxxxxxxxxx xxxxxxxx xxx xxxx, neboť se xxxxxxx xxxxxx x xxxxxx xxx xxxxxx xxxxxxxx, nemusí být xxxxxxx xxxxxxxxx.
Xx xxxxx xxxxxxxxx případech a xxxxx xxxxxxxx xxxxxxxxx xxxxxx x xxxxxxxx x xxxxxxxxxxx uzávěru xxx xxxx, může xxxxxxxxxxxx orgán xxxxxxxxx, xxx osoba xxxxxxxxx xx xxxxxxx xxxxxxx xx xxx xxxxxxxxxx xxxxxxxxxx xxxxxx xxxxxxxxxx xxxxx xxxx. 3 xxxx 1 konstatující, xx xxx
- typ xxxxxxx je takový, xx xxx xxxx xxxxxxxx xxxxxxx xxxxx xxxx xxxxxxxxx norem XXX a XXX,
xxxx
- xx xxxxxx xxx xxxxxxx x byl xxxxxxx vyhovujícím podle xxxx xxxxxxxxx xxxxx.
XXXX X
Xxxxxxxx xxxxxxxx xx xxxxxxxxxxxx xxxxxxx
Xxxxxxxxx xxxxxxxxxxx xxx hmatatelné xxxxxxxx xxxx xxx v xxxxxxx x xxxxxx XX XXX 11683 (xxxxxx z xxxx 1997) "Obaly — Xxxxxxxxxx xxxxxxxx xxxx xxxxxxxxxx — Xxxxxxxxx".
"